Circulating Tumour Cells and Biomarkers in Neuroendocrine Tumours by Khan, MS
1Circulating Tumour Cells and Biomarkers in Neuroendocrine
Tumours
by
Mohid Shakil Khan
A thesis submitted to University College London (UCL) in fulfilment of the
requirements for the degree of
Doctor of Philosophy (PhD), Department of Oncology
UCL Cancer Institute,
University College London (UCL)
August 2012
2DECLARATION OF ORIGINALITY
‘I, Mohid Shakil Khan, confirm that the work presented in this thesis is my own. Where
work has been derived from other sources, I confirm that this has been indicated in the
thesis.’
……………………………………………………
M S Khan
3‘When a plant goes to seed, its seeds are carried in all directions’[1]
Stephen Paget, 1889
4ABSTRACT
Neuroendocrine tumours (NETs) are heterogeneous with respect to biological behaviour
which ranges from indolent to highly aggressive. Consequently the prognosis is variable
and biomarkers that are able to predict the rate of tumour progression or survival are
required to inform clinical management. In practice, histological grade has proved to be
one of the best available indicators of prognosis. The histopathologial biomarkers, Ki-
67 proliferation index and mitotic count, are used to assign grade in a three-tiered
grading system proposed by international NET guidelines. Agreement between Ki-67
and mitotic count is implied in guidelines but in a series of 131 metastatic pancreatic
and 136 metastatic midgut NETs, I demonstrate a discordance of 44% and 38%,
respectively, when assigning grade. Multivariate analysis of this data suggest Ki-67 is a
superior prognostic marker, and the additional value of mitotic count is questionable.
Although Ki-67 offers prognostic information, biomarkers detected in blood have the
advantage in being obtainable by relatively non-invasive methods and in being easily
repeated during the disease course. Current biomarkers, used in routine clinical practice,
include plasma chromogranin A (CgA) and 24-hour urinary 5-hydroxy indole-acetic
acid (5-HIAA) but there is a lack of prospective trials evaluating these as prognostic and
predictive biomarkers in NETs. Circulating tumour cells (CTCs) have been investigated
in other cancers and found to provide prognostic and predictive information. Detection
of CTCs using the Cellsearch™ platform requires the expression of epithelial cell
adhesion molecule (EpCAM) which has not been systematically evaluated in NETs. By
immunohistochemistry I have demonstrated EpCAM expression in the majority of
NETs and, for the first time, detected CTCs patients with metastatic NETs. In 175
patients prospectively recruited, one or more CTCs was detected in 51% of midgut and
36% of pancreatic NETs. In patients commencing a new treatment for metastatic NET,
one or more CTCs at baseline was an independent poor prognostic factor, offering
better prognostic value than existing markers including grade and CgA. Furthermore, a
change in CTCs at 3 to 5 weeks after commencing therapy was predictive of response to
treatment and survival, suggesting CTCs could provide an opportunity to assess
response, and to change therapy at an early time-point than with conventional imaging.
I have also evaluated circulating free DNA (cfDNA) as a potential molecular biomarker.
After extraction from plasma and quantification using chip-based capillary
5electrophoresis for the first time, cfDNA was demonstrated in patients with NETs. A
higher concentration of cfDNA was found in in a series of 88 patients with metastatic
NETs compared to healthy controls and there was a correlation between quantity of
cfDNA and CTCs. However, since cfDNA was only detected in 25% of cases, more
sensitive methods of detecting cfDNA may be required before further studies are
conducted to validate cfDNA as a biomarker and to analyse mutations in cfDNA.
The hypervascular nature of NETs and their response to anti-angiogenic therapy such as
sunitinib suggested that circulating endothelial cells (CECs) might also be informative
in this tumour group. The presence of CECs was demonstrated in a series of 55 patients
with NETs, using immunomagnetic separation and phenotyping with CD105. Although
not significantly elevated, there was a wider range of CECs in NETs compared to
healthy controls, possibly reflecting the underlying angiogenic process. Although no
definite conclusions can be made, further studies investigating the relationship with
markers of angiogenesis, and changes with anti-angiogenic therapy could prove
valuable.
Given the increasing number of treatment options available and varied survival, it is
unclear what treatments to offer, in which patients, and in which sequence. Grade
according to Ki-67 offers some prognostic information at the time of diagnosis but my
research suggests that circulating biomarkers, specifically CTCs, provide additional and
better prognostic and predictive information repeatable at numerous time-points during
the disease course. Furthermore, detection of CTCs and cfDNA in NETs allows the
possibility of future studies into their molecular analysis which may enhance our
understanding of NET pathogenesis and metastasis.
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Chapter 1. Introduction to Neuroendocrine Tumours
(NETs) and Biomarkers
1.1. Background of NETs
1.1.1. Epidemiology
Originally thought to be rare, incidence rates in the 1980’s reported fewer than 2 per
100,000 per year.[2] Recent data, however, suggests an incidence of 5.25 per
100,000[3]. This increase, particularly in gastroenteropancreatic NETs (GEP-NETs),
probably reflects changes in detection, better pathological expertise and awareness,
incidental findings on imaging/endoscopy rather than increasing burden since GEP-
NETs were found in up to 1% of necropsies[4], more than expected (see Figure 1.1).
NETs are a heterogeneous group of tumours arising from midgut, pancreas, stomach,
lungs, or colorectum, exhibiting diverse biological behaviour from relatively indolent to
highly aggressive cancers. Given heterogeneity in survival, it is not surprising that
recent prevalence rates have been reported up to 35 per 100,000, more common than
that of most gastrointestinal cancers including hepatobiliary, oesophageal and
pancreatic carcinomas[3].
Survival rates vary depending on grade and site of tumour. Pancreatic NET 5-year
survival from the SEER registry was only 37.6%, but within this group, survival
heterogeneity existed[5]. Survival ranged from 30% for somatostatinomas to 95% for
insulinomas at 5 years. 5-year survival for other GEP-NETs were 68.1% for midgut
NETs, 64.7% for gastric NETs, 81.3% for appendix NETs and 88.6% for rectal NETs.
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Figure 1.1 Incidence of neuroendocrine tumours (NETs) over time, by site and by disease stage. (A)
Annual age-adjusted incidence of NETs by year (1973 to 2004) expressed as the number of tumours per
100,000 (95% CIs) age-adjusted. (B) Time-trend analyses of the incidence of NETs by primary tumour
site (1973 to 2004). Statistically significant increases in incidence at all stages are shown (P < 0.001).
[From Yao et al. One Hundred Years After "Carcinoid": Epidemiology of and Prognostic Factors for
Neuroendocrine Tumors in 35,825 Cases in the United States. JCO 26(18)3063-72. Reprinted with
permission. © American Society of Clinical Oncology. All rights reserved.]
A
B
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1.1.2. Origin, Nomenclature and Aetiology
Neuroendocrine tumours (NETs) are malignant transformations of cells of the diffuse
neuroendocrine system (DNES), the collection of various neuroendocrine cells scattered
throughout the body[6]. Nomenclature through history has varied. Initially described in
1888 by Lubarsch as ‘little carcinomata’ in the distal ileum[7], the established term,
carcinoid (or ‘karzinoide’), was introduced by Obendorfer in 1907.[8] It was originally
postulated that these various tumours throughout the body arise from common
embryological tissue derived from the neural crest. This theory was supported by the
Amine Precursor Uptake Decarboxylation (APUD) theory; the common ability of such
cells to take up amine precursor molecules and to undertake decarboxylation of these
substances resulting in the production of peptide hormones and biogenic amines.[9, 10]
The APUD theory is still valid but the origin of NETs are increasingly thought to be the
DNES, from cells of the pancreas and GI tract[11] and whether they are similar to other
epithelial cancers remains controversial. Wnt signaling is required for renewal of
intestinal stem cells and carcinogenesis in the gastrointestinal epithelium[12]. Wnt has
also recently been reported to take part in the process of neuroendocrine
differentiation[13] and thus this pathway may play a role in the development of NETs.
Through most of the 20th century, these tumours were labelled as ‘carcinoid’ tumours
and confusingly ‘carcinoid syndrome’ was applied to clinical features of diarrhoea and
flushing due to serotonin metabolite secretion from metastatic tumours derived from a
midgut primary. By the start of the 21st century, terms such as ‘neuroendocrine tumour’
or ‘endocrine tumour’ were used in the WHO guidelines[14] and most recently,
‘neuroendocrine neoplasms’[15] to encompass tumours of all behaviours.
The risk of NET in an individual with one affected first degree relative has been
estimated to be approximately four times that of the general population; increasing to 12
times with two affected first degree relatives[16]. Although GEP-NETs are usually
sporadic, familial syndromes including von Hippel-Lindau (vHL), tuberous sclerosis,
multiple endocrine neoplasia 1 (MEN-1) syndrome and neurofibromatosis (NF-1) may
be associated with pancreatic and proximal intestinal NETs.[17]
MEN-1 is an autosomal dominant disorder classically comprising of primary
hyperparathyroidism (95%), pancreatic NETs (25-75%) and pituitary tumours (25-
30%)[18]. NF-1 is an autosomal dominant disorder where loss of heterozygosity of NF-
1 gene results in mTOR activation and tumour development[19]. It is usually diagnosed
clinically, characterized by café au lait spots, cutaneous neurofibromas, optic gliomas
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and iris harmatomas. vHL syndrome is caused by mutations in the VHL tumour
suppressor gene (3p25-26) involved in regulating hypoxia-induced cell proliferation and
angiogenesis. Clinical features include retinal or central haemangioblastomas, clear cell
renal carcinomas, phaechromocytomas and pancreatic cysts. Pancreatic NETs occur in
15% so this should be screened for in cases[20].
Although the genetic basis of NETs has been difficult to elucidate due to heterogeneity,
recently exome sequencing of sporadic pancreatic NETs resulted in the discovery of
mutations of the MEN1 gene in 44%, and DAXX/ATRX genes (involved in chromatin
remodelling) in 43% of cases[21]. These were associated with better prognosis. The
p16/MTS1 tumour suppressor gene was also found to be homozygously deleted in 42%
and methylated 58% of gastrinoma and non-functioning pancreatic NETs[22].
1.1.3. Classification
Since NETs exhibit a diverse spectrum of pathology, different classification systems
have been devised to provide useful information for descriptive and prognostic
purposes. However, many of these classification systems differ in criteria for grading
and staging and also with regards to nomenclature and terminology.
Since the 1960’s, NETs have been divided into fore-, mid- and hind-gut groups
disregarding the mixed cell types of the foregut which include stomach, pancreas,
duodenum and bronchial. Modern day practice involves classifying cases by primary
site e.g. pancreatic, rectal or gastric NET. However, the term ‘midgut NETs’ is still used
to identify tumours of the ileum or proximal colon.
Guidelines produced by the World Health Organisation (WHO) and European
Neuroendocrine Tumour Society (ENETS) incorporate staging by tumour-node-
metastasis (TNM) criteria for NETs of the gastrointestinal tract[23, 24, 25, 26]. Separate
classification systems are in use for bronchial, thyroid and thymic NETs.
Classification is made according to site of primary tumour, size, invasion to muscularis
propria and histological grade. Grade is particularly useful prognostically. It utilises
mitotic count per 10 high power fields (HPF) or Ki-67 proliferation index to group
NETs (Table 1.1). Ki-67 is a nuclear antigen associated with ribosomal RNA
transcription, recognised by the MIB-1 antibody [27]. It is found in active phases of the
cell cycle, in G1, S, G2 and M phases but not in resting G0 cells[28]. It is thus
associated with cell proliferation and the percentage of cells staining for Ki-67 indicates
the growth fraction. The higher the Ki-67 index, the more aggressive the tumour.
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Grade Ki67 (%) Mitotic Count/10hpf
G1 (Low) ≤2 <2
G2 (Intermediate) 3-20 2-20
G3 (High) >20 >20
Table 1.1 Grading classification of NETs according to the European Neuroendocrine Tumour Society
(ENETS) Consensus Guidelines; hpf (high power fields)
Ki-67 proliferation index should be assessed in 2000 tumour cells in areas where the
highest nuclear labelling is observed and mitoses in at least 40 high power fields.
The primary site and grade of NET affects survival. 5-year survival rates for pancreatic
NETs are 94%, 63%, and 14% for low, intermediate and high-grade tumours
respectively.[29] For midgut NETs, the figures are 95%, 82% and 51%.[30]
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1.2. Diagnosis
GEP-NETs can be asymptomatic, diagnosed incidentally on imaging but may produce
specific symptoms. Symptoms may relate to physical compression or obstruction of
viscera by the tumour causing pain, nausea, vomiting or as a consequence of bioactive
hormones released by the tumour. The syndromes described below are typically seen in
patients with secretory pancreatic tumours[31] (Table 1.2).
Tumour/Syndrome Symptoms
Insulinoma Confusion, sweating, dizziness, weakness,
unconsciousness, relief with eating
Gastrinoma Zollinger-Ellison syndrome of severe peptic
ulceration and diarrhoea
Glucagonoma Necrolytic migratory erythema, weight loss,
diabetes mellitus, stomatitis, diarrhoea
VIPoma Werner-Morrison syndrome of profuse watery
diarrhoea with marked hypokalaemia
Somatostatinoma cholelithiasis; weight loss; diarrhoea and
steatorrhoea. Diabetes mellitus
Non-syndromic pancreatic
neuroendocrine tumour
Symptoms from pancreatic mass and/or liver
metastases
Table 1.2 Syndromes associated with functioning pancreatic NETs
‘Carcinoid syndrome’, characterised by diarrhoea and flushing, is commonly a result of
metastases to the liver, usually from a midgut NET with release of hormones such as
serotonin and other vasoactive compounds, directly into the systemic circulation. In
addition, midgut NETs may be associated with desmoplasia manifesting as intestinal
and ureteric obstruction or heart failure associated with cardiac valve fibrosis.
The diagnosis of NET is confirmed on histology but the diagnosis of carcinoid
syndrome is based on clinical symptoms, hormone profile, radiological and nuclear
medicine imaging together with histology. NETs are often diagnosed with advanced
disease after numerous years of vague symptoms typical of irritable bowel syndrome.
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1.3. Imaging and Nuclear Medicine
Primary midgut NETs, being small, may be difficult to identify on imaging. Frequently,
however, a lymph node metastasis with surrounding desmoplasia can be demonstrated
as a ‘mesenteric mass’. Pancreatic NETs and some NET liver metastases can be
diagnosed on contrast-enhanced CT or MRI and are typically hypervascular in the
arterial phase[32].
Endoscopic Ultrasound (EUS) can be performed to assess local invasion of gastric and
duodenal NETs and for identifying and aspirating pancreatic lesions for tissue diagnosis
(mean sensitivity 90%).[33, 34] The sensitivity of EUS may be reduced with extra
pancreatic gastrinomas (80% of gastrinomas in MEN1 are found in the duodenum) for
which an upper gastrointestinal endoscopy and CT or MRI should be performed.[35]
Most NETs express somatostatin receptors (SSTRs) of which there are five SSTR
subtypes (SSTR 1-5) with SSTR-2 and SSTR-5 expressed in at least 80% and 77% of
gastrointestinal NETs respectively.[36, 37] With the exception of insulinomas (only
50% express SSTR2), somatostatin receptor imaging e.g. OctreoscanTM or 68Gallium-
DOTA-Octreotate PET is the mainstay of staging and may assist in localising primary
lesions in GEP-NETs.[38, 39]
Unlike adenocarcinomas, PET with 18-fluorodeoxyglucose ([18F]FDG) is often
negative in low or intermediate grade NETs. However PET radionuclides such as
68Gallium can be conjugated to somatostatin analogues for SSTR imaging. 68Gallium-
DOTA-Octreotate and 68Ga-DOTA-Octreotide and more recently 68Ga-DOTANOC
have been found to be sensitive for NETs due detection of more SSTR subtypes and
enhanced affinity compared to OctreoScanTM.[40] These imaging modalities can help
characterise metastases, assess extent of disease and locate primary lesions.
As with other cancers, monitoring the response of the tumour to therapy is currently
achieved by measuring changes in size of target tumour lesions on interval imaging.
The criteria has been standardised for most cancers by use of RECIST (Response
Evaluation Criteria In Solid Tumours).[41] However, this may not be an ideal method
of assessing response in NETs due to poor sensitivity in identifying necrotic lesions and
also due to the slow-growing nature of most NETs.[42] Monitoring response in NETs
with PET imaging is unproven and is undergoing evaluation[43].
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1.4. Management in brief
Wherever possible, surgery should be attempted to achieve curative resection. In some
cases with liver metastases, where the primary is resectable, resection of the liver
metastases +/- ablation of non-resectable lesions may be considered as a curative
approach.
Metastases are often present at the time of diagnosis e.g. in 60% of midgut NETs[44],
where curative resection is usually not possible but surgery can be undertaken for
palliation in selected cases[45].
The aim of medical treatment is thus to control tumour growth, prolong survival and
improve symptoms (including those from excess hormone secretion) and quality of life.
Treatment choice depends on site of primary, grade, co-morbidities, patient tolerability
and availability of options. Management is guided by guidelines produced by the
European Neuroendocrine Tumour Society (ENETS)[45, 46, 47] although the evidence
base contains very few randomised-controlled or prospective studies.
Somatostatin analogues are the mainstay of treatment in low and intermediate grade
metastatic midgut NETs. Until recently, this treatment was only indicated in functioning
midgut NETs with ‘carcinoid syndrome’, symptoms of diarrhoea and cutaneous
flushing as a consequence of secretion of serotonin and active metabolites from the
metastases of a ‘functioning’ midgut NET into the circulation. The somatostatin
analogues, octreotide and lanreotide in short and long-acting forms, have shown
consistent benefit in alleviating the symptoms of carcinoid syndrome[48, 49]. However,
a recent study suggests their use can be extended to non-functioning midgut NETs to
prolong progression-free survival[50]. This placebo-controlled, double blind study in
well-differentiated metastatic midgut NETs demonstrated that monthly injections of
octreotide LAR prolongs time-to-progression. Median time to tumour progression in the
treatment and placebo groups were 14.3 and 6 monthly respectively (HR=0.34 95%CI
0.2 to 0.59).
Interferon-α was introduced as a treatment for GEP-NETs in the early 1980’s and exerts
an anti-proliferation and anti-secretory effect. The usual dose employed is 3 to 5 million
units subcutaneously, 3 to 5 times a week and symptomatic and biochemical responses
have been noted in approximately 50% of patients with disease stabilisation in 60-80%
at a follow up of 4 years[51, 52]. However, significant tumour reduction only occurs in
10-15%. Limitations in use of interferon include its side effects which include flu-like
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symptoms, bone marrow suppression, thyroid disorders, psychiatric phenomenon and
chronic fatigue syndrome. Therefore, it may be considered as second line therapy.
Systemic chemotherapy is widely used but its precise role is not known due to studies
including various grades, sites, and inconsistent response criteria. Thus there is no
standard regimen. Systemic chemotherapy has been the standard treatment for
pancreatic NETs based on the data from Moertel et al with an objective response of
69%[53]. This study used one of the first combinations with streptozocin (STZ) and 5-
fluorouracil (5-FU). For well-differentiated pancreatic NETs, chemotherapy is
associated with a response rate of 6-70% but survival benefit is uncertain. A recent
series (n=79) combined 5-FU, cisplatin and STZ (FCiSt) in chemo-naive patients with
metastatic or locally advanced NETs[54]. Response rates were 38% for pancreatic and
25% for non-pancreatic sites with median time to progression 9.1 months and median
overall survival 31.5 months with an acceptable toxicity profile and an advantageous
one-day outpatient administration.
The use of chemotherapy in midgut and hindgut NETs has a much lower response rate,
with <20% of patients deriving benefit, which may only last 6-8 months[55, 56]. The
alkylating agent temozolomide, in combination with thalidomide in a Phase II trial,
induced a response rate of 25% with median duration of response 13.5 months[57]. A
more recent retrospective analysis found temozolomide monotherapy achieved
radiological response in 14% and stable disease in 53%[58]. Temozolomide might also
be used in pancreatic NETs. In a retrospective series of chemotherapy-naïve patients
with metastatic pancreatic NETs, the combination of temozolomide and capecitabine
resulted in an objective radiological response in 70% with 92% 2-year survival rate and
only 14% grade 3 or 4 adverse events[59]. Temozolomide is generally well tolerated
with minimal side effects including leucopenia, nausea and abdominal pain. Its response
rate and duration of effect are similar to those of other established regimens. For poorly
differentiated or high grade NETs, chemotherapy is first line with a response rate of
approximately 70% but with rapid relapse and poor survival[60].
Sunitinib and Everolimus might be considered first line options for G1 and G2
pancreatic NETs with progressive disease[61, 62]. Sunitinib is an oral tyrosine kinase
inhibitor with action against all VEGFR, PDGFR, stem cell factor receptor, and FMS-
like tyrosine kinase-3. The recent phase III study of sunitinib vs placebo in slowly
progressing pancreatic NETs (n=171) was halted due to the interim analysis showing
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significant benefit with progression-free survival (PFS) 11.4 months for Sunitinib and
5.5 months with placebo[61].
Mammalian target of rapamycin (mTOR) is a threonine kinase and part of the
phosphatodylinositol-3-kinase (PI(3)K)/Akt/mTOR pathway which is crucial in
regulation of cell survival and proliferation. RADIANT-3 is a randomized double-blind,
placebo-controlled, multicentre phase III study of everolimus, an mTOR inhibitor, plus
best supportive care versus placebo and best supportive care in patients with progressive
advanced pancreatic NETs. Results from the latter have recently been published
(n=410) and demonstrate prolonged PFS with median PFS of 11.0 months with
RAD001 (Everolimus) compared to 4.6 months with placebo[62]. Similarly, in patients
with progressing NETs and symptoms of carcinoid syndrome, in the phase III study,
RADIANT-2, everolimus and octreotide prolonged PFS compared to placebo and
octreotide (median PFS 16.4 vs 11.3 months).[63]
If first line treatment fails or there is progression after an interval period, second line
therapy includes peptide receptor radionuclide therapy (PRRT). This involves directing
radioactivity internally to the tumour site delivered by a radionuclide, such as 90Yttrium
(90Y) or 177Lutetium (177Lu), coupled to a somatostatin analogue. In a recent study of
90Y-labelled DOTA-0-Tyr3-octreotate (DOTATATE) radiological partial response
occurred in 23%, stable disease in 77% at 6 months with symptomatic response in
72%[64].
Other options for second-line therapy include re-challenging with chemotherapy,
radiofrequency ablation, and trans-arterial hepatic embolisation. Ideally, all therapeutic
options should be discussed within a dedicated NET multidisciplinary team.
Randomised trials of radiofrequency ablation (RFA) are lacking in NET metastases but
series indicate patients with bilobar metastases less than 5 in number with diameter less
than 5cm may benefit in terms of relief from the symptoms of NET liver metastases and
in achieving local control of the metastases. It may also be considered in combination
with resection with a better survival rate than with RFA alone[65]. In one large series,
34 patients with a total of 234 NET metastases were treated with RFA[66]. 80%
experienced complete or significant relief from symptoms lasting an average of 10
months and 41% showed no evidence of progression. Another series found similar
results with 69% demonstrating relief from tumour-related symptoms[67].
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Embolisation of a hepatic artery branch is indicated for those with multiple non-
resectable and hormone-secreting liver metastases. The intention is to reduce tumour
bulk and thus hormone output which may improve quality of life and survival. It can be
effective in both symptom control and as an anti-proliferative treatment. The
mechanism is to induce ischaemia in tumour cells thus reducing their hormone output.
Symptomatic response is achieved in 40-80%, biochemical response in 50-60% with
overall 5-year survival 50-60% post-embolisation[68, 69, 70]. Obliterating agents
include polyvinyl chloride and gel-foam powder. It appears that ischaemia may increase
the sensitivity to chemotherapeutic agents, hence the rationale behind trans-arterial
chemoembolisation (TACE) utilising concomitant doxorubicin or cisplatin[71].
Mortality has been quoted as 2-6% with adverse events in 8-17%, the most common
being post-embolisation syndrome (nausea, fever, abdominal pain).
Due to the prolonged course of disease, many patients undergo several lines of therapy
at different time-points. The optimal sequence has yet to be elucidated. The assessment
of overall survival (OS) due to an intervention may be difficult to assess in clinical trials
due to the prolonged disease course. Progression-free survival (PFS) or time-to-
progression (TTP) may be more reliable as an endpoint and is used a number of recent
clinical trials. However, response or progression as assessed by RECIST may not reflect
the underlying tumour biology, and requires waiting for an arbitrary interval before
post-therapy imaging is undertaken. PFS may not relate to OS and therefore, a
biomarker that could be used as a surrogate endpoint for OS would be highly desirable.
1.5. Biomarkers in general
The definition of a biomarker is: a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathological processes, or
responses (pharmacologic or otherwise) to a therapeutic intervention[72].
Biomarkers can be considered in the following categories:
 Predisposition biomarkers: to identify individuals at risk of developing
cancer
 Early detection biomarkers: to screen patients for the presence of cancer
 Diagnostic biomarkers: to determine the presence or absence of cancer and
to assess the cancer type
 Prognostic biomarkers: to identify the likely clinical disease course
(predicting survival outcomes) and to help select appropriate therapy
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 Predictive biomarkers: to predict response to therapy and monitor drug
effects to maximise the likely benefit from specific therapies i.e. as surrogate
endpoints
There is a general lack of prospective trials to validate prognostic and predictive
biomarkers in most cancers including NETs.
Given that most NETs present with advanced disease, the development of early
detection and diagnostic biomarkers are important. Even though the majority of NETs
have a more prolonged survival than other cancers, they are extremely heterogeneous in
terms of survival[3]. Consequently, prognostic biomarkers are helpful for providing
treatment recommendations. Additionally, predictive biomarkers are important to
predict response to treatments in a clinical setting, as many patients will have numerous
courses of treatments over their disease course. Predictive biomarkers would be
valuable in a trial setting since use of biomarkers as surrogate endpoints for PFS or OS
may accelerate trials that would otherwise need very prolonged follow-up to report
survival outcomes. There is little data on the relationship between PFS and OS in NETs
but Delea et al. demonstrated a correlation between PFS and OS in pooled data from 22
trials but did not find that risk reduction (RR) in PFS correlated with RR in OS[73].
1.6. Circulating markers specific to NETs
1.6.1. Chromogranin A
The neuroendocrine cells that give rise to NETs secrete a variety of bioactive products
that define their role. The best ‘general’ marker for NETs is Chromogranin A (CgA)
which is elevated in approximately 90% of GEP-NETs[74] and its measurement can
help in NET diagnosis. It is measured commonly in plasma (and sometimes in serum)
prepared from blood in a heparinised tube, chilled once collected, and centrifuged
within 30 minutes in a non-fasting state. Common commercial kits include detection by
enzyme-linked immunosorbent assay (ELISA) or radio-immunoassays[75].
CgA is an acidic, hydrophilic protein (~460 amino acids) with a molecular mass of ~70-
85 kDa.[76] Alongside other members of the granin family, it is a precursor protein that
can be processed at multiple cleavage sites to produce a large number of small bioactive
peptides with a wide range of biological activity, although questions on physiological
function remain. These include roles in the regulation of parathormone secretion,[77]
inhibition of insulin secretion,[78] regulation of catecholamine secretion,[79] regulation
of vascular tone,[80] and roles in the inflammatory response.[81]
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Evidence suggests that CgA is the most useful general circulating marker for NETs and
this is significant considering the poorly understood extensive DNES. CgA is a member
of the granin family together with Chromogranin B (CgB), Chromogranin C (CgC),
secretogranins III, IV, V, VI and VGF. These are proteins, found as components of
dense-core secretory granules in NE cells and are secreted by these NE cells in a
regulated fashion.
There are also individual amines and peptide hormones which are specific to certain
NETs including insulin (insulinoma), gastrin (gastrinoma), glucagon (glucagonoma),
and serotonin (midgut NET).
There have been numerous studies looking at CgA in NET diagnosis. Plasma CgA is
raised in GEP-NETs, bronchial NETs, and phaeochromocytomas amongst other NETs.
Excluding medullary thyroid carcinomas and paragangliomas, CgA has a sensitivity of
over 60%. Sensitivity and specificity vary depending on the type on NET and burden. In
a recent large study, sensitivity was 85.3%, specificity 96% when compared with
healthy controls.[82]
Although there have been several retrospective studies, there are few prospective
studies investigating the prognostic or predictive value of CgA in NETs and these are
mostly where biomarkers are incorporated as part of a larger clinical trial.
These studies can be categorised into:
1) those correlating CgA to clinicopathological features
2) those investigating the prognostic value of CgA and investigating utility of CgA
in detecting recurrence
3) those using CgA to monitor response to therapy (as a predictive marker)
1.6.1.1. Correlation of CgA to Clinicopathological Features
Several studies have shown plasma CgA correlates with tumour stage or burden in
NETs. In a retrospective study, Campana et al. demonstrated CgA was higher in
patients with diffuse disease than with localised or hepatic disease.[82] Nehar et al.
showed that there was a difference in CgA levels between those with metastases
compared to localised disease (sensitivities 73% and 26% respectively)[83] with similar
results reported by Bajetta et al. (78% and 37% respectively).[84] All these studies were
in heterogeneous populations of NETs but mainly with midgut or pancreatic primaries.
When measuring tumour burden (albeit with a different methodology) in midgut NETs,
Janson et al. found CgA levels were higher in those with >5 liver metastases compared
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to those with <5 or lymph node metastases.[85] Similarly, in a large study (n=143) CgA
levels were higher in cases with 3 or greater ‘localisations’ of tumour[86]. When
hepatic tumour burden was classified by percentage of liver involved in another study,
this also correlated with CgA[87].
CgA has also been found to inversely correlate with quality of life as determined by a
standardised questionnaire.[88] However, it does not seem to correlate with symptoms
of carcinoid syndrome.[89]
1.6.1.2. Prognostic Value of CgA
Plasma CgA, as a prognostic marker, has been adopted into clinical practice but in
several retrospective studies, evidence is not consistent in proving its prognostic value.
These studies followed on from utility of CgA in a different cancer, neuroblastoma.[93]
Baseline serum CgA was found to be a significant predictor of PFS but the authors did
not perform multivariate analysis and a cut-off of 190ng/ml was derived from
preliminary data.
Several retrospective studies are summarised in Table 1.3. On univariate analysis of a
large (n=324) retrospective series of pancreatic NETs, plasma CgA (elevated more than
three times the upper normal limit) was a significant predictor of shorter overall survival
but was not on multivariate analysis[90]. A baseline CgA >1000 μg/L (but not urinary
5-HIAA) was found to be associated with worse overall survival in a prospective phase
II trial of long acting octreotide[88] although this cut-off seemed to be arbitrarily
produced and only univariate analysis performed. A cut-off of CgA>5000 μg/L (levels
fixed arbitrarily) was found to be an independent predictor of OS in another
retrospective study of 301 patients[85].
One of the landmark prospective randomised control trials, looking at the effect of
octreotide LAR in non-functional midgut NETs (PROMID), did not find elevated CgA
to be prognostic or predictive and did not find any significant reduction in CgA, with
either placebo or active treatment at 6 months[50]. This was despite a highly significant
difference in time to progression (TTP) between the two arms of the study. Similar
results were found in a large multi-centred, retrospective series of midgut NETs with
liver metastases (n=360) where Ki-67 and age were independent predictors of survival,
but CgA was not.[91]
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PFS OSAuthor No.
Patients
CgA Cut-
off Univ Multiv Univ Multiv
Ekeblad[90] 324
(pancreatic)
3XULN ND ND 2.6 N
Korse[88] 30 (midgut) 1000ug/L ND ND Y ND
Janson[85] 301
(midgut)
5000ug/L ND ND 4.5 ND
Rinke[50] 85 (midgut) ULN not
specified
N ND N N
Ahmed[91] 360
(midgut)
‘increasing
levels’
ND ND N (but
increasing
CgA was)
N
Oberg[92] 207
(pancreatic)
2 X ULN
(73ng/mL)
N ND ND ND
Turner[54] 79 (mixed) ULN (60
U/L)
ND 2.77 ND 6.77
Table 1.3 Summary of studies evaluating CgA as a prognostic marker. If prognostic, of PFS or OS,
hazard ratios shown else Y/N. ULN=upper limit of normal; ND=not done; Y=Yes, prognostic; N=No, not
prognostic; Univ=univariate analysis; Multiv=multivariate analysis; PFS=progression-free survival;
OS=overall survival
The prognostic value of CgA has been assessed in other prospective clinical trials. In
the RADIANT-3 trial, serum CgA and NSE were evaluated monthly in patients given
oral everolimus or placebo with best supportive care in pancreatic NETs[92]. Although
this was a subgroup analysis, elevated NSE at baseline was associated with shorter
progression-free survival (PFS). Although suggested otherwise in the report there was
no significant difference in median PFS between those with elevated versus normal
CgA. This contradicts results from RADIANT-1 trial, the earlier phase II study, where
elevated baseline CgA and NSE were associated with shorter PFS and overall survival
(OS)[94]. In a separate study looking at patients undergoing chemotherapy with
Fluorouracil, Cisplatin and Streptozocin, elevated baseline CgA (above upper limit of
normal) was found to be a prognostic factor although was not predictive of
response[54].
1.6.1.3. CgA in Monitoring Response
Use of CgA as a predictive marker is more controversial. In a large study of 344
patients, an increase in CgA was associated with tumour progression and shorter
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survival in a heterogeneous group undergoing surveillance or treatment.[87] Nehar et al.
investigated serial measurements of CgA during the follow up of 42 patients.[83] A
concordance of 80% was found between rising CgA levels and progression (and
diminishing CgA levels and response) but the ‘change’ in levels of CgA was not
defined. In a study looking at CgA response to a variety of treatments, the authors
concluded that CgA changes corresponded to tumour response or progression but this
was only found in a subset of 10 out of 33 patients.[95] In a small series of 24
pancreatic NETs, although the authors concluded that levels of CgA correlated with
progression or response, neither response rates nor statistical analysis were
reported[96]. In another prospective study of octreotide long-acting release (LAR) in 40
patients with carcinoid syndrome, no correlation was found with response[89].
In one of the few prospective biomarker studies where a response was defined, CgA,
urinary 5-HIAA, and NSE were evaluated at unspecified intervals but only CgA was
assessed as a marker predicting response in a subgroup of 46 patients.[84] An arbitrary
change in >25% from baseline was significantly associated with response to a variety of
therapies in a heterogeneous NET sample but there was a 20% discordance. In a
subgroup analysis of the RADIANT-2 trial, of placebo and octreotide vs. everolimus
and octreotide, monthly serum CgA and urinary 5-HIAA were evaluated.[97] These
markers were considered elevated if above normal reference range. A biochemical
response was defined as a normalisation or >50% reduction. Patients on both treatments
had higher biochemical response rates than the single treatment arm (46% vs. 29%
CgA, 61% vs. 47% 5-HIAA) and greater reductions in both biomarker levels. Since
there was a better PFS in the double treatment arm, it was concluded that reductions in
these biomarkers correlate with response. In the phase II study of everolimus in
pancreatic NETs, an early reduction in CgA or NSE was associated with a longer PFS
compared to those without a reduction[98].
Twenty-two patients, in another study, who had cytoreductive surgery for
neuroendocrine hepatic metastases had CgA measure before and after surgery[99]. A
reduction of >80% in CgA was predictive of symptomatic and radiological response but
this was a small study.
Response to treatments apart from somatostatin analogues has also been studied. In a
study investigating the effect of FCiSt chemotherapy, neither CgA or CA19-9 was
found to be predictive of response but AFP was.[54] Desai et al. demonstrated that
changes (>20%) in plasma pancreastatin (derivative of CgA) before and 2-weeks after
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TACE corresponded with radiological response.[100] However, very few patients died
or progressed. CgA has also been shown to rapidly diminish or normalise after radical
resection of primary lesion and metastases.[101] Although this study had few cases
(n=7), median follow up was 36 months with recurrence or progression signified by a
progressive increase in CgA levels. CgA may also be useful in monitoring for
recurrence after ‘curative’ resection of midgut NETs with a sensitivity of 85-91%.[102,
103]
In addition to monitoring response in midgut and pancreatic NETs, there is some utility
of CgA (and gastrin) in monitoring response in phaeochromocytomas[104] and type I
gastric NETs[105].
To summarise, various retrospective and few prospective studies have investigated CgA
as a prognostic or a predictive marker with inconsistent results. This is not surprising as
some only include univariate analysis, some are small studies and are based on a
heterogeneous population undergoing many treatments. Additionally, cut-off levels or
definitions of ‘response’ or ‘change’ in CgA vary between studies and are often
arbitrarily chosen. The majority have explored the relationship of CgA with overall
survival and not progression-free survival.
Furthermore, pitfalls exist with measuring plasma CgA due to false-positive elevation in
impaired renal function,[106] steroid treatment,[107] chronic atrophic gastritis,[108]
and treatment with proton pump inhibitors (PPIs).[109] Additionally, there is no
recognised international standard for the CgA assay. Stridsberg et al. compared the
three commercially available assays and demonstrated sensitivities varying between
67% and 93% in NET patients[75]. To conclude, although adopted into clinical practice,
there is a need for properly designed prospective studies evaluating CgA as a
biomarker.
1.6.2. Chromogranin B
Chromogranin B (CgB) (also known as secretogranin I) is a protein of 76kDa and co-
localises with CgA in the secretory granules of NE cells. It is considered to have a role
in regulating secretion and is a major granin of the human adrenal medulla. There is a
scarcity of clinical studies incorporating CgB, possibly due to a lack of commercially
available assays, but preliminary studies have found patients with elevated plasma CgB
may have a worse prognosis than with elevated CgA[110]. Additionally, it may be a
more sensitive marker for phaeochromocytomas[111]. In patients with
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phaeochromocytoma, CgB concentrations in plasma correlated with the content in
tumour tissue and declined to normal levels after tumour resection[112].
1.6.3. Urinary 5-HIAA
Neuroendocrine tumours arising from the midgut may result in symptoms due to the
secretion of serotonin or other peptides i.e. carcinoid syndrome, signified by diarrhoea
and flushing. The urinary breakdown metabolite of serotonin is 5-hydroxyindole acetic
acid (5-HIAA) and is usually measured over a 24-hour collection. 24-hour urinary 5-
HIAA as a marker in NETs has not been investigated to the same extent as CgA.
The overall sensitivity and specificity of 5-HIAA in carcinoid syndrome is 70% and
90% respectively[113, 114] but it may be normal in non-metastatic midgut NETs.
1.6.3.1. Prognostic Value of 5-HIAA
A summary of retrospective studies evaluating 5-HIAA as a prognostic marker is shown
in Table 1.4. Urinary 5-HIAA levels of >20mmol/mol creatinine were found to be
associated with worse survival on univariate and multivariate analyses in a study of 76
patients with NETs.[115] However, in another retrospective study of 301 patients,
urinary 5-HIAA (dichotomised arbitrarily >300 μmol/24hours) was a prognostic factor
on univariate but not multivariate analysis[85].
In a retrospective study of a heterogeneous group of 314 patients with midgut NETs,
urinary 5-HIAA >250 μmol/24hours was associated with shorter median survival but
only univariate analysis was undertaken.[116] Interestingly in this study, levels of
urinary 5-HIAA diminished following resection of primary lesions despite liver
metastases. In an older study of 50 patients, elevated 5-HIAA above normal was a
prognostic factor on univariate analysis.[117] In a more recent national retrospective
study of 316 midgut NETs, increasing urinary 5-HIAA was prognostic for worse
survival on univariate but not multivariate analyses[91].
Raised baseline urinary 5-HIAA levels greater than 2 times the upper limit of normal
(corresponding to median) was a predictor of survival on both univariate and
multivariate analyses in a retrospective series of 119 metastatic midgut NETs[118].
In a retrospective study of a heterogeneous group of 139 midgut NETs, elevated urinary
5-HIAA, above normal reference range, correlated with extent of metastases and was
associated with poorer survival on univariate but not on multivariate analyses.[119]
48
PFS OSAuthor No.
Patients
5-HIAA
Cut-off Univ Multiv Univ Multiv
Van der Horst-
Schrivers[115]
76 20mmol/mol
creatinine
ND ND 3.33 1.007
Janson[85] 301 200umol/24h ND ND Y N
Hellman[116] 314 250umol/24h ND ND Y ND
Agranovich[117] 50 8mg/24h ND ND Y ND
Ahmed[91] 316 Unclear ND ND Y N
Formica[118] 119 2X ULN
(median)
ND ND 1.87 2.36
Turner[119] 139 42umol/24h ND ND Y N
Table 1.4 Summary of studies exploring prognostic value of urinary 5-HIAA. If prognostic, of PFS or
OS, hazard ratios shown else Y/N.ND=not done, Y=Yes, prognostic; N=No, not prognostic;
Univ=univariate analysis; Multiv=multivariate analysis; ULN upper limit of normal; PFS=progression-
free survival; OS=overall survival
1.6.3.2. Monitoring Response to Treatment
A subset on 52 patients were treated with somatostatin analogues in one study but
reduction in urinary 5-HIAA did not correlate with response to treatment[119].
The above prognostic studies were conducted in mixed populations undergoing various
treatments. However, on univariate analysis of patients undergoing trans-hepatic arterial
embolisation (TAE), over half of patients had a 50% reduction in 5-HIAA levels. A
correlation was found with survival and on multivariate analysis, percentage change in
5-HIAA was an independent predictor of survival.[68, 102]
In a more focussed study, 15 patients with midgut NETs, carcinoid syndrome and
progressive disease were treated with hepatic artery embolization (HAE) or
radiofrequency ablation of liver metastases.[120] Reduction in urinary 5-HIAA was
associated with a symptomatic response to treatment but sample size was small.
Somatostatin analogues, being the mainstay of therapy in GEP-NETs and in carcinoid
syndrome, have been demonstrated to reduce levels of urinary 5-HIAA and in some
cases this occurs alongside symptomatic improvement.[121, 122, 123]. In an open-label
study of prolonged release lanreotide (n=71), urinary 5-HIAA was useful in monitoring
response.[124] Reductions in urinary 5-HIAA were seen alongside symptomatic
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improvement but follow up was short. Although CgA correlated with survival and
quality of life in patients treated with somatostatin analogues, urinary 5-HIAA did
not.[88]
In one of the largest series (n=111) investigating treatment with interferon (75% midgut
NETs) demonstrated >50% reduction of urinary 5-HIAA in 42% of cases (termed a
biochemical response).[125] However, although implied, the relationship between this
reduction in markers and objective radiological response was not mentioned.
Since approximately 20% of patients with carcinoid syndrome have carcinoid heart
disease, 5-HIAA has been evaluated in this situation. Correlations have been
demonstrated between 5-HIAA and severity of carcinoid heart disease[126] and
between rising urinary 5-HIAA and progression of carcinoid heart disease.[127]
1.6.3.3. Surveillance
Reduced levels of 5-HIAA were seen after radical resection of primary lesion and
metastases in a small study.[101] However, unlike rising CgA indicating tumour
progression during post-operative surveillance, urinary 5-HIAA levels did not increase.
In surveillance following radical resection of midgut NETs, serial measurements are a
relative insensitive method to detect recurrence compared to plasma CgA (18% vs.
85%).[102]
1.6.3.4. 5-HIAA Overview
In summary, as with CgA, various retrospective and few prospective studies have
investigated 5-HIAA as a prognostic or a predictive marker and results are inconsistent.
Many studies only include univariate analysis while others have studied heterogeneous
populations undergoing numerous treatments. Cut-off levels or definitions of ‘response’
or ‘change’ in 5-HIAA vary between studies, often arbitrarily chosen.
The measurement of 5-HIAA is also subject to confounding factors including
compliance with 24-hour urine collection. Patients are required to adhere to a strict diet
for 3 days prior to collection. This is as a result of tryptophan-rich foods including
plums, pineapples, bananas, aubergines, tomatoes, avocados, and walnuts increasing
urinary levels. Additionally, certain drugs increase levels e.g. acetanilide, phenacetin,
glyceryl guaiacolate (found in cough syrups), cisplatin, fluorouracil (used in NET
treatment), and melphalan. Other medications may reduce levels including
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chlorpromazine, heparin, tricyclic antidepressants, levodopa, monoamine oxidase
inhibitors, and promethazine.
False negative results occur in renal impairment and dialysis. Falsely raised levels occur
in malabsorption of coeliac disease, tropical sprue, Whipple’s disease, and cystic
fibrosis where increased tryptophan metabolites are encountered in urine.
This has led to the European Neuroendocrine Tumour Society (ENETS) guidelines
stating that urinary 5-HIAA is not a consistently reliable prognostic factor in this
disease[128].
1.6.4. Other Markers
In a large retrospective series, elevated α-fetoprotein and human chorionic
gonadotropin-β were found to be associated with worse overall survival but only 10-
12% of patients had elevated levels.[129] Interestingly, these also correlated with CgA.
Turner et al. demonstrated neurokinin A (NKA) correlated with extent of metastatic
disease and was independently prognostic of survival.[119] Reduction in levels also
correlated with response to treatment with somatostatin analogues.
Fasting gut hormones have a role as diagnostic markers in functioning pancreatic NETs
as shown in Table 1.2. Their role as prognostic or predictive markers is unclear. Levels
of gastrin reduced significantly after resection of gastrinomas but there was a low
sensitivity and specificity of detecting tumour progression or stabilisation[130]. Using
vasoactive intestinal peptide (VIP) to monitor response to therapy is limited to case
reports and series[131]. There is evidence to suggest Calcitonin is useful in medullary
thyroid cancer. Persistently elevated calcitonin after thyroidectomy can signify residual
disease[132]. The probability of local or distant metastases is strongly related to
calcitonin levels; patients with calcitonin levels >150 ng/L, systemic imaging of the
thorax, liver and bones is indicated, and the probability of detecting distant metastases
increases as the calcitonin levels increase[133].
Neurone specific enolase (NSE) has been mentioned above but it is less sensitive than
CgA (sensitivity less than 40% in NETs)[86] and subgroup analysis has suggested a
relationship to survival but not as a marker predictive of response[84, 92].
Markers of angiogenesis in serum such as angiopoietin-2 have been found to elevated in
NETs compared to controls and also associated with reduced time-to-progression[134,
135].
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Screening of carcinoid heart disease (CHD) in patients with midgut NETs has been
revolutionised by use of circulating N-terminal pro-brain natriuretic peptide (NT-pro-
BNP)[136] although this is not a NET-specific marker and is utilised in left sided
cardiac failure. Using NT-pro-BNP as a screening marker compared to regular
echocardiography, the number of patients needed to diagnose one case of CHD reduced
from 5.1 to 1.4 with elevated levels in those with CHD.
Novel markers are being discovered by new techniques. Gene expression profile
analysis has suggested paraneoplastic antigen Ma2 autoantibody as such a marker and
this has been validated as a marker of PFS and recurrence-free survival, albeit in a small
study of 36 patients[137, 138]. Proteomic analysis of secretomes of cell lines have
revealed Mac-2-binding protein (MAC-2BP) as another marker. Using ELISA, serum
levels are increased compared to controls[139]. Finally, using real-time polymerase
chain reaction (rtPCR), circulating mRNA of certain transcripts have been found to be
elevated in some NETs[140].
1.6.5. Statement on Circulating Biomarkers
In conclusion, CgA is currently the best circulating marker in NETs but there are other
promising markers in development. However, these need proper validation in large
prospective studies with agreed and defined cut-off levels together with standardised
methods of assay measurement.
1.7. Histopathological Markers
Neuroendocrine cells are characterised by uniform nuclei and clear granular cytoplasm.
Originally, to assist in characterisation of NETs, silver staining was used (hence the
term, ‘Argentaffinoma’) but immunohistochemistry superseded this using specific
antibodies to relevant cellular products. Several general neuroendocrine markers are
used to identify NETs including chromogranin A (CgA), neurone specific enolase
(NSE), synaptophysin and protein-gene product 9.5 (PGP9.5). Immunohistochemical
staining is used to identify the peptides and biogenic amines produced by the NET cells
specific to the tumour type such as serotonin or insulin. None of these have been shown
to have prognostic value.
Historically, GEP-NETs were separated into well differentiated and poorly
differentiated, according to the degree to which the neoplastic cells resemble their
normal cell phenotype. Well-differentiated NETs have nesting, trabecular or gyriform
patterns of tumour cells, and produce neurosecretory granules with strong expression of
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neuroendocrine markers such as Chromogranin A and synaptophysin on
immunohistochemistry. Poorly differentiated NETs often lose expression of
neuroendocrine immunohistochemical markers and have a much worse outcome.[141,
142]
The ‘grade’ of a NET refers to the biological aggressiveness of the tumour.
Classifications of low- versus high-grade tumours have not been uniformly based on
consistent pathologic characteristics but high-grade tumours often have worse
outcomes. Some authors have utilised presence of necrosis, atypia, mitotic count[14, 90,
143] and others focussed on Ki-67 proliferation index[23, 24].
Several authors including the European Neuroendocrine Tumour Society (ENETS) have
suggested a 3-tiered prognostic grading system for GEP-NETs based on similar tiered
classification systems of bronchial and thymic NETs that correlate with survival [143,
144] These systems, assign grade by evaluation of certain pathological markers. Ki-67
proliferation index, using immunohistochemistry with the MIB-1 antibody, and
counting cells undergoing mitosis are routinely used to classify NETs as low,
intermediate and high grades[26].
The use of Ki67 and mitotic count as prognostic markers have mainly been evaluated
retrospectively on NET specimens but these 3-tiered grading systems have been adopted
into clinical practice to aid clinical decision making. Ki-67 and mitotic counts as
prognostic markers are discussed further in chapter 2.
Several studies have investigated the prognostic and predictive utility of expression of
novel markers on NET tissue. Akt, p53, human mutL homolog 1 (hMLH1), and
hypoxia-inducible factor-1 (HIF-1) were associated with overall survival on tissue prior
to chemotherapy and Akt, hLMH1, phosphatase and tensin homolog (PTEN),
thymidylate synthase (TS) and CA9 correlated with treatment response.[145]
Downstream targets of the mTOR pathway have been shown to be associated with
poorer survival including overexpression of p-S6K with strong expression of mTOR
associated with higher proliferative capacity.[146]
1.8. Rationale for Studying Biomarkers in NETs
There is an unmet need for validated biomarkers for use in clinical practice using
translational research methods. The disease course is frequently long and choice of
treatments may be informed by historical information from a diagnostic biopsy.
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Circulating biomarkers could provide real-time information on the biology of the
tumour that can be repeated at several time-points throughout the disease. This would
also have the advantage over tumour biopsies as repeated blood tests are more
acceptable to patients than repeated biopsies and may be more representative of current
tumour biology. Furthermore, progress of clinical trials in NETs tends to be slow due to
prolonged survival endpoints compared to other cancers and a surrogate marker of
survival would help development of new therapies.
1.9. Novel Biomarkers
Traditionally, biomarkers in cancer and other disease has been limited to circulating
peptides and amines and histological markers on archival tissue. However, there is
increasing research into tumour-derived cells and nucleic acids in the circulation which
may better reflect tumour biology. Hundreds of biomarkers have shown initial promise
yet have often yielded inconsistent conclusions or contradictory long-term studies[147].
1.9.1. Circulating Tumour Cells
Circulating Tumour Cells (CTCs) were first described in a patient with cancer by
Ashworth in the nineteenth century where cells were found in peripheral blood similar
to that of cells of the tumour[148]. The general model of the metastatic process is
tumour growth, angiogenesis, epithelial to mesenchymal transition, local invasion,
active intravasation, dissemination, circulating in the blood (CTC), attraction to specific
organs, active extravasation, mesenchymal to epithelial transition and
proliferation[149]. Thus, CTCs represent a great opportunity to investigate this process
with access from a simple blood test. They have been detected at very low
concentrations at a ratio of approximately 1:109 normal peripheral blood cells and it is
only relatively recently that technological advances have enabled their isolation and
enumeration.
Techniques to detect CTCs are required to be highly sensitive, specific and
reproducible. To date, several methods have been used including
immunocytochemistry, reverse-transcription-PCR (RT-PCR), PCR, and flow
cytometry[150, 151]. However, the majority of studies have utilised immunomagnetic
separation where CTCs are captured by magnetic beads coated with antibodies typically
against carcinoma antigens. The carcinoma antigen which has been commonly
employed is Epithelial Cell Adhesion Molecule (EpCAM), a common antigen in
epithelial cancers[152].
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Immunomagnetic separation using EpCAM is the principle behind CTC enrichment by
the CellSearch™ System[153]. This is a semi-automated platform that uses which
captures CTCs and with a separate staining system enables microscopic identification
and enumeration. Its high sensitivity, specificity, and reproducibility led to it being
approved by the Food and Drug Administration (FDA) to monitor metastatic breast,
colorectal and prostate cancers. Using this system, CTCs have been validated as
prognostic and predictive markers in these cancers[154, 155].
Despite a significant proportion of NETs being diagnosed with advanced disease, CTCs
have not been demonstrated in NETs and the systematic analysis of EpCAM expression
in NETs has not been performed to date.
1.9.2. Circulating Nucleic Acids
Cell-free DNA (cfDNA) is defined as extracellular DNA found in the circulation of
patients with cancer and other disease, in either plasma or serum. There is increasing
interest in the utility of cfDNA as a diagnostic, prognostic and predictive marker. In
major cancers, levels of cfDNA are higher than in healthy subjects with changes in
quantity of cfDNA after treatment correlating with response[156, 157].
cfDNA, originating from tumour cells, has the advantage of carrying genetic alterations
from the primary tumour, some of which may be tumorigenic. Thus mutations in
tumour suppressor genes or oncogenes can be detected in blood with levels having a
prognostic value and in some cases, value in predicting response to therapy[158].
Epigenetic phenomenon have also been studied in cfDNA with some aberrant
methylation of tumour suppressor promoter regions found in serum or plasma as well as
in tumour tissue[159]. Tumour derived cfDNA, therefore, has great potential and
versatility as a biomarker. However, cfDNA has not yet been demonstrated in NETs.
1.9.3. Circulating Endothelial Cells
Circulating endothelial cells (CECs) have been found to be increased in the peripheral
blood of patients in a number of diseases e.g. sickle cell anaemia[160], myocardial
infarction[161], and endotoxaemia[162]. Since angiogeneisis and co-option of pre-
existing blood vessels are important steps in cancer progression and metastasis[163], it
has been hypothesised that CECs may have a role to play in these processes.
New blood vessels are formed by endothelial cells derived from the tumour
microenvironment and it has also been shown that bone-marrow derived endothelial
55
progenitor cells mobilised by tumour signals may contribute to vasculogenesis[164].
The main surface marker used to detect CECs by immunomagnetic separation or by
fluorescence-activated cell sorting (FACS) is CD146.
CECs are increased in a number of cancers compared to healthy subjects and may be
associated with progressive disease[165]. Furthermore, numbers of CECs are affected
by treatment and may be useful as a predictive marker[166]. Neuroendocrine tumours
are considered to be hypervascular tumours but it is not known whether CECs are
detectable in NETs.
1.10. Aims of This Thesis
Currently, tumour grade provides the best method of defining prognosis and is used in
clinical practice routinely, adopted into international guidelines. My first aim (chapter
2) was to assess whether the current methods of assigning tumour grade with either Ki-
67 or mitotic count were comparable and of equal prognostic value. Additionally, I
define new thresholds for Ki-67 proliferation index which provide better prognostic
value than current grading thresholds.
Given that tumour grade can be based on a small biopsy specimen which may have been
taken years before a treatment decision needs to be made, and with the lack of
prospectively validated biomarkers, I went on to explore the novel biomarkers in
patients with NETs.
In chapter 3, I investigated whether NETs express EpCAM and hence, whether
CTCs can be identified in the blood of patients with CTCs. Once identified, I
investigated CTCs as prognostic biomarkers in chapter 4. I also studied CTCs as
predictive biomarkers, monitoring response to therapy.
With traditional circulating biomarkers in NETs based on detection of peptides and
amines, my aim in chapter 5 was to determine whether another form of circulating
biomarker, cfDNA, is detectable in blood of patients with NETs. This would be the first
step in determining whether NET DNA is detectable in blood, and whether it has any
prognostic value as a biomarker. Since some authors suggest circulating nucleic acids
are a surrogate marker of CTCs, I also explored this association.
Lastly, with the prior chapters dealing with non-peptide circulating biomarkers derived
from the tumour itself, I focussed on CECs. Since NETs are though to be hypervascular
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with anti-angiogenic agents, including Sunitinib, having proven clinical effect, I
determined whether CECs are detectable and of prognostic use in NETs in chapter 6.
This thesis thus defines new thresholds utilising Ki67 proliferation index for NETs as
well as demonstrating how CTCs can be utilised for prognostication and potentially for
understanding the native tumour in an individual.
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Chapter 2. Grading of NETs using Ki-67 Proliferation
Index and Mitotic Count
2.1. Introduction
As discussed earlier, histopathological markers previously studied in NETs and used
clinically include mitotic count and Ki-67 proliferation index. Gastroenteropancreatic
(GEP)-NETs are largely indolent low-grade neoplasms with few aggressive cancers.
Originally, GEP-NETs were separated into well-differentiated and poorly-differentiated
tumours. Whether some well differentiated NETs behave as high grade tumours is
controversial[167] but generally poorly differentiated NETs behave like high grade
tumours.
Classifications of low- versus high-grade tumours have not been uniformly based on
histological characteristics. Some authors have used presence of necrosis, atypia,
mitotic count and others focus on Ki-67 proliferation index.
The Ki-67 nuclear protein is one of several cell-cycle-regulating proteins, most
commonly demonstrated by immunohistochemistry with the mouse anti-human
monoclonal MIB-1 antibody[168]. Ki-67 is a DNA-binding protein that is expressed in
all phases of the cell-cycle except in G0 and is widely used to assess tumour
proliferation[169]. Despite numerous studies as a prognostic biomarker, its exact
function is yet to be elucidated.
Some authors question the use of Ki-67 proliferation index as an independent
prognostic indicator[170]. The controversy of Ki-67 is not limited to NETs;
proliferative markers have been used particularly in breast and prostate cancers.
Similar to NETs, there are a number of treatments available for prostate cancer with a
proportion of cancers just requiring surveillance where mitoses are not frequently
seen[171]. In a large study from the Trans-Atlantic Prostate Group (n=693), Ki-67
staining was a significant negative prognostic factor of survival on multivariate analysis
in conservatively treated patients[172]. Interestingly, prognostication based on crude
(semi-quantitative) estimation of Ki-67 proliferation index by a histopathologist was not
inferior to formal quantitative assessment which could save arduous counting of cells.
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In breast cancer, Ki-67 has become the most widely used method for comparing
proliferation between tumour samples. Although studies suggest Ki-67 is a prognostic
marker in breast cancer, cut-off thresholds vary considerably[173]. Recently, a
consensus group was convened by co-chairs of the Breast International Group and
North American Breast Cancer Group Biomarker Working Party[174]. They
recognised, similarly to NETs, that many studies validating Ki-67 are retrospective with
heterogeneous groups of patients treated by many methods. They were unable to
suggest thresholds despite staining levels of 10-20% being the most common used to
dichotomise populations but concluded that Ki-67 is the most robust prognostic
immunohistochemical marker. In addition to a prognostic marker in breast cancer, it has
been studied as a predictive marker[175], and as an endpoint for suppression of
proliferation in clinical trials of neoadjuvant endocrine therapy[176].
Advantages of Ki-67 include the ability of most histopathology departments to perform
immunohistochemistry on small quantities of paraffin-embedded tissue with verifiable
control tissue.
Similarly, the prognostic value of mitotic counts is well established in breast cancer. In
a series of 364 patients with invasive ductal breast cancer, mitotic activity was
expressed per 10 hpfs and optimal thresholds (13 and 35 mitoses per 10hpf) for a three-
tiered grading system were evaluated, clearly distinguishing prognostic groups based on
survival[177].
Where tumour tissue is limited it may not be possible to perform an accurate mitotic
count and in these cases, Ki-67 may provide a more accurate proliferative index. The
NANETS guidelines still suggest that where adequate tissue is available, Ki-67 provides
no additional information.
In breast cancer, investigators have incorporated Ki-67 into a panel of
immunohistochemistry biomarkers to produce an prognostic algorithm[178]. However,
the single measurement of mitotic activity was superior to a complex prognostication
program[179]. Predictive models have been suggested in NETs but have not been
systematically clinically validated[180].
Several authors have suggested a three-tiered grading system for GEP-NETs based on
similar tiered classification systems of bronchial and thymic NETs that correlate with
survival[143, 144]. In each system, the low and intermediate grades are related closely
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with distinction made by proliferative rate or necrosis[26]. The criteria that define each
category are not, however, perfectly matched between each proposed system.
The intermediate grade prognostic category is supported by various studies. Tomassetti
et al found that a Ki-67 >2.6% was a negative prognostic factor in well-differentiated
ileal NETs[181]. Various other groups also found that a cut-off of approximately 2%
stratified different prognostic groups in pancreatic and midgut NETs[182, 183, 184].
Prior to these studies, subdividing well-differentiated NETs into low and intermediate
grade based on mitotic count was also suggested[185, 186].
Other studies did not find low and intermediate grade subdividing of well-differentiated
NETs to be prognostic. Durante looked at numerous candidate pathological factors but
did not find a grading system (with intermediate grade Ki-67 of 2-10%) to be prognostic
in 215 metastatic GEP-NETs[187].
However, it is difficult to compare these studies as they are mixture of retrospective and
prospective series in heterogeneous populations with heterogeneous treatments.
The European Neuroendocrine Tumour Society (ENETS) have proposed a 3-tiered
grading system for foregut, midgut and hindgut NETs based on findings by Rindi et
al[23, 24]. This classifies NETs into low (G1), intermediate (G2) and high (G3) grade
tumours according to Ki-67 ‘and/or’ mitotic count as detailed in Table 2.1. There has
been inconsistency between a number of different grading/ staging systems and
guidelines throughout the history of NETs with but the major guidelines have all been
updated recently and are more comparable than with previous versions.
Grade Ki-67 (%) Mitoses per 10 hpf
G1 ≤2 <2
G2 3-20 2-20
G3 >20 >20
Table 2.1 Grading of NETs as proposed by ENETS[23]. Hpf = high power fields
In 2009, the AJCC/UICC (American Joint Committee on Cancer/ Union for
International Cancer Control) introduced TNM staging of gastrointestinal and
pancreatic NETs which differ in several aspects from the ENETS guidelines[188]. High
grade NETs are not included and there are differences in the primary tumour
classification (T of TNM) for pancreatic and appendiceal NETs, a discrepancy studied
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specifically by Liszka et al[189]. The guidelines do concede that Ki-67 is a useful
prognostic marker. In 2010, the North American Neuroendocrine Tumours Society
(NANETS) provided guidelines for clinical management and refer to diagnosis by either
ENETS and AJCC/UICC systems but states that it should be indicated which is
used[170, 190, 191, 192, 193].
The recent 2010 WHO guidelines suggest the AJCC/UICC system should be used but
briefly mentions the ENETS TNM system and for the first time, a grading system that
resembles that suggested by ENETS based on Ki-67 or mitotic count[26].
The 3-tiered grading systems have been adopted into clinical practice to aid clinical
decision-making. The ENETs proposal implies that there is a clear agreement between
grade according to Ki-67 index and grade according to mitotic count based on the above
cut-off values. Definitive data do not exist to determine whether this assumption is
correct or whether the cut-off values used to distinguish the 3 grades are optimal.
Strosberg et al found complete agreement (apart from one isolated case) between
grading according to a 2-tiered system based on Ki-67 above and below 20% and
mitotic count above and below 10 mitoses per 10 HPF[194]. Although this was a study
of 83 GEP-NETs, a proportion were hindgut NETs and the categories were not the same
as the 3-tiered system proposed by ENETs which has been adopted into routine practice
throughout Europe.
To date, there has been no study systematically investigating the agreement between Ki-
67 and mitotic count when using the ENETS grading system. I therefore investigated
the agreement between grade according to Ki-67 index and grade according to mitotic
count per 10 HPF at the time of diagnosis in midgut and pancreatic NETs. Additionally,
I explored the prognostic value of each in terms of progression-free and overall survival
in order to assess the validity of the 3-tiered classification.
This analysis provides a comparator for the assessment of novel biomarkers such as
circulating tumour cells (CTCs) discussed in subsequent chapters.
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2.2. Materials and Methods
2.2.1. Clinical Specimens
Prior to investigating a new biomarker, I wished to assess the clinical validity of these
established biomarkers and grading system which have been internationally adopted. I
have obtained Ki-67 immunohistochemical analyses on NET specimens as well as
mitotic counts per 10 HPF as part of routine pathological evaluation.
Patients with metastatic gastroenteropancreatic NETs diagnosed between January 1989
and October 2009 were identified from a database at the Neuroendocrine Tumour Unit,
Royal Free Hospital. Patients were diagnosed as having a NET morphologically and
immunohistochemically with presence of metastatic disease measurable by RECIST
1.1[41]. Diagnostic tissue from either biopsy or surgical specimen prior to
commencement of treatment had been fixed in formalin, then processed and embedded
in paraffin. Sections were reviewed by a pathologist with expertise in NETs to establish
diagnosis, degree of differentiation (well or poorly differentiated) and mitotic count. On
light microscopy, mitotic figures (per 10 high power fields (HPF)) were evaluated in at
least 40 fields of highest mitotic activity.
2.2.2. Immunohistochemistry
Sections from tumours were submitted for immunohistochemical examination to
evaluate Ki-67 proliferation index. Three micrometer sections of tumour tissue were
deparaffinised in xylene and rehydrated in graded alcohols. Endogenous peroxidase was
blocked with 0.5% H2O2 in methanol for 10 minutes. Thereafter, sections were
subjected to 3 minute pressure cooking heat-mediated antigen retrieval (HMAR).
Immunohistochemical staining was performed with the NovoLink™ Polymer detection
system (Novocastra, Newcastle-upon-Tyne, UK). Sections were incubated with MIB-1
antibody detecting Ki-67 (DAKO, Cambridgeshire, UK) at a dilution of 1:200 for 1
hour at room temperature, post-primary block for 30 minutes, followed by Novolink™
polymer for 30 minutes. Reaction products were visualised with application of
diaminobenzidine substrate chromogen solution. Slides were counterstained in
haematoxylin and mounted.
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2.2.3. Assessing Ki-67 Proliferation Index
The Ki-67 proliferation index was determined by assessing the percentage of positively
staining tumour cell nuclei in 2000 neoplastic cells in areas with highest degree of
nuclear labelling where possible.
2.2.4. Assigning Grade
Histological grading was assigned to each case according to TNM classification
proposed by the European Neuroendocrine Tumours Society (ENETS) [23, 24]. Low-
grade (G1) NETs were defined by a Ki-67 index of 2% or less, or a mitotic count of less
than 2 per 10 HPF; intermediate-grade (G2) by Ki-67 between 3 and 20%, or a mitotic
count between 2 and 20 per 10 HPF; and high-grade (G3) by Ki-67 greater than 20%, or
a mitotic count greater than 20 per 10 HPF (Table 2.1). Each case was assigned two
grades, one grade according to Ki-67 proliferation index and one grade according
mitotic count.
Cases were then reclassified into grades with alternative cut-offs, firstly defined by
tertiles, and then into Ki-67 thresholds suggested by Scarpa et al.[29] G1:1-5%, G2:6-
20%, and G3: >20%. These alternative classifications were analysed similarly to
existing classifications.
2.2.5. Interobserver Reliability
To assess reliability, 44 H&E stained sections (for mitotic count) and 44 Ki-67 stained
sections (for Ki-67 proliferation index) were reviewed by a second independent expert
pathologist blind to the initial assessments. Sections were chosen to distribute low and
intermediate grades evenly with a small proportion of high grade sections, reflecting
clinical practice. Mitotic count and Ki-67 were assessed as above. Grade was assigned
using both indices.
2.2.6. Clinical Data
Pre-treatment biochemical data obtained at the time of diagnosis included plasma
Chromogranin A (CgA), and for midgut NETs, 24-hour urinary 5-hydroxy-indoleacetic
acid (5-HIAA).
Patients underwent CT or MRI scans to monitor for disease progression. Imaging was
interpreted by an independent radiologist using RECIST criteria. Progression-free
survival (PFS) was recorded as the time from diagnosis to radiological disease
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progression or death. Overall survival (OS) was recorded as the time from diagnosis to
the patient’s death.
2.2.7. Statistical Analysis
Statistical analyses were performed using SPSS for Windows (SPSS Inc., Chicago, IL)
where P values of <0.05 were considered significant. Pancreatic and midgut NETs were
analysed separately. Correlation between grades assigned by Ki-67 and mitotic count
was assessed using non-parametric correlation. Agreement between grades was assessed
with weighted kappas (κW) with significance of values stated in Table 2.2.
Interobserver reliability was assessed using weighted kappas. Since CgA was not
normally distributed (even when transformed onto a logarithmic scale) this was
analysed in two groups: above and below twice the upper limit of normal (120
pmol/L)[92].
Weighted Kappa (κW) Agreement
0-0.2 Poor
0.21-0.4 Fair
0.41-0.6 Moderate
0.61-0.8 Good
0.81-1.00 Very good
Table 2.2 Significance of weighted kappas as a measure of
agreement between categorical variables
Survival was estimated using Kaplan-Meier methodology stratified by both grading
systems and differences in survival between groups analysed by log-rank testing. I
explored potential markers that were prognostic in terms of PFS or OS. Grading
assigned by either index were analysed as categorical variables. Since CgA was not
normally distributed (even when transformed onto a logarithmic scale) this was
analysed in two groups: above and below 2 times the upper limit of normal (120
pmol/L)[92].Urinary 5-HIAA was analysed in two groups: above and below the
median[118]. Cox-proportional hazards regression analysis was used to obtain
univariate and multivariate hazard ratios for PFS or OS.
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2.3. Results
2.3.1. Patient Characteristics
A total of 285 cases of GEP-NETs, 144 (51%) with primary tumour site in the pancreas,
141 (49%) of midgut origin were identified. 131 and 136 of these, respectively, had
complete data and were included in the analysis. Patient characteristics are shown in
Table 2.3.
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Primary Site Pancreatic Midgut Total
Number 131 136 267
Age at Diagnosis
median years (range) 51.5 (21-81) 56 (22-84) 54 (21-84)
Gender
Male
Female
65
66
70
66
135
132
Grade according to Ki-67
Low
Intermediate
High
34
68
29
68
58
10
102
126
39
Grade according to Mitotic
Count
Low
Intermediate
High
65
55
11
84
50
2
149
105
13
Chromogranin A in pmol/L
≤120
>120
90
41
68
68
158
109
Urinary 5-HIAA (µmol/24hr)
≤96
>96
Missing
-
-
-
61
60
15
-
-
-
Subsequent Therapy
None
Surgical resection
Chemotherapy
Somatostatin analogues
Interferon
Radiofrequency ablation
Embolisation
Radionuclides
1
49
78
33
5
2
6
14
5
70
28
84
3
1
10
40
6
119
106
118
8
3
16
54
Table 2.3 Background characteristics of patient group
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2.3.2. Inter-observer Agreement
44 cases (22 pancreatic and 22 midgut NET) had both H&E and Ki-67 stained sections
evaluated by a second expert pathologist. Inter-observer reliability was assessed
between the grade assigned (according to ENETS) according to both indices, rather than
the absolute mitotic counts or Ki-67 index. The matrix of this grading agreement is
shown in Table 2.4 and Table 2.5.
The weighted kappa for agreement on grade assigned by mitotic count was 0.83 (95%
CI 0.68-0.99). The weighted kappa for agreement on grade assigned by Ki-67 was
slightly higher at 0.87 (95% CI 0.74-1.00). Although not perfect agreement, both these
signify very good agreement. The four disagreements were between G1 and G2.
Observer B
G1 G2 G3
G1 21 4 0 25
G2 0 18 0 18
O
bs
er
ve
r
A
G3 0 0 1 1
21 22 1 44
Table 2.4 Interobserver Agreement of Grade Assigned by Mitotic Count
Observer B
G1 G2 G3
G1 17 3 0 20
G2 1 18 0 19
O
bs
er
ve
r
A
G3 0 0 5 5
18 21 5 44
Table 2.5 Interobserver Agreement of Grade Assigned by Ki-67 Proliferation Index
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2.3.3. Agreement Between Grading According to Ki-67 Proliferation Index
and Mitotic Count
Of 267 cases, 242 were well differentiated and 25 poorly differentiated NETs. Of the 21
pancreatic NETs that were poorly differentiated, one was graded as G2 and 20 as G3
according to Ki-67; one G1, 11 G2, and 9 G3 according to mitotic count. Four midgut
NETs were considered to be poorly differentiated. These were all designated as G3
according to Ki-67 and all as G2 according to mitotic count.
There was a moderate (approaching strong) correlation between absolute Ki-67 index
and mitotic counts (ρ=0.65 P<0.001 for pancreatic and ρ=0.59 P<0.001 for midgut
NETs) (Figure 2.1). There was agreement between grade assigned by Ki-67 and grade
assigned by mitotic count in 74 of 131 (56%) pancreatic NET cases; and in 84 of 136
(62%) of midgut NETs (Table 2.6 and Table 2.7 respectively). Thus there was a
discordance of 44% and 38% respectively when assigning grade using Ki-67 or mitotic
count. This corresponded with weighted kappas of 0.41 (95% CI 0.30-0.53) and 0.35
(95% CI 0.22-0.48) respectively (moderate and fair agreement respectively).
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Figure 2.1 Correlation between Ki-67 and Mitotic Counts in A Pancreatic NETs B Midgut NETs
P<0.001***
ρ= 0.65
P<0.001***
ρ = 0.59
Line of best fit
Line of best fit
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PANCREATIC Grade according to mitoticcount/10HPF
G1 G2 G3
G1 29 5 0 34
G2 34 34 0 68
Grade
according to
Ki-67
G3 2 16 11 29
65 55 11 131
Table 2.6 Agreement between grade assigned by Ki-67 and mitotic counts for pancreatic NETs
(agreement in 74/131 cases)
MIDGUT Grade according to mitoticcount/10HPF
G1 G2 G3
G1 55 13 0 68
G2 29 28 1 58
Grade
according to
Ki-67
G3 0 9 1 10
84 50 2 136
Table 2.7 Agreement between grade assigned by Ki-67 and mitotic counts for midgut NETs (agreement
in 84/136 cases)
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2.3.4. Survival
Patients were followed up for a median of 46 months (pancreatic) and 42 months
(midgut).
For pancreatic NETs, median PFS was 33 months and median OS 84 months. For
midgut NETs, median PFS was 42 months, median OS 82 months. 1-, 3-, 5-, and 10-
year survival data is shown in Table 2.8.
Pancreatic 1Yr (%) 3Yr (%) 5Yr (%) 10Yr (%)
PFS 76.9 44.8 29.3 13.4
OS 89.6 78.6 58.8 35.8
Midgut 1Yr (%) 3Yr (%) 5Yr (%) 10Yr (%)
PFS 85.4 57.5 37.3 14
OS 92.7 73.8 61.3 36.4
Table 2.8 PFS and OS for Pancreatic and Midgut NETs
The three-tiered grading systems according to either Ki-67 or mitotic counts were able
to distinguish significantly different groups prognostically in pancreatic NETs (Figure
2.2). There was some overlap of Kaplan-Meier curves, however, between G1 and G2 in
estimating OS using mitotic count.
When analysing midgut NETs, however, only grade according to Ki-67 was able to
distinguish the 3-tiered prognostically different groups in terms of PFS and OS (Figure
2.3). Grade according to mitotic count was not able to distinguish G1 from G2 in terms
of OS or PFS.
On multivariate analysis, there was evidence to suggest that a higher grade according to
Ki-67 was a independent prognostic indicator of both PFS and OS in both pancreatic
and midgut NETs (Table 2.9 and Table 2.10 respectively). Grade according to mitotic
count, however, was found not to be prognostic. CgA above 120 was significantly
associated with worse OS in pancreatic NETs only.
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Figure 2.2 Survival curves for PFS and OS of pancreatic NETs using grade according to Ki-67 (A and B) or grade according
to mitotic count (C and D); blue (G1), green (G2), red (G3)
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Figure 2.3 Survival curves for PFS and OS of midgut NETs using grade according to Ki-67 (A and B) or grade according to
mitotic count (C and D); blue (G1), green (G2), red (G3)
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Risk Factor PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Differentiation
Well
Poorly
1.00
1.026 (0.68-1.56) 0.906
1.00
1.237 (0.79-1.95) 0.359
CgA
CgA≤120
CgA>120
1.00
1.662 (0.97-2.84) 0.062
1.00
2.66 (1.42-4.99) 0.002
Grade (Ki67)
1
2
3
1.00
2.37 (1.22-4.62)
7.21 (2.55-20.4)
0.011
<0.001
1.00
2.24 (0.75-6.75)
9.84 (2.48-39.04)
0.151
0.001
Grade (mito)
1
2
3
1.00
1.35 (0.81-2.24)
1.66 (0.97-2.84)
0.253
0.099
1.00
0.914 (0.46-1.81)
1.19 (0.39-3.64)
0.795
0.764
Table 2.9 Multivariate analyses of independent prognostic factors for Pancreatic NETs
Risk Factor PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Differentiation
Well
Poorly
1.00
1.84 (0.73-4.62) 0.194
1.00
0.82 (0.33-2.05) 0.675
CgA
CgA≤120
CgA>120
1.00
1.55 (0.8-3.02) 0.451
1.00
1.37 (0.61-3.09) 0.45
Urinary 5-HIAA
5HIAA≤96
5HIAA>96
1.00
0.81 (0.43-1.54) 0.522
1.00
1.69 (0.73-3.92) 0.22
Grade (Ki67)
1
2
3
1.00
2.87 (1.67-4.92)
11.74 (3.61-38.3)
<0.001
<0.001
1.00
2.25 (1.1-4.59)
27.13 (7.07-104)
0.025
<0.001
Grade (mito)
1
2
3
1.00
0.735 (0.43-1.27)
0.989 (0.1-9.95)
0.271
0.993
1.00
0.676 (0.33-1.37)
0.719 (0.06-8.04)
0.278
0.789
Table 2.10 Multivariate analyses of independent prognostic factors for midgut NETs
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2.3.5. Alternative Thresholds for Grade Classification (according to
tertiles)
Tumour grades were reassigned using alternative cut-offs, designated by tertiles. For
pancreatic NETs, this was:
 G1: mitotic count 0-1/10 high power fields (hpf) or Ki-67<5%
 G2: mitotic count 2-3/10 hpf or Ki-67 5-15%
 G3: mitotic count >3/10hpf or Ki-67>15%
For midgut NETs, this was:
 G1: mitotic count 0-1/10hpf or Ki-67<3%
 G2: mitotic count 2-3/10hpf or Ki-67 3-5%
 G3: mitotic count >3/10hpf or Ki-67>5%
Agreement between grades assigned by these new thresholds are shown in Table 2.11
and Table 2.12. Weighted kappas were 0.66 (good agreement) in pancreatic NETs and
0.38 (fair agreement) in midgut NETs. This is slightly better agreement than with the
ENETS guidelines. An inevitable consequence of making the G2 Ki-67 threshold higher
is that many more cases are G1 using Ki-67 but still G2 using mitotic count.
Univariate analyses with survival curves for this new grading classification are shown
in Figure 2.4 for pancreatic NETs and Figure 2.5 for midgut NETs. For both pancreatic
and midgut NETs, Ki-67 was able to distinguish three different prognostic groups better
than with mitotic count where there was overlapping with survival curves. Although this
was a similar result to that when using the ENETS thresholds, the G2 curve appears
closer to G3 with these new thresholds.
Mutlivariate analyses are shown in Table 2.13 and Table 2.14 respectively which
confirms Ki-67 as an independent prognostic marker. Hazard ratios for grade using Ki-
67 were lower using tertiles compared to the ENETS thresholds. This suggests that
these new thresholds are not as good as original ENETS thresholds.
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PANCREATIC Grade according to mitoticcount/10HPF
G1 G2 G3
G1 37 30 2 69
G2 5 14 8 27
Grade
according to
Ki-67
G3 1 9 29 39
43 53 39 135
Table 2.11 Agreement between grades assigned according mitotic count and Ki-67 but with thresholds
assigned by tertiles in pancreatic NETs; weighted kappa 0.66 (95% CI 0.54-0.77)
MIDGUT Grade according to mitoticcount/10HPF
G1 G2 G3
G1 55 17 13 85
G2 13 6 12 31
Grade
according to
Ki-67
G3 0 5 16 21
68 28 41 137
Table 2.12 Agreement between grades assigned according mitotic count and Ki-67 but with thresholds
assigned by tertiles in midgut NETs; weighted kappa 0.38 (95% CI 0.26-0.51)
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Figure 2.4 Univariate anlayses (Kaplan-Meier curves with log-rank tests) demonstrating survival in pancreatic NETs (A) PFS and (B) OS using
Grade according to Ki-67 divided into teritlles; (C) PFS and (D) OS using Grade according to mitotic count divided into tertiles
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Figure 2.5 Univariate anlayses (Kaplan-Meier curves with log-rank tests) demonstrating survival in midgut NETs (A) PFS and (B) OS using Grade
according to Ki-67 divided into teritlles; (C) PFS and (D) OS using Grade according to mitotic count divided into tertiles
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??????Risk
Factor
PFS HR
(95% CI) P - value
OS HR
(95% CI) P - value
Age (for every
10 years)
1.01 (0.99-1.03) 0.137 1.02 (0.99-1.05) 0.119
CgA
CgA≤120
CgA>120
1.00
1.35 (0.83-2.21) 0.226
1.00
2.60 (1.37-4.92) 0.003
Grade (Ki67)
1
2
3
1.00
2.48 (1.27-4.89)
9.71 (3.95-23.85)
0.008
<0.001
1.00
2.13 (0.68-6.67)
24.6 (6.15-98.5)
0.193
<0.001
Grade (mito)
1
2
3
1.00
1.02 (0.52-2.02)
1.43 (0.65-3.14)
0.947
0.368
1.00
0.32 (0.10-1.00)
0.50 (0.16-1.54)
0.052
0.228
Table 2.13 Multivariate analyses of prognostic factors for pancreatic NETs, with grade according to Ki-
67 and mitotic count thresholds according to tertiles
Risk Factor PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Age (for every
10 years) 0.99 (0.83-1.20) 0.991 1.13 (0.89-1.44) 0.325
CgA
CgA≤120
CgA>120
1.00
1.49 (0.91-2.45) 0.111 1.85 (0.99-3.43) 0.052
Grade (Ki67)
1
2
3
1.00
2.14 (1.13-4.05)
4.40 (2.36-8.20)
0.019
<0.001
1.00
1.76 (0.75-4.12)
4.37 (2.08-9.19)
0.192
<0.001
Grade (mito)
1
2
3
1.00
0.77 (0.43-1.37)
0.97 (0.49-1.93)
0.370
0.940
1.00
0.81 (0.40-1.66)
1.01 (0.46-2.21)
0.572
0.979
Table 2.14 Mutlivariate analyses of prognostic factors in midgut NETs with grade according to Ki-67 or
mitotic count assigned using thresholds divided into tertiles
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2.3.6. Alternative Thresholds for Grade Classification (according to
Scarpa et al.[29])
Tumour grades were again reassigned with alternative cut-offs for Ki-67 suggested by
Scarpa et al. for Ki-67[29]. This group validated this in pancreatic NETs but I applied
this system to both pancreatic and midgut NETs.
 G1: Ki-67≤5%
 G2: Ki-67>5% and ≤20%
 G3: Ki67>20%
Univariate analyses with survival curves for this new grading classification are shown
in Figure 2.6 for pancreatic and midgut NETs. Ki-67 using these alternate thresholds
appeared to separate three prognostically different groups with no overlap (which there
was with the ENETS thresholds in pancreatic NETs with OS). Mutlivariate analyses are
shown in Table 2.15 and Table 2.16 where Ki-67 was again confirmed as an
independent prognostic indicator. The hazard ratios, particularly for G2, were higher
than with ENETS thresholds, suggesting that these alternate thresholds may be more
optimal when prognosticating.
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Figure 2.6 Univariate anlayses (Kaplan-Meier curves with log-rank tests) demonstrating survival in pancreatic NETs (A) PFS and (B)
OS; midgut NETs (C) PFS and (D) OS with grade (G1,G2,G3) according to Ki-67 classifications according to Scarpa et al[29]
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????Risk
Factor
PFS HR
(95% CI) P - value
OS HR
(95% CI) P - value
Age (for every
10 years) 1.01 (0.99-1.03) 0.164 1.022 (0.99=1.05) 0.103
CgA
CgA≤120
CgA>120
1.00
1.10 (0.66-1.84) 0.715
1.00
2.09 (1.08-4.06) 0.029
Grade (Ki67)
1
2
3
1.00
2.86 (1.58-5.17)
8.97 (3.90-20.6)
0.001
<0.001
1.00
5.97 (1.97-18.14)
33.8 (9.50-120)
0.002
<0.001
Grade (mito)
1
2
3
1.00
1.32 (0.76-2.30)
1.68 (0.62-4.59)
0.330
0.311
1.00
0.72 (0.32-1.58)
0.91 (0.29-2.88)
0.409
0.872
Table 2.15 Multivariate analyses of prognostic factors in pancreatic NETs with grade (G1,G2,G3)
according to Ki-67 classifications according to Scarpa et al[29]
Risk Factor PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Age (for every
10 years) 0.99 (0.82-1.19) 0.887 1.12 (0.89-1.43) 0.001
CgA
CgA≤120
CgA>120
1.00
1.64 (1.02-2.62) 0.040
1.00
2.03 (1.12-3.68) 0.020
Grade (Ki67)
1
2
3
1.00
3.09 (1.80-5.32)
10.34 (3.95-27.1)
<0.001
<0.001
1.00
3.02 (1.58-5.75)
22.1 (7.12-68.4)
0.001
<0.001
Grade (mito)
1
2
3
1.00
0.71 (0.41-1.22)
1.48 (0.28-7.93)
0.210
0.650
1.00
0.61 (0.30-1.21)
1.57 (0.27-9.21)
0.158
0.620
Table 2.16 Multivariate analyses of prognostic factors in midgut NETs with grade (G1,G2,G3) according
to Ki-67 classifications according to Scarpa et al[29]
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2.4. Discussion
2.4.1. Survival Compared to Other Studies
Although difficult to assess, our overall survival data appears to be comparable to
previous series. In a Swedish single-centre series of 324 pancreatic NETs, 5- and 10-
year survival was 64% and 44% respectively (median follow-up 54 months) compared
to 59% and 36% in our series (median follow up 46 months)[90]. However, the patients
in our series were more advanced: only 180 of 324 in the Swedish series had metastatic
disease compared to all of the patients in our series. In addition, a more recent series has
reported 5- and 10-year survival rates 35% and 17% respectively in a metastatic
subgroup[29].
In an American series based on Surveillance, Epidemiology and End Results (SEER)
data, the 5-year survival of all small intestinal NETs was 61% for all stages, and 50%
for metastatic disease. This is slightly worse than our series (61% 5-year overall
survival) for metastatic midgut NETs. Although a higher 5-year survival rate was
quoted with more recent SEER data (68%), a breakdown of stage was not given[5]. A
higher 5-year survival rate (83%) was experienced in a recent European series but this
did include a number of slow growing hindgut NETs[30]. PFS cannot be compared due
to lack of consistency in definitions of progression and surveillance protocols
throughout the literature.
2.4.2. Inter-observer Agreement Between Pathologists
In my subset of 44 cases, the agreement between independent pathologists for assessing
Ki-67 and mitotic count was very good defined by weighted kappas as a measure of
agreement, although not perfect with 9% discordance. I recognise that this is not a large
validation subset but the make-up is divided evenly between midgut and pancreatic
NETS and this is a larger sample than in previously published data[195]. Despite
studies in a variety of cancers consistently demonstrating its utility as a biomarker, poor
inter-rater agreement between pathologists in assessment of Ki-67 in lymphoma
samples has been demonstrated in a small sample (n=36)[195] although not assessed in
other tumour types. Although there were not many high grade NETs in my subgroup,
this reflects the infrequency of G3 NETs. Additionally, the distribution of this subgroup
was divided evenly between low and intermediate grade NETs. Regardless of the
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absence of complete agreement, grading was prognostic in our survival data below and
using one of a panel of expert NET pathologists, this reflects clinical practice.
2.4.3. Agreement (Discrepancy) in Grading
There is a correlation between absolute Ki-67 index and mitotic count. This is as
expected since both are markers of cell division. However, when using these indices to
assign a grade, there was 44% and 38% discordance in pancreatic and midgut NETs i.e.
moderate and poor agreement defined by weighted kappas. This is clinically important
since if the ENETS guidelines are followed, either mitotic count or Ki-67 can be used to
assign the grade. In practice, most centres provide both indices and this could provide
conflicting information about grading which can impact on clinical management since
intermediate grade NETs may be treated in a more aggressive manner than low grade
NETs. When a case is G2 by one index and G1 by another, it is unclear which grade to
use and hence confusion arises as to when and how to treat these cases. What is
apparent from my data is that some cases can be classified G2 or G3 depending on
which index is used. This can have major implications as G3 NETs are usually treated
aggressively, with chemotherapy first line.
My findings conflict with the findings by Strosberg et al[194], who demonstrated
complete agreement between grade by Ki-67 and mitotic count. They, however, used a
two-tiered rather than three-tiered grading system which is a simplification of and not a
true representation of the ENETS grading classification.
2.4.4. Prognosis Using Grade According to Ki-67 and Mitotic Count
Since there was disagreement between grade assignment depending on whether Ki-67
or mitotic count was used, I investigated which index was more clinically valuable by
analysing the prognostic value of each.
In pancreatic NETs, although grade according to mitotic count was prognostic (in terms
of PFS and OS) on univariate Kaplan-Meier analyses, it was not an independent
prognostic factor on multivariate analyses. Only grade according to Ki-67 was
prognostic in univariate and multivariate analyses in both pancreatic and midgut NETs.
Baseline CgA>120 at the time of diagnosis was the only other risk factor found to be
associated with worse OS on multivariate anlaysis, but only in metastatic pancreatic
NETs.
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This suggests that given the discrepancy in grade assignment above, grade according
Ki-67 is a better prognostic variable than grade according to mitotic count.
One of the reasons why there is a discrepancy in grade assignment and why grade
according to mitotic count does not hold the same prognostic value as Ki-67 could be
that mitotic count is affected by pre-analytical or analytical factors such as delay in
tissue fixation[196, 197], problems in identification of a mitotic figure[198], selection
of measurement area[199, 200], or assessment of mitotic cells in relation to tumour
tissue in the sample[201]. However, similarly, this also applies to Ki-67 with pre-
analytical factors such as time to fixation, type of fixation, time in fixative, and storage;
and analytical issues including assessment of staining. Furthermore, the ENETS
guidelines stipulate that Ki-67 is assessed in areas of highest proliferative activity
whereas mitoses are expressed by ten separate high power fields over an average of 40
high power fields and many fields may not have any activity. In NETs, Ki-67
assessment has been standardised to 2000 cells with highest activity whereas the breast
cancer consensus is 500 to 1000 cells and assessment of ‘hot spots’ being less
consistent[174].
Another reason for the discrepancy in grading and prognostic value is that the grading
thresholds may not be optimal. The 2% threshold was derived from previous data[181].
However, the thresholds may not apply to all populations of NETs studied as there is
heterogeneity in terms of primary tumour, stage of disease and subsequent treatments. I
have separated midgut and pancreatic NETs in the analyses and also attempted to make
the sample homogeneous by recruiting cases with measurable metastatic disease. It is
this population which makes up the majority of clinical practice and also the population
where clinical management pathways are still debated. However, I acknowledge that
this is still a heterogeneous group in terms of subsequent treatments and timing of
treatments. This makes the prognostic data for OS more valuable than PFS. Another
limitation is that this was a retrospective study in a single tertiary centre and larger
prospective multi-centred studies are required.
The grading system has been validated in retrospective series. In foregut NETs (n=158),
Pape et al found survival of G1 tumours better than that of G2 tumours, and in turn
better than G3[202]. However, the authors opted to use Ki-67 and not mitotic count and
also included patients without metastases. More recently, Scarpa et al also opted to use
grading according to Ki-67 in a series of 237 pancreatic NETs and found the cut-offs of
2% and 20% unable to distinguish G1 and G2 tumours according to survival on
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multivariate analysis but did distinguish G3 from G1 NETs[29]. However, the authors
found a modified grading system with cut-offs of 5% and 20% to be significantly
prognostic, incorporating modified TNM staging into the multivariate model. Pape et al
found another modified grading system with cut-offs of 5 and 10% and to be prognostic
in a heterogeneous series of 239 NETs but again did not use mitotic count[203].
However, Jann et al demonstrated the original grading system to be prognostic in
midgut and hindgut NETs (n=189)[30]. Due to these differing thresholds in the
literature, I went on to analyse my data using alternate thresholds.
2.4.5. Alternate Thresholds for Grading
When the grading strata thresholds were divided into tertiles rather than the ENETS
classification, there was moderate and fair agreement when assigning grade according
to Ki-67 or mitotic count in pancreatic and midgut NETs respectively. However, with
survival analyses, this grading system was only prognostic of PFS and generally, the
Kaplan-Meier curves were not as separable as with the ENETS classification.
Using thresholds of 5% and 20% for Ki-67 grading, Scarpa et al validated an alternate
grading stratification but this was a study of pancreatic NETs and the sample did not
contain any midgut NETs[29]. I used these thresholds to assign grade according to Ki-
67 in both midgut and pancreatic NETs (and grade according to mitotic count using the
ENETS thresholds). In both midgut and pancreatic NETs, on univariate and multivariate
analyses, this was the best prognostic grading system in terms of both PFS and OS.
2.4.6. Conclusions
Here I have attempted to clinically validate the grading system proposed by ENETS
guidelines in patients with NETs with metastatic disease, a more homogenous group
than the large published pathology datasets. Since the majority of patients present with
metastases at the time of diagnosis, this is a clinically relevant population. My data
suggests that the grading guidelines suggested by ENETS, should not assume agreement
between Ki-67 and mitotic count and needs to suggest which index is used. I also
conclude that grade according to Ki-67 is more clinically valuable in predicting
prognosis than mitotic count. Furthermore, the alternate grading strata suggested by
Scarpa et al.[29], were found to prognostic in both metastatic pancreatic and midgut
NETs and more optimal than ENETS guidelines. In conclusion, with mitotic count
adding no additional information, and both these indices measuring proliferation,
clinical grading in NETs should use Ki-67 and make a departure from mitotic count.
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Although grade according to Ki-67 is a valuable prognostic factor, it is far from ideal as
it is commonly based on a specimen at the time of diagnosis which, given the variable
survival of NETs, may be many years in the past. Therefore, it may not reflect current
tumour biology which is a dynamic process. For dynamic prognostication throughout
the course of the disease, repeatedly evaluating markers in blood or urine is a more
acceptable form of sampling than repeated biopsy. However, the established
biomarkers, plasma CgA and urinary 5-HIAA are not thoroughly validated prognostic
or predictive biomarkers as explained in the introductory chapter. Therefore there is a
requirement for prospectively validated biomarkers.
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Chapter 3. EpCAM Expression and Enumerating
Circulating Tumour Cells (CTCs) in Neuroendocrine
Tumours
3.1. Introduction
Recent technological advances have enabled enumeration and characterisation of
circulating tumour cells (CTCs) by different methods. One such method is the
CellSearch™ System. This is a semi-automated platform that uses immunomagnetic
enrichment of CTCs from blood and has been shown to detect CTCs with high
sensitivity, specificity, and reproducibility[153]. Large studies have demonstrated that
the number of CTCs in patients with metastatic breast cancer to be an independent
predictor of progression-free and overall survival[154, 204]. These results have been
reproduced in metastatic prostate and colorectal cancer[205, 206] and the system has
been approved by the United States of America (USA) Food and Drug Administration
(FDA) to monitor metastatic breast, colorectal and prostate cancers.
The CellSearch™ system requires Epithelial Cell Adhesion Molecule (EpCAM)
expression to isolate CTCs. EpCAM is a 39-42 kDa transmembrane epithelial
glycoprotein[207] and is overexpressed in human carcinomas[152]. Its exact function is
yet to be elucidated but its expression enables the CellSearch™ platform to enrich
CTCs via immunomagnetic separation with iron particles coupled to EpCAM
antibodies. The platform consists of a semi-automated system that enriches the sample
for cells expressing EpCAM by immunomagnetic separation. The system incubates
samples with ferrofluids coated with epithelial cell-specific EpCAM antibodies and a
magnetic field isolates CTCs by immunomagnetic separation. The system also labels
the cells with the fluorescent nucleic acid, DAPI. Fluorescently-labelled monoclonal
antibodies specific for leukocytes (CD45–allophycocyanin) and epithelial cells
(cytokeratin 8,18,19–phycoerythrin) are used to distinguish epithelial cells from any
leukocytes which may inadvertently isolated (see Figure 3.1).
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Figure 3.1 Schematic representation of immunomagnetic separation and immunofluorescent staining
employed by the CellSearch platform to enrich CTCs from peripheral blood; CTC Circulating Tumour
Cell; EPCAM Epithelial Cell Adhesion Molecule CK-PE Cytokeratin-Phycoerythrin; CD-45APC CD-45
Allophyocyanin DAPI 4’, 6-diamidino-2-phenylindole
Although some series have reported a small neuroendocrine subset of lung cancers and
insulinomas to overexpress this epithelial marker[152, 208], the systematic analysis of
EpCAM expression in NETs has not been undertaken. Since NETs were originally
thought to be derived from cells of the neural crest sharing secretory and histological
properties with neural cells, it has been debated whether NETs are epithelial in
origin.[10, 11] It has thus been assumed NETs do not express EpCAM and in one study,
NET patient samples were used as ‘negative’ controls for CTC detection using the
Cellsearch™ system[209, 210, 211, 212].
I therefore performed an initial study to determine the level of EpCAM expression in
NETs. Having demonstrated widespread expression, I proceeded to investigate whether
circulating NET cells could be detected in patients.
3.2. Materials and Methods
3.2.1. Cell Lines
Cells from a bronchial neuroendocrine tumour cell line, NCI-H727, were maintained in
RPMI 1640 medium (PAA Laboratories, Somerset, UK) supplemented with 10% fetal
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bovine solution (FBS), 2mM L-Glutamine, penicillin and streptomycin. A breast cancer
cell line, MCF-7, was maintained in Minimal Essential Media Eagle (MEM) (PAA
Laboratories, Somerset, UK) supplemented with 10% FBS, 2mM L-Glutamine,
penicillin and streptomycin. All cells were cultured in 75cm2 culture flasks (Corning,
NY, USA) in a humidified incubator at 37°C and 5% CO2.
3.2.2. Cell Culture
Approximately 106 cells per cell line were seeded into 75cm2 tissue culture flasks. After
approximately 48 hours when more than 80% confluent, the media were removed.
Trypan Blue exclusion indicated >99% viability of the attached cells. Sterile 12mm
diameter coverslips were placed in wells of a 24 –well plate (BD Falcon, Oxford, UK).
Approximately 2 X105 cells were seeded into each well and incubated at 37°C for 24
hours at 5% CO2.
3.2.3. Immunofluorescence
Media were removed from each well and cells washed twice with Phosphate Buffer
Solution (PBS) prior to fixing in 1mL of 1% formaldehyde for 10 minutes. Fixative was
removed and cells were washed 3 times with PBS. 1mL 0.1M glycine was added to
each well to neutralise for 5 minutes and cells were washed again 3 times with PBS. To
permeabilise the cells, 0.1% Triton X-100 was added to each well for 10 minutes before
3 further washes with PBS. To prevent non-specific binding, cells were blocked with
0.1% Bovine Serum Albumin (BSA) for 30 minutes and then washed with PBS. Cells
were incubated with the FITC-conjugated anti-synaptophysin mouse monoclonal
antibody (Acris Antibodies, Herford, Germany) at a dilution of 1:20 or the Alexa Fluor
488-conjugated anti-CD56 mouse monoclonal antibody (BD PharMingen, San Diego,
CA) at a dilution of 1:20 for 1 hour at room temperature. After further washing in PBS,
coverslips were removed from each well and mounted onto slides with Vectashield
(Vector Laboratories Ltd, Peterborough, UK) containing 4’, 6-diamidino-2-
phenylindole (DAPI) and sealed with clear nail varnish before visualisation. Negative
controls included substitution of the primary antibody with normal horse serum. MCF-7
was used as a negative control for CD56 staining. Cells were visualised on a Zeiss LSM
510 meta confocal microscope Zeiss Axioskop 2, AxioImager Z1 microscope, Zeiss,
Welwyn Garden City, UK) using Axiovision v4.3 software (Zeiss).
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3.2.4. Immunohistochemistry
Consecutive blocks of formalin-fixed and paraffin-embedded tissue were available from
75 patients with a histopathological confirmed diagnosis of Neuroendocrine Tumour
(NET). Three micrometre sections of tumour tissue were made. After de-paraffinisation
in xylene and rehydration in graded alcohols, endogenous peroxidase in tissue sections
was blocked with 0.5% H2O2 in methanol at room temperature for 10 minutes.
Thereafter, sections were subjected to antigen retrieval for 10 minutes in 0.1% trypsin at
37°C (EpCAM retrieval) or subjected to 3 minute pressure cooking heat-mediated
antigen retrieval (HMAR) (Ki-67 retrieval). Sections were incubated with mouse anti-
EpCAM monoclonal antibody (ESA, clone VU-1D9, Novocastra, Newcastle-upon-
Tyne, UK) at a dilution of 1:50 for 1 hour at room temperature or with MIB-1 antibody
detecting Ki-67 (DAKO, Cambridgeshire, UK) at a dilution of 1:200 for 1 hour at room
temperature. Immunohistochemical staining was performed with the NovoLink™
Polymer detection system (Novocastra, Newcastle-upon-Tyne, UK). Sections were
incubated with post-primary block for 30 minutes, followed by Novolink™ polymer for
30 minutes. Reaction products were visualised with application of diaminobenzidine
(DAB) substrate chromogen solution. Slides were counterstained in haematoxylin and
mounted. Negative controls were performed by omitting the primary antibody. For
negative and positive tissue controls, internal normal tissues with known EpCAM
negativity/positivity were used.
Two examiners (T.L. and M.K.) performed the immunohistological scoring
independently of each other with light microscopy. Any discordant results were
reviewed together to reach agreement. EpCAM scoring was based on intensity of
staining: 0=negative, 1=weakly positive, 2=moderate, 3=strongly positive. Extent of
tumour staining was also scored, where 10 random high power fields (HPF) were
assessed and the average percentage of positive staining cells was estimated: 1= <25%,
2= 25-75%, 3= >75%. The product of staining density and extent was used as the
immunohistochemical score giving final values of 0, 1, 2, 3, 4, 6, and 9. Scores of 0
were counted as negative, 1-2 as weak staining, 3-4 as moderate staining, and 6-9 as
strong staining. The Ki-67 proliferation index was determined by assessing the
percentage of positively staining tumour cell nuclei in 2000 neoplastic cells in areas
with highest degree of nuclear labelling where possible.
All cases were classified according to site of origin and had their tumour graded using
the systems proposed by the European Neuroendocrine Tumour Society (ENETS)
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consensus group and the World Health Organisation including Ki-67 proliferation index
and/or mitoses per 10[23, 26]. Using this classification, a low grade tumour was
regarded as Ki67≤2% or mitotic count <2 per 10 HPF; intermediate grade Ki67 3-20%
or mitotic count 2-20 per 10 HPF; and high grade Ki67>20% or mitotic count>20 per
10 HPF; grade according to Ki67 proliferation index or initial mitotic count as above;
and level of differentiation.
3.2.5. Patient Recruitment
176 patients were recruited between August 2009 and June 2011 for blood sampling and
CTC evaluation. This study was approved by the Local Ethics Committee (Ref
09/H0704/44) and all patients provided written informed consent. All eligible
participants had histologically proven NET and metastatic disease measurable by
RECIST criteria. They were categorised according to the site of primary NET: midgut,
pancreas, bronchopulmonary, hindgut or of unknown primary. Patients that had
undergone chemotherapy, interferon, receptor-targeted radiolabeled therapy, or
embolisation within the previous two months were excluded.
Radiological burden was assessed by quantification of hepatic tumour load from 4 to 6
slices of a CT/MRI scan with the most amount of disease by a semi-quantitative
approach. Hepatic tumour burden was categorised as 25% or less, more than 25% but
50% or less, more than 50% but 75% or less, or more than 75%. Data were collected on
primary site, duration of diagnoses, any previous treatment received, WHO performance
status (PS) and whether the primary tumour had been resected. Grade of tumour
according to Ki-67 proliferation index was recorded according to ENETs guidelines[23,
24].
CgA analysis was performed on plasma samples from patients using a radio-immuno
assay (RIA) kit (Roche). 5-HIAA analysis was performed on 24-hour urine samples
from patients using a manual in-house radio-immunoassay. As these assays have
previously been validated and are currently used in clinical practice, 0 samples were run
on normal healthy controls.
3.2.6. Immunomagnetic Separation, CTC Isolation and Enumeration on
the Cellsearch™ Platform
7.5ml blood was drawn from each patient into CellSave tubes (Veridex LLC) containing
EDTA and a cellular preservative. Samples were maintained at room temperature and
processed within 96 hours using the Cellsearch™ (Veridex LLC) platform as previously
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described for the isolation and enumeration of CTCs. Briefly, 7.5mL of blood were
mixed with 6mL of buffer, centrifuged at 800 X g for 10 minutes and then placed on the
AutoPrep part of platform. The instrument then added ferrofluids after aspirating the
plasma and buffer layer. After the incubation and subsequent magnetic separation,
unbound cells and remaining plasma were aspirated. The staining reagents were added
together with a permeabilisation agent to fluorescently label the immunomagentically
labelled cells. After incubation, excess staining reagents were aspirated and magnetic
separation repeated. In the final step, cells were resuspended in the MagNest Cell
Presentation device (Veridex LLC) which consists of a chamber and two magnets that
orient the cells for analysis.
The identification and enumeration of CTCs on the display unit were performed with the
use of the CellSearch™ Analyser II, a semi-automated fluorescence-based microscopy
system that permits computer-generated reconstruction of cellular images of cells in the
MagNest Cell Presentation device. All evaluations were performed without knowledge
of the clinical status of the patients by 2 independent operators (M.K and T.T.). CTCs
were defined as intact nucleated cells (DAPI+) lacking CD45 and expressing
cytokeratin (see Figure 3.2). Any discordant results were reviewed together to reach
agreement. Technical details of the CellSearch™ platform including accuracy,
precision, linearity, CTC and reproducibility, have been described elsewhere[153]. The
platform has been evaluated using the blood of healthy controls leading it to be
approved by the FDA for evaluation in patients with carcinomas. I did not repeat these
published experiments using healthy controls[153].
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Figure 3.2 Image reconstruction from the CellSearch™ Analyser with identification of CTCs. Each
horizontal ‘event’ is a possible cell or cells focused on by the automated microscope; there are 4 events
depicted here. The columns refer to channels where the same event is imaged through different filters to
view staining patterns: from right to left, CD45 (APC filter), DAPI (for nuclear staining), cytokeratin (PE
filter) and a composite of all 3 stains. Event number 1 demonstrates a CTC (encircled in red for
illustrative purposes) – a nucleus within a cytokeratin skeleton with absence of CD45 expression. In this
same event, another cell circled in yellow for illustrative purposes is CD45 positive, DAPI positive, and
represents a leucocyte rather than a CTC. Events 2-4 demonstrate further CTCs.
3.2.7. Characterising CTCs as Neuroendocrine on the Cellsearch™
Platform
The Cellsearch™ platform allows use of one additional marker processed
simultaneously with CK-PE and CD45-APC antibodies on the platform to characterise
CTCs. To confirm the neuroendocrine origin of CTCs, analysis of synaptophysin and
CD56 expression on CTCs was performed with either FITC-conjugated anti-
synaptophysin mouse antibody (Acris Antibodies, Herford, Germany) and Alexa Fluor
488-conjugated anti-CD56 mouse antibody (BD PharMingen, San Diego, CA) as
additional markers. A selected patient’s sample was processed alongside samples of
healthy control blood spiked with 103 NCI-H727 and 103 MCF-7 cells as well as un-
spiked healthy blood as a negative control. MCF-7 was used as a negative control for
CD56 staining. The antibodies were substituted for PBS for antibody omission controls.
The antibody concentrations were 100µg/mL for anti-synaptophysin and 12µg/mL for
anti-CD56. The positivity of synaptophysin and CD56 of neuroendocrine CTCs was
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evaluated by 2 independent operators using the research mode of CellSearch™
Analyser II with an integration time of 0.8 seconds.
3.2.8. Statistical Analysis
Analysis was performed using SPSS for Windows (SPSS Inc., Chicago, IL) and
GraphPad Prism (GraphPad Software, San Diego, CA) where p values of <0.05 were
considered significant. Differences in baseline characteristics between progressors and
non-progressors were analysed with Fisher’s exact, Mann–Whitney, and t tests.
Associations between level of CTCs and clinicopathological data were evaluated with
Mann-Whitney U or Kruskal-Wallis tests. Association between presence/absence of
CTCs and clinicopathological data was analysed using Chi squared (or Fishers exact)
tests.
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3.3. Results
3.3.1. Immunohistochemical Interpretation of EpCAM Expression
In normal tissue, EpCAM was expressed mostly on the basal or basolateral cell
membrane of small and large intestinal, appendiceal, and bile duct epithelia (Figure
3.3). Variable EpCAM expression, including some cytoplasmic staining, was seen in
pancreatic islets, pancreatic acini, and gastric oxyntic glands. EpCAM was negative in
hepatocytes, mesothelium, and gastric foveolar epithelium. Variable staining, including
some cytoplasmic staining, was seen in pancreatic islets.
All ileal (n=26), pancreatic (n=16), unknown primary (n=2), and gastric (n=4) NETs
showed strong (score 6–9) homogeneous membranous staining for EpCAM (Figure
3.3). Moderate to strong staining was seen in appendiceal (n=7) NETs. EpCAM
expression was not affected by grade. Bronchopulmonary NETs (n=13) showed
variable EpCAM expression from negative, weak to strong staining. EpCAM
distribution was also variable in bronchopulmonary NETs: EpCAM was observed in
cell membranes and in cytoplasm. EpCAM was not expressed in paraganglioma (n=1).
Details can be found in Table 3.1.
3.3.1. Patients for CTC Evaluation
176 patients with metastatic NETs were recruited and had 7.5ml blood drawn for CTC
evaluation. One sample was discarded due to haemolysis. Baseline characteristics are
shown in Table 3.2.
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Figure 3.3 Immunohistochemistry with EpCAM. A) gastric mucosa with absent
expression, apart from, in oxyntic cells. B) ileal NET resection with intense
membranous staining of NET and of normal mucosa (short arrow) with negative
stroma (long arrow). C) EpCAM positivity in ileal NET at high power. D)
EpCAM-positive appendiceal NET (short arrow) with positive normal appendix
mucosa (long arrow). E) normal pancreas with positive acini, islet, and duct. F)
pancreatic NET with membranous staining at high power. G) poorly differentiated
gastric NET with membranous and cytoplasmic staining. H) bronchopulmonary
NET with cytoplasmic staining (short arrow) and negative lung parenchyma/
alveoli (long arrow).
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EpCAM StainingNET Primary Grade Total
Cases Positive
n
Score Staining
Pattern
Bronchopulmonary Typical 4 4 2-9 C+M
Atypical 9 8 1-9 C+M
Gastric Low 0
Intermediate 2 2 6-9 M
High 2 2 6-9 M
Pancreatic Low 7 7 9 M
Intermediate 4 4 6-9 M
High 5 5 9 M
Ileal Low 15 15 9 M
Intermediate 9 9 9 M
High 2 2 9 M
Appendix Low 6 6 4-9 M
Intermediate 0
High 1 1 9 M
Rectal Low 1 1 4 M
Intermediate 1 1 9 M
High 2 2 6-9 M
Unknown Low 0
Intermediate 2 2 9 M
High 0
Nasal Intermediate 1 1 6 M
Paraganglioma Intermediate 1 0 0
Total 74 72
Table 3.1 EpCAM Expression in NETs (m=membranous; c=cytoplasmic)
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Pancreatic
n=42
Midgut
n=101
Broncho-
pulmonary
n=17
Unknown
Primary
n=12
Hindgut
n=3
Total
n=175
Age, median years
(range)
53
(23-87)
63
(34-85)
55
(30-80)
62.5
(31-78)
74
(43-75)
63
(23-87)
Sex
Male
Female
25
17
54
47
8
9
4
8
1
2
92
83
Grade
Low
Intermediate
High
17
10
15
59
36
6
6
8
3
1
7
4
0
2
1
83
63
29
Burden of Liver
metastases
≤25%
25%≤50%
50%≤75%
>75%
19
15
3
5
48
36
11
6
11
4
2
0
4
4
3
1
1
0
1
1
83
59
20
13
Duration of diagnosis,
median months (range) 41
(2-166)
30
(1-134)
22
(9-287)
13
(1-67)
18
(5-22)
26
(1-287)
Performance Status
0
1
2
3
4
29
13
0
0
0
60
34
6
0
1
12
5
0
0
0
6
5
0
1
0
1
2
0
0
0
108
59
6
1
1
Previous treatments
Resection of primary
SST
Chemotherapy
TAE
Radionuclides
Interferon
Liver resection
18
13
18
3
5
3
7
50
59
10
13
16
2
10
6
3
4
0
1
0
0
0
3
6
2
1
0
0
1
1
1
0
0
0
0
75
79
39
18
23
5
17
Number of previous non-
surgical treatments
0
1
2
3
4
12
21
6
3
0
36
38
20
6
1
10
6
1
0
0
4
5
2
1
0
1
2
0
0
0
63
72
29
10
1
Table 3.2 Clinical Characteristics of NET Patient Sample
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3.3.2. CTC Enumeration in Patients with NETs
Enumeration of CTCs according to primary NET is shown in Figure 3.4. Fifty-one per
cent (51/101) of metastatic midgut NET patients had CTCs identified with a mean +/-
SEM of 11.6 +/- 3.6 CTCs per 7.5ml whole blood (range 0-294). In comparison, 36%
(15/42) of pancreatic NETs and 41% (7/17) of bronchopulmonary NETs had CTCs
detected (mean 414.3 +/- SEM 233). In addition, 92% (11/12) patients with NETs of
unknown primary had CTCs present. Hindgut NETs are not shown in the figure; 1 of
these 3 cases had presence of CTCs (10/7.5ml). Number of CTCs were not normally
distributed.
n 42 101 17 12
CTC ≥1 15 (36%) 52 (51%) 7 (41%) 11 (92%)
Mean CTCs
(+/- SEM)
95% CI
20.4
+/-11.3
0-43
11.6
+/-3.6
5-19
49.6
+/-148
0-123
414.3
+/-233
0-1109
Median* 6 8 1 6
Range CTCs 0-430 0-294 0-542 0-3731
* median in those who had greater than 0 CTCs
Figure 3.4 CTC Enumeration According to Primary NET
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3.3.3. Characterisation of CTCs as Neuroendocrine in Origin
Using immunofluorescence, NCI-H727 and MCF-7 both expressed synaptophysin.
NCI-H727 expressed CD56 but MCF-7 did not. On the Cellsearch system™, spiked cell
lines were easily identified as CTCs, being CK+DAPI+CD45-. When the fluorescent
antibodies were translated to the CellSearch platform, spiked NCI-H727 was positive
for synaptophysin and CD56; MCF-7 was positive for synaptophysin but negative for
CD56. When the selected patient’s sample was processed on the system, 82% per cent
of the patient’s CTCs were positive for synaptophysin and 21% for CD56 (Figure 3.5).
3.3.4. CTCs and Tumour EpCAM Expression
Archival histopathologic tissue was available from 26 of the patients who underwent
CTC evaluation. EpCAM expression was evaluated in these samples which included 7
midgut, 2 liver metastases unknown primary, 8 pancreatic, 9 bronchopulmonary NETs.
All seven midgut NETs, and two liver metastases with unknown primary demonstrated
strong EpCAM staining. 5 and 2 of these had CTCs present, respectively. All eight
pancreatic NETs demonstrated strong EpCAM expression but only one had CTCs
present. Five of the 9 bronchopulmonary NETs had none or weak EpCAM staining and
none of these had CTCs. This is as expected since EpCAM expression was utilised to
isolate CTCs. CTCs were only detected in those bronchopulmonary NETs displaying
moderate to strong EpCAM expression.
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Figure 3.5 Diagram demonstrating CTCs expressing synaptophysin and CD56 from a patient’s sample.
Each horizontal event depicts the same cell(s) viewed with different filters (vertically). The top group of
three demonstrates three CTCs positive for synaptophysin (in the FITC-SYNAPTO channel). The bottom
two events show two CTCs positive for CD56 (ALEXA 488-CD56 channel).
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3.3.5. Numbers of CTCs in NETs compared to other cancers
Numbers of CTCs from this study were compared to numbers of CTCs enumerated in
other metastatic cancers using the same technology (Table 3.3)[153]. Previous studies
have stated the median of cases with 2 CTCs and above. When taking all NETs
regardless of primary, and using this criteria for comparison, the median CTC count in
our study was 10/7.5ml. This is similar to metastatic breast and prostate, the two main
cancers utilising this CTC technology, and greater than the other cancers. In fact, 42%
of patients of NET patients had CTCs of two or above which is second only in
frequency to metastatic prostate cancer.
Comparing midgut NETs to metastatic colorectal adenocarcinomas, NETs had a higher
median CTC count (10 vs. 5 respectively) and greater percentage of cases (47% vs.
30%) with CTCs of 2 or above. Pancreatic NETs had a higher median (48) and
percentage of cases with CTCs of 2 or above (24%) when compare to pancreatic
adenocarcinomas (median 3.5 and 19% respectively), Levels of CTCs in metastatic
bronchial NETs were similar to metastatic lung cancer.
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No. of
patients
Mean
CTC
(SD)
Media
n with
≥ 2
No.
(%) ≥
2
No.
(%) ≥
5
No.
(%) ≥
10
No.
(%) ≥
50
Healthy[153] 145 0.1 (0.2) N/A 0 (0) 0 (0) 0 (0) 0 (0)
Metastatic Cancer Type
Breast[153] 422 84 (855) 10 489
(37)
340
(26)
256
(19)
129
(10)
Prostate[153]
Prostate[205]
(progressive)
123
219
75 (333) 13 107
(57)
77 (41)
125
(57)
61 (32) 27 (14)
Gastric[153]
Gastric[205] [213]
9
27
24 (83)
0.4 (0.7)
3
0
4 (31)
4 (14)
1 (8) 1 (8) 1 (8)
Lung[153]
SCLC[214]
Non-SCLC[215]
99
50
101
30 (178)
2915
(8115)
9
28
34 (20)
21 (21)
24 (14)
15 (15)
16 (10) 10 (6)
Pancreatic
adenocarcinoma[153]
Pancreatic
adenocarcinoma[216]
16
32
2 (6)
17 (31)
3.5
0.5
4 (19)
11 (42)
1 (5) 1 (5) 0 (0)
Colorectal[153] 196 4 (11) 5 99 (30) 56 (17) 30 (9) 5 (2)
All NETs 175 45 (300) 10 74 (42) 53 (30) 39 (22) 15 (9)
Midgut NET 101 12 (35) 10 47 (47) 32 (32) 24 (24) 6 (6)
Pancreatic NET 42 20 (72) 48 10 (24) 8 (19) 7 (17) 5 (12)
Bronchial NET 17 414
(1095)
16 5 (29) 4 (24) 3 (18) 2 (12)
Table 3.3 CTCs in NETs compared to other cancers, enumerated by Cellsearch™ method
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3.3.6. CTC Correlation with Existing Markers and Clinicopathological
Data
Associations between CTCs and clinicopathological data are shown in Table 3.4. The
liver metastases burden categories, 25-50%, 50-75% and >75%, were combined due to
small number of events in these categories (n=59, 20 and 13 respectively) compared to
that <25% (n=83). PS scores of 1-4 were grouped together due to the few numbers
compared to patients with PS of 0. Since CgA was not normally distributed (even when
transformed onto a logarithmic scale) this was analysed in two groups: above and below
twice the upper limit of normal (120 pmol/L)[92]. In addition to CTCs being analysed
as a continuous variable, they were also analysed as a dichotomous variable: presence
or absence of CTCs i.e. CTC1.
There were associations between presence of CTCs and grade (Chi-squared P=0.036),
metastatic burden (Chi-squared P<0.001), CgA (Chi-squared P<0.001) (Figure 3.8) and
presence of bone metastases (Chi-squared P=0.03). These associations were also
present when CTCs were analysed as a continuous variable (Figure 3.6, Figure 3.7,
Figure 3.10). CTCs were not associated with performance status (Figure 3.9).
There was a weak correlation between CTC levels and urinary 5-HIAA in midgut and
unknown NETs where available (r=0.4, P=0.007, n=28) although 5-HIAA levels were
higher in those with CTCs present (Mann-Whitney, P=0.04).
There was no significant difference in the presence (Chi-squared, P=0.61) or levels
(Mann-Whitney, P=0.21) of CTCs between those on somatostatin analogues and those
who were not. In addition, there was no association between CTCs and whether the
primary tumour had been resected (Mann-Whitney, P=0.68).
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Percentage of patients
with CTC1
CTCs as continuous
variable (mean CTC)
Metastatic Burden
≤25%
>25%
P value
33
64
<0.001
16
71
<0.001
Tumour Grade
G1
G2
G3
P value
40
54
66
0.036
11
11
218
0.006
Performance Status
0
1
P value
49
50
1.0
25
469
0.794
CgA Levels
≤120
>120
P value
29
64
<0.001
20
64
<0.001
Bone metastases
Present
Absent
P Value
45
66
0.030
38
75
0.028
Table 3.4 Summary of association of CTCs with existing NET clinicopathological factors; CTCs analysed
as dichotomous variable (CTC1) and as a continuous variable
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Figure 3.6 Association between Metastatic Burden and CTCs (Horizontal bars indicate median)
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Figure 3.7 Association between Grade according to Ki-67 proliferation Index and CTCs G1=low grade;
G2=intermediate grade G3=high grade. (Horizontal bars indicate median)
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P <0.001
Figure 3.8 CgA levels according to absence or presence of CTCs (horizontal bars represent median)
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Figure 3.9 Association between performance status (WHO) and CTCs (Horizontal bars indicate median)
Figure 3.10 CTCs in the absence and presence of bone metastases
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3.4. Discussion
This is the first systematic analysis of EpCAM expression and CTC detection in NETs.
Regardless of grade and degree of differentiation, all GEP-NETs demonstrated strong
EpCAM expression. Given the origin of NETs is still debated, the expression of this
carcinoma-associated protein adds evidence to an epithelial origin rather than cells of
the neural crest as once thought.[10, 11] Some of the proposed functions of EpCAM
include regulating c-myc and cyclins, promoting cell cycling and enhancing
proliferation[217, 218, 219, 220, 221]. Anti-EpCAM therapy has been trialled in
metastatic breast, colorectal cancer and in malignant ascites[222, 223, 224, 225, 226,
227] and our results presents an opportunity for EpCAM directed therapy in NETs.
However, due to normal pancreas and small intestine tissue expressing EpCAM, caution
must be taken.
The Cellsearch™ method of CTC enrichment has been validated previously and only
0.3% of healthy controls and benign cases have 2 or more CTCs per 7.5mL of
blood[153]. Hence, the absence of healthy controls in our study. I have demonstrated
the neuroendocrine origin of the CTCs by using NET specific immunohistochemical
markers (synaptophysin or CD56).
Fifty-one per cent of midgut NETs and 36% of pancreatic NETs had one or more CTCs.
Numbers of CTCs from this study were compared to numbers of CTCs in other
metastatic cancers using the same technology (Table 3.3). This is a limited comparison
since the patient populations are invariably heterogeneous albeit all with metastatic
disease. However, when analysing cases with CTCs of 2 or above (as done in other
cancers), the median CTC count was 10 per 7.5ml which is similar to metastatic breast
and prostate cancer, and more than the other cancers. 42% of patients of NET patients
had CTCs of 2 or above which, as a proportion, is second only to prostate cancer.
Comparing midgut and pancreatic NETs to colorectal and pancreatic adenocarcinomas,
NETs had a higher median CTC count and higher proportion of patients with CTCs.
Levels of CTCs in metastatic bronchial NETs were similar to metastatic lung cancer.
This has important implications. The majority of CTC biomarker and downstream CTC
research, to date, has been conducted in metastatic breast and prostate cancer because of
the relatively high frequency of CTCs compared to other cancers and due to this
research, led to approval by the FDA. The abundance of CTCs in NETs found in our
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experiments lends itself to further research in CTCs similarly to that in those other
cancers. Given the variable and often prolonged survival of NETs, CTCs may be
incorporated into clinical trials as a biomarker to elucidate predictive and prognostic
value. This has important implications especially if validated as a surrogate endpoint
since the outcomes in NET trials i.e. PFS, OS are often much longer than other tumours.
Prognostic CTC cut-off levels have been determined in other cancers[205, 228] and
further studies are required to define these in NETs.
Despite abundant EpCAM expression in pancreatic NETs, only a small proportion
(36%) had CTCs detected compared to midgut NETs. Possible reasons include less
shedding of CTCs i.e. less haematogenous spread, loss of EpCAM expression or
unidentified factors particular to this sample of pancreatic NETs.
CTCs were only detected in bronchopulmonary NETs when the primary tumour
expresses EpCAM. Absent EpCAM expression has been cited as a reason for absence
of CTCs in metastatic breast cancer[229] but for the first time, I report synchronous
CTC detection and differential EpCAM expression. EpCAM positive
bronchopulmonary NETs had the highest levels of CTCs possibly due to absence of
portal circulation which filters CTCs[210].
More patients in the higher burden group (>25% liver involvement) had CTCs present
and CTC levels were higher in patients with greater burden. This suggests that in NETs,
the finding of CTCs may reflect the burden of the underlying disease and higher
metastatic potential, contradicting studies in breast cancer[228] but supporting a study
in prostate cancer[230]. This may be due to the indolent nature of NETs compared to
breast cancer.
There appeared to be an association between CTCs and the existing biomarker CgA.
Together with the association between CTCs and 24-hour urinary 5-HIAA, this may be
due to tumours being more metabolically active when CTCs are present or CTCs
secreting serotonin and other vesicle products into the circulation. This relationship
requires further investigation into the biochemical properties of CTCs.
Although there were associations between CTCs and tumour grade, and between CTCs
and presence of bone metastases, caution must be taken in interpretation. Although P
values were below the 0.05 level, there were multiple significance tests in this section,
increasing the likelihood of a significant result occurring by chance. Thus, a large,
homogenous trial is required to elucidate the validity of these associations.
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Nevertheless, the suggestion of an association between bone metastases and higher CTC
counts would support previous data in breast cancer[231]. The relationship with grade
could suggest that more aggressive tumours shed more CTCs into the circulation. With
grade based on a specimen that may have been taken many years ago, CTCs could be
more representative of current tumour biology. However, a study with repeated tumour
sampling, correlating with CTC enumeration is required.
This confirmation of CTCs in NETs offers an opportunity to molecularly characterise
NETs without invasive biopsies, which may accelerate development of new therapies
and allow the natural history of the metastatic process to be studied i.e. ‘the liquid
biopsy’. In view of the increasing arsenal of treatment options [50, 54, 61, 62, 232, 233,
234] and the variable survival of NETs, CTCs could be used as a prognostic marker in
NETs to stratify therapy, and in real-time monitoring of tumour growth or treatment
response.
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Chapter 4. Circulating Tumour Cells as Prognostic and
Predictive Biomarkers
4.1. Introduction
In the first chapter, I established that there is a lack of prospectively validated
biomarkers in neuroendocrine tumours (NETs). Given the variable survival and
heterogeneity of NETs, clinically validated prognostic and predictive biomarkers are
needed. The current most widely used circulating biomarker, chromogranin A (CgA),
has not been robustly prospectively validated. The most widely used tissue biomarker,
Ki-67, samples a small population of the tumour mass and is often performed at
diagnosis which may be years from treatment decisions. Endpoints used in clinical
practice and in clinical trials are based on radiological assessment but given the variable
survival, this is often assessed over a long period of time, sometimes years, Some NETs
are very stable over time, in terms of size, whereas others progress. Therefore, a
biomarker which can predict progression and response to therapy at an early time-point
would be useful as well as discriminating stable from progressive tumours.
4.1.1. CTC detection and other technologies
The presence of CTCs was first described by the Australian physician, Thomas
Ashworth, in 1869[148]. Recent technological advances in CTC detection and
enumeration have made routine evaluation of CTCs feasible. In most cases, there are
two steps: isolation-enrichment and detection. The CellSearch™ platform employed in
my study, and explained in chapter 2, is just one of many technologies used but it is the
only method which has been approved by FDA. Other methods include
immunomagnetic enrichment, multiplex reverse transcription quantitative PCR (RT-
qPCR)-based methods, microfilter and microchip devices or a combination of these.
The main analytical approaches are shown in Table 4.1.
A disadvantage of the anti-EpCAM antibody-based methods is that some tumour cells
do not express EpCAM as shown by a study looking at ‘normal-like’ breast cancer cell
lines[235]. However, a combination of anti-CD146 and anti-EpCAM has been
proposed to improve CTC detection[236].
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The CTC filtration devices listed in Table 4.1 are only those which have been evaluated
on peripheral blood samples. Isolation by size of epithelial tumour cells (ISET) is based
on individual isolation of epithelial tumour cells by filtration due to their larger size
compared to leukocytes[237]. FISH and PCR-based genetic analyses have been applied
to ISET-isolated cells[237]. A microfluidic device, called the CTC-chip[238], has been
developed to capture CTCs through use of EpCAM antibody-coated micro-posts with
the same group recently developing the herringbone chip which is a high-throughput
microfluidic mixing device[239].
Other methods to detect surrogate markers of CTCs include molecular assays to detect
circulating free DNA or RNA in serum or plasma. These allow high throughput but are
dependent on looking for particular sequences of mRNA or DNA (If known to be
specific for a tumour) and cannot be used to enumerate CTCs or for morphological
analysis. Assays to detect cytokeratin-19 by RT-qPCR have been used on clinical
samples. Numerous circulating DNA/RNA markers have been studied mainly in breast
cancer, in particular as part of a multiplexed PCR-coupled liquid bead array which
utilised CTC targets SCGB2A2 (mammaglobulin), melanoma antigen A, TWIST1 and
KRT19.
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Assay Enrichment Detection Advantages Disadvantages References
CellSearch™ Immunomagnetic positive
selection (EpCAM
antibody)
Markers: CK-8/9/19,
CD45, DAPI
FDA approved
Visual confirmation
Clinical relevance
EpCAM dependent
Limited markers
Allard et al[153]
CTC Chip EpCAM antibody covered
micro-posts
Markers: CKs, CD45 High detection rate
Visual confirmation
Subjective analysis
EpCAM dependent
Nagrath et al[238]
CTC-filtering
devices
Size (filters) Markers: CKs Capture and analysis
platform
Multiplexed imaging
Genetic analysis
CTCs can be heterogeneous
in size
Contamination
Vona et al[237]
Zheng et al[240]
Laser-
scanning
cytometer
EpCAM antibodies
coupled to columns
Fluorophore-conjugated
anti-epithelial antibody
Automated microscope
10000-fold enrichment
EpCAM dependent Pachmann et al[241]
EpiSpot assay Negative selection
(CD45)
Detection of secreted
proteins: CK19, mucin-1,
cathepsin-D
Only viable cells detected Clinical relevance not
studied
Alix-Panabieres et al[242]
RT-PCR Ficol gradient
centrification
Markers: CK19, HER2, h-
MAM, CEA, GABA A
High sensitivity
Only viable cells detected
No morphological analysis Slade et al[243]
Reinholz et al[244]
RT-qPCR Ficol gradient
centrification
CK19, BST1, PTPRC High sensitivity
Only viable cells detected
No morphological analysis Stathopoulou et al[245]
Sieuwerts et al[246]
RT-qPCR OncoQuick enrichment
and RNA pre-
amplification
EpCAM, hMAM, PPIC,
SLC6AB, CCNE2, EMP2
High sensitivity
Only viable cells detected
No morphological analysis Obermayr et al[247]
Multiplex RT-
PCR Adnatest
EpCAM and MUC1
antibodies coupled to
ferrofluids
Multiplex PCR for
MUC1, HER2, EpCAM
High sensitivity
Only viable cells detected
Saves time
No morphological analysis
EpCAM dependent
Aktas et al[248]
Liquid bead
array
Ficol gradient
centrifugation and
EpCAM antibody
ferrofluids
Multplex PCR for CK19,
HER2, MAGE-A3,
hMAM, TWIST1
On viable cells detected
Multiple markers
No morphological analysis
EpCAM dependent
Markou et al[249]
Table 4.1 Overview of analytical methods for detection and characterisation of CTCs. EpCAM Epithelial cell adhesion molecule; CK-19 Cytokeratin-19; CKs cytokeratins; HER2
human epidermal growth factor receptor-2; h-MAM human mammaglobulin; CEA Carcinoembryonic antigen ; GABA-A γ-aminobutyric acid; BST1 bone marrow stromal cell
anitgen; PTPRC protein tyrosinase phosphatase, receptor type, C; PPIC peptidylprolyl isomerase C; SLC6AB soluble carrier family 6 (neurotransmitter transporter, creatine);
CCNE2 cyclin E2; EMP2 epithelial membrane protein 2; MAGE melanoma associated antigen
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4.1.2. Clinical Application and Characterisation of CTCs
It has been hypothesised that CTC counts could reflect on-going metastasis[230] and
accumulating evidence correlating CTCs with clinically relevant outcomes such as
progression-free (PFS) and overall survival (OS) supports this[204, 250].
Using the CellSearch™ platform, prospective studies in patients with metastatic breast
cancer about to undergo new systemic therapy, have demonstrated patients with ≥5
CTCs at baseline having significantly shorter median PFS and OS than those with <5
CTCs[154, 204]. After first follow-up, those patients with persistent elevated counts or
that exceeded the threshold of 5 CTCs were associated with an adverse outcome. CTC
counts have demonstrated utility as a predictive biomarker with Nakamura et al
demonstrating those with no change or a reduction in CTCs at 3-4 and 12 weeks after
treatment onset as showing better outcome than those with an increase[251].
In metastatic prostate cancer, similar results were shown with those ≥5 CTCs having
significantly worse PFS and OS than those with <5 CTCs. As with breast studies, pre-
and post-treatment CTC counts were prognostic and predictive and had superior
predictive value compared to PSA[205]. Similarly, Cohen et al prospectively
investigated 430 patients with metastatic colorectal cancer[206]. Their results
demonstrated patients with ≥3 CTCs had significantly worse PFS and OS compared to
those with <3 CTCs. Furthermore, persistence of CTCs after ‘curative’ resection was
associated with high incidence of relapse and worse relapse-free survival[252]. With
another method, using circulating mRNA, expression of four mRNA markers were
associated with significantly shorter disease-free survival in this cancer type[253].
Moreover, a meta-analysis concluded that despite inter-study heterogeneity, CTC
detection should be considered as a surrogate prognostic marker[254]. Other studies in
lung cancer have had similar findings[215].
CTCs are very rare cells and downstream analysis presents difficult analytical and
technical challenges. However, CTCs have the potential to provide a ‘liquid biopsy’ that
can facilitate personalised, stratified therapy. Molecular and cytogenetic analyses of
CTCs have been reported. Using FISH, chromosomal amplification of androgen
receptor, rearrangement of ERG gene, loss of PTEN, and relative gain in MYC were
detected in CTCs from patients with prostate cancer[255]. Other studies may have
implications for therapy. CTC HER2 status may be different to that of the primary
tumour which may have clinical relevance for selecting patients who would benefit
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from molecular targeted therapy. Molecular analyses of CTCs have also been studied
recently. The presence of an EGFR-activating mutation in CTCs was observed in 92%
of patients while it was present in 33% responding to tyrosine-kinase inhibitors and
64% who had clinical progression[256]. Thus the authors concluded that this mutation
in CTCs might be relevant to drug resistance. mRNA and miRNA expression in CTCs
has also had promising initial results despite the high background of leukocytes[257].
4.1.3. Aims
Having detected CTCs in NETs using the CellSearch™ platform, and considering the
clinical utility of CTCs in other cancers, I set out to demonstrate the clinical relevance
of CTCs in NETs. My aims were:
 to investigate the relationship between CTC detection and radiological
progression
 to evaluate CTCs as a prognostic biomarker in terms of PFS and OS
 to evaluate CTCs as a predictive biomarker i.e. investigate their utility in
predicting response to treatment
 to evaluate CTCs as biomarkers in comparison to grade and chromogranin A
(CgA)
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4.2. Materials and Methods
4.2.1. Patient Recruitment and Laboratory Measurements
This study was approved by the local ethics committee (Ref 09/H0704/44) and patients
provided written informed consent.
In order to investigate the relationship between CTCs and progression of disease and to
justify prospective studies, an initial pilot series (n=63) comprising of patients
undergoing surveillance and treatment was analysed. In this initial dataset, progression
was assessed retrospectively. In order to classify a patient as having progressive or non-
progressive disease, target lesions (according to RECIST 1.1) were defined using CT or
MRI within six weeks of blood sampling and compared retrospectively with the
previous imaging.
Patients (n=138) about to commence a new treatment for metastatic NET were
prospectively recruited between August 2009 and August 2011. Additionally, patients
(n=37) were prospectively recruited if undergoing surveillance without any change in
management. The combined dataset (n=175), comprising of treatment and surveillance
groups were prospectively studied for survival analysis.
All eligible participants had histologically proven NET and metastatic disease
measurable by RECIST criteria. They were categorised according to the site of primary
NET: midgut, pancreas, bronchopulmonary, hindgut or of unknown primary. New
treatment was defined as NET-specific therapy not given to the patient previously and
patients who had treatment in the previous 4 months (except for somatostatin
analogues) were excluded.
All patients had blood samples taken at baseline (within 4 weeks prior to treatment for
the treatment cohort). For the treatment cohort, further samples were taken at 3-5 weeks
after commencing treatment (first post-treatment sample) and at 10-15 weeks (second
post-treatment sample). Blood was processed for CTC enrichment and enumeration as
described in chapter 3, section 3.2.6. CTC enumeration was performed by two
independent observers blinded to clinical endpoints.
Plasma CgA was also evaluated at the same time-points using a radio-immuno assay
(RIA) kit (Roche). 5-HIAA analysis was performed on 24-hour urine samples from
patients using a manual in-house radio-immunoassay. As these assays have previously
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been validated and are currently used in clinical practice, no samples were run on
normal healthy controls.
Quantification of hepatic tumour load (from 4 to 6 slices of a CT/MRI scan) was used to
assess radiological burden by a semi-quantitative approach. Hepatic tumour burden was
categorised as less than 25%, more than 25% but less than 50%, more than 50% but
75% or less, or more than 75%.
Data were collected on primary site, duration of diagnoses, any previous treatment
received, WHO performance status and whether the primary tumour had been resected.
Grade of tumour according to Ki-67 proliferation index was recorded according to
ENETs guidelines[23, 24]. The study design met the REMARK (REporting
recommendations for tumor MARKer prognostic studies) criteria[258].
4.2.2. Treatments
Treatments were prescribed as clinically indicated and listed in Table 4.2.
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Treatment Number of
patients
(n=138)
Details Timing of post-treatment scan
Somatostatin analogues (SST)
Chemotherapy
Peptide Receptor Radionuclide
Therapy (PRRT)
Trans-arterial Embolisation
(TAE)
Radiofrequency Ablation (RFA)
Sunitinib
Interferon alpha
Surgical resection of
primary/metastases
34
29
40
18
2
4
4
7
Daily subcutaneous octreotide, or monthly Octreotide
LAR/Somatuline Autogel
Based on previous data for 5-fluorouracil, cisplatin and
streptozocin (FCiSt)[54]
3 doses of intravenous 90Yttrium-DOTA-Octreotate as
per hospital protocol
Selective cannulation of a branch of the hepatic artery
and injection of polyvinyl chloride microparticles
Percutaneously under image guidance
Oral dose of 37.5mg a day
3 million units subcutaneously three times a week
6 months+
after completion
after completion
6 months*
3 months*
6 months+
6 months+
6 months*
Table 4.2 List of treatments undertaken in treatment cohort. *after procedure/therapy. +after commencement of therapy
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4.2.3. Outcomes, Endpoints and Statistical Analyses
Association between presence of CTCs and radiological status in the pilot series (n-63)
was assessed with Fisher’s exact test. For the combined dataset (n=175), PFS and OS
were estimated using Kaplan-Meier methods from date of baseline sample to date of
radiological progression (RECIST 1.1); and date of death (due to neuroendocrine
cancer) or last follow-up. Survival curves were compared using log-rank testing. Cox-
proportional hazards regression analysis was used to obtain univariate and multivariate
hazard ratios for PFS or OS.
In order to stratify patients into those with favorable and unfavorable prognosis, results
(in terms of differences in PFS) obtained for the first 90 patients enrolled (training set)
were used to select a cut-off level of CTCs. This cut-off level was then validated with
the 85 patients subsequently enrolled in the study (validation set).
For the treatment cohort (n=138), PFS and OS were analysed according to baseline
CTC count and changes in CTCs analysed at first and second post-treatment time-points
separately. In order to assess therapy-induced changes in number of CTCs, data were
split into tertiles comparing post-treatment CTCs to baseline: those with a reduction of
65% or more from baseline, those with less than a 65% reduction to less than 33%
increase from baseline (including no change), and those with a greater than 33%
increase over baseline. Those patients with zero CTCs at baseline and zero CTCs at
post-treatment time-points were used as a reference group for comparison. These groups
were compared for association with response to therapy, and with survival outcomes.
With a median PFS in the worst and best prognostic groups, as defined by CTC cut-off,
of 6 and 12 months respectively, a minimum sample size of 142 was required with 80%
power and an alpha of 0.05 (hazard ratio 2.0).
To assess response to therapy, CT or MRI after therapy (according to timing listed in
Table 4.2) was compared with baseline imaging to assess whether a patient had
progressive or non-progressive (stable disease or minor/partial response) disease.
Comparisons were performed by an independent radiologist who also recorded
percentage changes in target lesion dimension and classified them according to RECIST
1.1.
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4.3. Results
4.3.1. The Relationship between CTCs and Progressive Disease using Pilot
Data
In order to explore the relationship between CTCs and growth of tumours, patients
(n=63) from an initial pilot, who had undergone serial imaging of tumours, were
selected. All patients had imaging within 6 weeks of sampling and a previous scan for
comparison evaluated by an independent radiologist. Bronchopulmonary NETs were
excluded from this analysis because of variable EpCAM expression.
Eighteen of 19 (95%) patients who had progressive disease according to RECIST had
CTCs detected compared with 9 of 44 (20%) patients who had non-progressive disease
(Figure 4.1). This was a significant difference (χ2=31.4, P<0.001), with no statistical
difference in other factors between progressors and non-progressors (Table 4.3).
Figure 4.1 Presence of CTCs and Progressive Disease
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Characteristic Non-Progressive
Disease
n=44
Progressive
Disease
n=19
Test
P value
Age
median years (range) 59.5 (38-79) 56.1 (30-77)
U=0.36
P=0.37
Grade
Low
Intermediate
High
22
19
3
8
9
2
Fishers exact
P=0.57
Burden of Liver metastases,%
<25
25≤50
>50
24
16
4
7
10
2
Fishers exact
P=0.39
Chromogranin A in pmol/L,
mean (range)
297.8
(33-1000)
359.4
(34-1000)
t=0.46
P=0.65
Resection of primary
Yes
No
16
28
8
11
Fishers exact
P=0.99
Duration of diagnosis,
median months (range) 58.5 (5-278) 55 (10-108)
U=343
P=0.99
On-going somatostatin
analogue therapy
Yes
No
22
12
11
8
Fishers exact
P=0.77
Interval to last scan, median
weeks (range)
18 (12-56) 18 (10-30) U=347
P=0.76
CTC
CTC=0
CTC≥1
35
9
1
18
Fishers exact
P<0.001
Table 4.3 Characteristics of cases with non-progressive vs. progressive disease in patients with metastatic
midgut, pancreatic or unknown primary
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When absolute changes in target lesions were assessed, 23 of 27 (85%) patients with
detectable CTCs had growth of tumour lesions, and 31 of 36 (86%) patients without
CTCs had no growth or spontaneous shrinkage (Figure 4.2). There was no association
between the number of CTCs and absolute increase in tumour size.
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Figure 4.2 Percentage Increase in lesions on imaging grouped by the presence of CTCs. Each bar
represents an individual case. Cases without CTCs are grouped on the left-hand side of the chart
(CTC=0); cases with CTCs detected on the right-hand side (CTC≥1)
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4.3.2. The Combined Dataset of Surveillance and Treatment Groups
Having established that CTCs are associated with progression of tumour when assessed
retrospectively, it was hypothesised that CTCs are associated with a poor prognosis.
The combined dataset of surveillance and treatment groups (n=175) from chapter 3 was
prospectively studied for this purpose.
The background characteristics of the combined dataset are shown in chapter 3, Table
3.2.
4.3.3. Training and Validation Sets to Establish CTC Prognostic
Threshold
I aimed to select a level of CTCs that most clearly distinguished patients with slow
progression or stable disease from those with rapid progression. To achieve this,
increasing thresholds of baseline CTC levels were systematically correlated with PFS
for a ‘training set’ comprising of 90 patients from the combined dataset (n=175).
Specifically, Kaplan-Meier survival curves were plotted comparing patient groups
above and below each threshold and log-rank testing performed to obtain significance
levels of difference across groups. Thresholds were tested commencing at CTCs of one
and above, increasing by 1 CTC until 50 CTCs. Thereafter, CTC thresholds between 50
and 1000 were tested at increments to include the next CTC count sequentially (Table
4.4).
Survival differences were greatest at a CTC level of one i.e. those without CTCs
(CTC=0) and those with CTCs (CTC≥1). Cox-proportional hazards also demonstrated
that survival difference was greatest at this level. Thus a cut-off of 1 CTC per 7.5ml was
chosen to distinguish patients with an unfavourable prognosis from patients with a
favourable prognosis. The same optimal cut-off was also identified when OS was
analysed instead of PFS.
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Groups
(CTC Cut-off)
Numbers in
each group
12 months
PFS (%)
Survival
Difference
Hazard
Ratio
P Value
0
1
35
50
88
50 38 4.3 0.001
0-1
2
40
50
87
50 37 4.3 0.002
0-2
3
46
44
85
55 30 3.3 0.002
0-3
4
49
41
78
52 26 3.3 0.002
0-4
5
54
36
77
49 28 3.4 0.001
0-5
6
55
35
76
45 31 3.1 0.002
0-6
7
58
32
74
45 29 2.8 0.004
0-7
8
60
30
70
51 18 2.4 0.013
0-8
9
62
28
71
47 24 2.4 0.012
0-9
10
64
26
71
54 17 2.4 0.015
0-10
11
66
24
71
51 20 2.8 0.005
0-11
12
68
22
71
50 21 2.5 0.015
0-12
13
69
21
71
48 23 2.3 0.023
0-13
14
69
21
71
48 23 2.3 0.023
0-14
15
69
21
71
48 23 2.3 0.023
0-15
16
69
21
71
48 23 2.3 0.023
0-16
17
70
20
71
48 23 2.3 0.023
0-17
18
71
19
72
45 27 3.0 0.004
0-18
19
71
19
72
45 27 3.0 0.004
0-20
21
72
18
73
41 32 3.3 0.001
0-21
22
73
17
73
37 36 3.7 0.001
0-22
23
73
17
73
37 36 3.7 0.001
0-23
24
73
17
73
37 36 3.7 0.001
0-24
25
73
17
73
37 36 3.7 0.001
0-25
26
73
17
73
37 36 3.7 0.001
0-26
27
74
16
72
39 33 3.3 0.002
0-27
28
74
16
72
39 33 3.3 0.002
0-28
29
74
16
72
39 33 3.3 0.002
0-29
30
74
16
72
39 33 3.3 0.002
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0-30
31
74
16
72
37 35 3.6 0.001
0-31
32
74
16
72
37 35 3.6 0.001
0-32
33
74
16
72
37 35 3.6 0.001
0-33
34
74
16
72
37 35 3.6 0.001
0-34
35
74
16
72
37 35 3.6 0.001
0-35
36
74
16
72
37 35 3.6 0.001
0-36
37
74
16
72
37 35 3.6 0.001
0-37
38
76
14
71
34 37 3.9 0.001
0-38
39
76
14
69
31.5 37.5 3.9 0.001
0-39
40
76
14
69
31.5 37.5 3.9 0.001
0-40
41
76
14
69
31.5 37.5 3.9 0.001
0-41
42
76
14
69
31.5 37.5 3.9 0.001
0-42
43
76
14
69
31.5 37.5 3.9 0.001
0-43
44
76
14
69
31.5 37.5 3.9 0.001
0-44
45
76
14
69
31.5 37.5 3.9 0.001
0-45
46
76
14
69
31.5 37.5 3.9 0.001
0-46
47
77
13
69
31.5 37.5 3.9 0.001
0-47
48
77
13
69
31.5 37.5 3.9 0.001
0-48
49
77
13
69
31.5 37.5 3.9 0.001
0-49
50
77
13
69
31.5 37.5 3.9 0.001
0-50
51
79
11
63
27 36 4.1 0.001
0-53
54
80
10
63
30 33 3.9 0.001
0-58
59
81
9
63
33 30 3.8 0.002
0-59
60
83
7
61
29 32 4.1 0.002
0-70
71
84
6
65
33 32 3.7 0.008
0-110
111
85
5
65
40 25 3.0 0.040
0-270
271
86
4
65
25 40 4.8 0.011
0-430
431
87
3
71
0 71 11.2 0.001
0-542
543
88
2
70
0 70 7.9 0.006
0-1150
1151
89
1
70
0 70 21.5 0.006
Table 4.4 Establishing the cut-off for CTCs in the 'training' set. Groups were split into below and above
different CTC cut-offs in rows. 12 months PFS with survival difference between groups, hazard ratio and
P value shown in rows.
127
To test for consistency, this CTC threshold was then tested with 85 subsequently
enrolled patients, the ‘validation set’. The distributions of patients above and below the
cut-off level in the training and validation sets were compared with the use of Fisher’s
exact tests, and median PFS and median OS in the two sets compared with
nonparametric k-sample test for equality of the medians. All P-values were two sided.
Neither PFS nor OS were significantly different between the validation and training sets
(log-rank PFS P=0.32, OS P=0.56) suggesting similar survival distributions. The
distribution of patients with CTC levels above the cut-off of ≥1 CTC per 7.5ml blood
did not differ between the training and validation sets (P=0.41). The cut-off level from
the training set was confirmed as separating two significantly different prognostic
groups in this validation set (Figure 4.3).
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Figure 4.3 Survival curves for training set PFS (A), training set OS (B), validation set PFS(C), validation set OS(D), demonstrating the
difference in survival between patients with CTCs present and those without CTCs i.e. a threshold of one or more CTCs
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4.3.4. CTCs as Prognostic Markers al in the Combined Dataset
Using the combined dataset incorporating both the surveillance and treatment groups
(n=175), Kaplan-Meier survival curves of PFS and OS are shown in Figure 4.4 with
univariate and multivariate analyses of prognostic indicators shown in Table 4.5 and
Table 4.6 respectively. Due to small numbers in some category groups, burden groups
25-50%, 50-75% and >75% were grouped together and PS 2, 3 and 4 were grouped
together. The median follow-up was 12.6 months (range 5-28).
Patients with CTCs had significantly worse PFS and OS than those patients without
CTCs. On univariate and multivariate analyses, presence of CTCs was a prognostic
factor for worse PFS and OS. Although CgA was a prognostic factor for OS on
univariate analyses, it was not significant on multivariate analyses and was not
significant in terms of PFS. G3 (high grade) was also an independent poor prognostic
indicator. A low burden (<25% liver involvement) was prognostic on univariate but not
on multivariate analyses.
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Figure 4.4 Survival curves demonstrating differences in PFS between groups according to (A)
presence of CTCs, (C) Grade, (E) CgA; and differences in OS between groups according to (B)
presence of CTCs, (D) Grade, (F) CgA (n=175)
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Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
CTC
Absence
Presence
89
86
1.0
6.6 (3.2-13.6) <0.001
1.0
8.0 (3.1-21) <0.001
CgA
CgA≤120
CgA>120
75
100
1.0
1.8 (0.9-3.3) 0.057
1.0
2.5 (1.2-5.3) 0.018
Grade (Ki67)
1
2
3
83
63
29
1.0
2.4 (1.1-5)
6.4 (3.0-14.0)
0.025
<0.001
1.0
1.6 (0.6-3.7)
4.3 (1.8-10.2)
0.330
0.001
Burden
<25%
≥25%
83
92
1.0
2.5 (1.3-4.6) 0.004
1.0
3.6 (1.6-7.9) 0.002
PS
0-1
≥2
167
8
1.0
1.7 (0.5-5.4) 0.385
1.0
1.3 (0.8-5) 0.401
Age
For every 10yrs 175 0.8 (0.6-1) 0.075 1.01 (0.8-1.4) 0.921
Table 4.5 Univariate analysis for prognostic indicators (n=175)
Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
CTC
Absence
Presence
89
86
1.0
3.3 (1.6-6.6) 0.001
1.0
3.7 (1.6-8.9) 0.003
CgA
CgA≤120
CgA>120
75
100 1.1 (0.5-2.2) 0.844 1.5 (0.6-3.7) 0.402
Grade (Ki67)
1
2
3
83
63
29
2.0 (0.9-4.2)
5.5 (2.4-12.3)
0.084
<0.001
1.2 (0.5-3.1)
3.4 (1.3-8.3)
0.633
0.008
Burden
<25%
≥25%
83
92 1.3 (0.6-2.6) 0.484 1.9 (0.8-4.6) 0.126
Age
For every 10yrs 175 1.3 (1.1-2.1) 0.034 1.1 (0.8-1.4) 0.543
Table 4.6 Multivariate analyses for prognostic markers allowing for age (n=175)
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4.3.5. CTCs as Prognostic Markers in Patients with Low (G1) and
Intermediate (G2) Grade NETs
Patients with G1 and G2 tumours constitute a large subgroup of NETs yet the clinical
behaviour within groups may vary significantly. There are no validated prognostic
markers that can be applied within these groups and I therefore examined the prognostic
value of CTCs within the G1 and G2 group combined and separately. Using the
combined dataset of surveillance and treatment groups (n=175), a subgroup of patients
who had either G1 or G2 grade NETs were analysed
There were 146 patients in this subgroup (28 progression and 19 death events). Survival
curves of PFS and OS are shown in Figure 4.5, with univariate and multivariate Cox-
proportional hazards regression shown in Table 4.7 and Table 4.8. Those with
detectable CTCs had significantly worse outcome compared to those who had no CTCs.
Presence of CTCs was an independent factor for worse PFS and OS whereas grade or
CgA were not prognostic.
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Figure 4.5 Survival curves demonstrating: differences in PFS between groups according to (A) presence
of CTCs, (C) Grade (G1 or G2), (E) CgA; and differences in OS between groups according to (B)
presence of CTCs, (D) Grade (G1 or G2), (F) CgA in a subgroup of G1 and G2 NETs
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Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
79
67
1.0
4.5 (2-10.1) <0.001
1.0
6.0 (2.0-18.1) 0.002
Baseline CgA
CgA≤120
CgA>120
58
88
1.0
1.7 (0.8-3.7) 0.170
1.0
2.2 (0.8-5.8) 0.112
Burden
<25%
≥25%
75
71
1.0
1.7 (0.8-3.5) 0.169
1.0
2.2 (0.9-5.7) 0.090
PS
0-1
≥2
139
7
1.0
1.7 (0.4-7.1) 0.479
1.0
2.7 (0.6-11.6) 0.191
Grade
1
2
83
63
1.0
2.2 (1-4.7) 0.043
1.0
1.8 (0.7-4.5) 0.206
Age
For every 10yrs 146 0.99
(0.7-1.4)
0.929 1.4 (0.9-2.0) 0.139
Table 4.7 Univariate analyses for prognostic factors in low and intermediate grade (G1 and G2) patients
(n=146)
Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
79
67
1.0
4.1 (1.6-9.4) 0.001
1.0
5.9 (2.0-18.1) 0.002
Grade
1
2
83
63
1.0
1.7 (0.8-3.8) 0.160
Not significant
in univariate
Age
For every 10 yrs 146 0.9 (0.7-1.3) 0.723 1.4 (0.9-2.1) 0.161
Table 4.8 Multivariate analyses for prognostic factors in low and intermediate grade (G1 and G2) patients
(n=146)
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4.3.6. CTCs as Prognostic Markers in Patients with Intermediate Grade
(G2) NETs
Using the combined dataset from the surveillance and treatment groups (n=175), a
subgroup of patients who had G2 grade NETs were analysed. This group was analysed
as it is unclear whether this intermediate grade group should be treated aggressively or
as more indolent tumours. There were 63 patients in this subgroup (17 progression
events, 11 death events). Survival curves of PFS and OS are shown in Figure 4.6 with
univariate and multivariate Cox-proportional hazards regression shown in Table 4.9 and
Table 4.10. Those with detectable CTCs had significantly worse outcome compared to
those who had no CTCs. Presence of CTCs was an independent factor for worse PFS
where neither CgA nor burden was prognostic. When OS was evaluated, although
presence of CTCs was prognostic on univariate analysis, it did not approach statistical
significance as an independent prognostic factor on multivariate analyses.
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Figure 4.6 Kaplan-Meier survival curves of (A) PFS and (B) OS demonstrating differences between groups according to presence of
CTCs in a subgroup with G2 NETs
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Risk Factor PFS HR(95% CI)
P -
value
OS HR
(95% CI) P - value
Baseline CTC
Absence (n-29)
Presence (n=34)
1.0
3.5 (1.2-10.1) 0.018
1.0
5.2 (1.1-24) 0.036
Baseline CgA
CgA≤120 (n=29)
CgA>120 (n=34)
1.0
1.7 (0.6-4.4) 0.293
1.0
3.6 (0.9-13.6) 0.060
Burden
<25% (n=31)
≥25% (n=32)
1.0
0.9 (0.3-2.4) 0.890
1.0
1.7 (0.5-5.7) 0.419
PS
0-1 (n=61)
≥2 (n=2)
1.0
1.3 (0.2-10) 0.805
1.0
2.9 (0.4-22.9) 0.308
Age
For every 10yrs 0.9 (0.6-1.4) 0.684 1.5 (0.9-2.6) 0.139
Table 4.9 Univariate analyses for prognostic indicators in intermediate grade (G2) patients (n=63)
Risk Factor PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence (n=29)
Presence (n=34)
1.0
3.7 (1.3-10.7) 0.016
1.0
4.2 (0.8-22) 0.091
Baseline CgA
CgA≤120 (n=29)
CgA>120 (n=34)
Not significant
in univariate 1.0
2.1 (0.5-8.8) 0.311
Age
For every 10 years 0.9 (0.6-1.3) 0.472 1.6 (0.8-3.2) 0.161
Table 4.10 Multivariate analyses for prognostic factors in intermediate grade (G2) patients (n=63)
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4.3.7. CTCs as Prognostic Markers in Patients with Low Grade (G1) NETs
Using the combined dataset from surveillance and treatment groups (n=175), a
subgroup of patients who had G1 grade NETs were analysed. It was important to
analyse this group as these are NETs with best survival, yet become more aggressive at
some point during the disease process often many years after the specimen was taken
that determines grade. There were 83 patients in this subgroup (11 PFS and 8 OS
events). Survival curves of PFS and OS are shown in Figure 4.7 with univariate and
multivariate Cox-proportional hazards regression shown in Table 4.11 and Table 4.12.
Those with detectable CTCs had significantly worse outcome compared to those who
had no CTCs. Presence of CTCs was an independent factor for worse PFS and OS
whereas neither CgA nor burden was prognostic.
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Figure 4.7 Kaplan-Meier survival curves of (A) PFS and (B) OS demonstrating differences between groups according to presence of CTCs
in a subgroup with G1 NETs
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Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
50
33
1.0
5.0 (1.3-18.5) 0.017
1.0
7.2 (1.3-39.4) 0.023
Baseline CgA
CgA≤120
CgA>120
29
54
1.0
2.4 (0.6-9.4) 0.200
1.0
1.3 (0.3-5.6) 0.724
Burden
<25%
≥25%
44
39
1.0
2.8 (0.8-9.8) 0.098
1.0
2.6 (0.6-10.8) 0.197
PS
0-1
≥2
78
5
1.0
2.2 (0.3-18.0) 0.449
1.0
3.0 (0.4-25.0) 0.311
Age
For every 10yrs 83 1.2 (0.7-2.0) 0.562 1.2 (0.7-2.2) 0.559
Table 4.11 Univariate analyses for prognostic factors in low grade (G1) patients (n=83)
Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
50
33
1.0
4.9 (1.3-18.2) 0.019
1.0
7.0 (1.3-38.7) 0.025
Age
For every 10 years 83 1.1 (0.6-1.9) 0.747 1.2 (0.6-2.1) 0.712
Table 4.12 Multivariate analyses for prognostic factors in low grade (G1) patients (n=83)
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4.3.8. Background Characteristics of Patients Undergoing Treatment
Background characteristics of the patient sample (n=138) commencing treatment in the
prospective study are shown in Table 4.13.
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Pancreatic
n=31
Midgut
n=81
Broncho-
pulmonary
n=12
Unknown
Primary
n=11
Hindgut
n=3
Total
n=138
Age, median years (range) 51.5
(23-72)
63
(34-85)
50.5
(30-77)
63
(31-78)
74
(43-75)
60
(23-85)
Sex, n (%)
Male
Female
20
11
47
34
4
8
4
7
1
2
76
62
Grade
Low
Intermediate
High
9
7
15
48
28
5
4
6
2
2
6
3
0
2
1
63
49
26
Burden of Liver metastases
<25%
25%≤50%
50%≤75%
>75%
10
13
3
5
35
30
11
5
7
3
2
0
4
4
2
1
1
0
1
1
57
50
19
12
Duration of diagnosis,
median months (range) 33
(1-145)
30
(1-149)
20
(9-116)
15
(1-67)
18
(5-22)
26
(1-149)
CgA (pmol/L), median
(range)
56
(23-1000)
380
(26-1000)
129
(42-1000)
215
(51-1000)
64
(44-835)
264
(23-1000)
PS
0
1
2
3
4
22
9
0
0
0
49
28
3
0
1
8
4
0
0
0
6
5
0
0
0
1
2
0
0
0
86
48
3
0
1
Naïve to non-surgical
treatment
9 32 7 4 1 53
Previous treatments
Resection of primary
SST
Chemotherapy
TAE
Radionuclides
Interferon
Liver resection
15
8
14
2
10
3
6
43
43
9
13
4
2
8
5
3
3
0
0
0
0
0
2
6
2
1
0
0
1
1
1
0
0
0
0
64
57
33
17
15
5
14
Number of previous non-
surgical treatments
0
1
2
3
4
9
16
3
3
0
32
29
13
6
1
7
4
1
0
0
4
4
2
1
0
1
2
0
0
0
53
55
19
10
1
Table 4.13 Background characteristics of sample commencing treatment
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4.3.9. Distribution of CTCs in The Treatment Group
The number of CTCs detected across different primary NETs in the prospective study in
patients undergoing treatment are shown in Table 4.14 (hindgut NETs are not shown).
Pancreatic Midgut Bronchial Unknown
n 31 81 12 11
CTC>0 15 (48%) 49 (60%) 6 (50%) 11 (100%)
Median
CTC≥1
6 8 12.5 6
Mean CTCs 28 14.5 70.2 451.9
(±SEM) 15 7.2 48.2 343
95% CI 0-58 5-23 0-176 0-1217
Range of
CTCs
0-430 0-294 0-542 0-3731
Table 4.14 Distribution of CTCs in prospective study across different primary NETs
4.3.10. Survival in Group Undergoing Treatment using Baseline CTC
Count
Using the group commencing a new treatment (n=138), Kaplan-Meier survival curves
of PFS and OS are shown Figure 4.8 with univariate and multivariate analyses of
prognostic indicators shown in Table 4.15 and Table 4.16 respectively. Due to small
numbers in some category groups, burden groups 25-50%, 50-75% and >75% were
grouped together and PS 2, 3 and 4 were grouped together. The median follow-up was
9.7 months (range 5-29).
Patients with CTCs had significantly worse PFS and OS than those patients without
CTCs. On univariate and multivariate analyses, presence of CTCs was a prognostic
factor for worse PFS and OS. CgA at the same time-point was not a prognostic factor in
any analyses. G3 (high grade) was also an independent poor prognostic indicator.
Again, a low burden (<25% liver involvement) was prognostic on univariate but not on
multivariate analyses.
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Figure 4.8 Kaplan-Meier survival curves of (A) PFS and (B) OS demonstrating differences between groups according to presence of CTCs at baseline in
group of patients undergoing treatment
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Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
56
82
1.0
4.3 (1.8-10.3) <0.001
1.0
6.1 (1.8-20.3) <0.001
Baseline CgA
CgA≤120
CgA>120
49
89
1.0
1.53 (0.8-2.9) 0.190
1.0
2.14 (0.9-5.1) 0.070
Grade (Ki67)
1
2
3
63
49
26
1.0
1.3 (0.5-3.0)
4.7 (2.1-10.5)
0.590
<0.001
1.0
1.5 (0.5-4.4)
5.0 (1.8-13.2)
0.439
0.001
Burden
<25%
≥25%
57
81
1.0
2.5 (1.2-5.4) 0.015
1.0
4.6 (1.6-13.4) 0.005
PS
0-1
≥2
134
4
1.0
2.5 (0.6-10.5) 0.210
1.0
1.8 (0.2-13.3) 0.569
Age
For every 10yrs 138 3.0 (1.1-1.7) 0.017 1.1 (0.8-1.4) 0.502
Table 4.15 Univariate analyses for prognostic factors in patient group undergoing treatment (n=138)
Risk Factor n PFS HR(95% CI) P - value
OS HR
(95% CI) P - value
Baseline CTC
Absence
Presence
56
82
1.0
3.7 (1.5-8.9) 0.005
1.0
5.1 (1.5-17.3) 0.008
Baseline CgA
CgA≤120
CgA>120
49
89
1.0
1.7 (0.8-3.6) 0.189
1.0
1.6 (0.6-4.0) 0.294
Grade (Ki67)
1
2
3
63
49
26
1.0
2.0 (0.9-4.4)
5.5 (2.3-13.4)
0.078
<0.001
1.0
1.3 (0.5-3.3)
4.4 (1.8-10.9)
0.544
0.001
Burden
<25%
≥25%
57
81
1.0
1.4 (0.6-3) 0.449
1.0
2.7 (0.9-8.1) 0.069
Table 4.16 Multivariate analyses for prognostic indicators allowing for age in patient group undergoing
treatment (n=138)
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4.3.11. Changes in CTCs in Predicting Progression-free and Overall Survival
Having established the prognostic value of CTCs, I went on to investigate the
significance of changes in CTCs with therapy. One-hundred and thirty-eight patients
(138) who were about to commence a new treatment were recruited for the prospective
study (Figure 4.9). Baseline blood samples for CTC enumeration were taken in all
cases. Post-treatment samples were taken in 118 (86%) of cases at the first time-point
(3-5 weeks, median 4.3 weeks) and in 92 (67%) at the second time-point (10-15 weeks,
median 13.7 weeks). Reasons for missing post-treatment samples were death or inability
for patient to either return to hospital (or send sample) at appropriate time-point. The
median follow up was 9.7 months (range 5-29).
The prognostic significance of baseline CTC counts has already been discussed above.
In order to analyse changes in CTC counts, each post-treatment time-point was
considered separately (first and second post-treatment time-points). The percentage
change from baseline CTC was divided into tertiles:
1) ≥65% reduction from baseline CTC
2) from <65% reduction to <33% increase from baseline CTC or no change (but
with CTCs at baseline)
3) an increase ≥ 33% from baseline CTC
Patients who had zero CTCs before and zero CTCs after therapy were used as the
reference group. Those with zero CTCs at baseline and >0 CTCs after treatment, i.e. an
infinite increase, were included and then excluded from group 3 to investigate their
effect on the analyses.
Using Cox-proportional hazards regression, the effect of changes in CTCs (using these
four groupings) on PFS and OS were analysed (Table 4.17). Survival curves for these
groups are shown in Figure 4.10.
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??Figure 4.9 Flow diagram demonstrating numbers of patients undergoing sampling for CTCs before and
after treatment
?? ??
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Figure 4.10 Survival curves estimating differences in (A) PFS and (B) OS across
patients grouped according to changes in CTCs at time-point one (3-5 weeks) after
treatment
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Change from baseline (CTCs) n PFS HR(95% CI) P-value Events/n OS HR (95% CI) P-value Events/n
No Change (zero CTCs) 43 1.00 <0.001 35/117 1.00 P<0.001 21/118
≥65% reduction 23 2.86 (0.47-17.1) 4.00 (0.36-44.2)
<65% reduction or no change1 or <33% increase 22 12.6 (2.76-57.8) 15.7 (1.92- 127.5)
Increase2 ≥33% 29 23.1 (5.37-99.0) 18.9 (2.4-146)
[Increase3≥33%] [22] [21.7 (4.95- 95.1)] [30/110] [18.2 (2.27-146)] [18/109]
Table 4.17 Effect on OS and PFS of changes in CTCs after treatment with groups comparing first post-treatment sample time-point to baseline CTC count
1But had CTCs at baseline
2Including patients who had zero CTCs at baseline and >0 CTCs after treatment
3 Not including patients who had zero CTCs at baseline and >0 CTCs after treatment
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According to Table 4.17, it appears that the groupings stratified according to CTC
changes are associated with OS and PFS. In other words, the greatest increase in CTCs
(≥33% increase) at time-point 1 after treatment had worse PFS and OS than those with a
smaller increase or modest reduction (<65% reduction or <33% increase). Excluding
those cases which had 0 CTCs before but CTCs of one or more after treatment, i.e. an
infinite increase, made no significant impact and thus these cases were included in the
group with ≥33% increase in CTCs.
The group with best outcome was those with zero CTCs before and after therapy, then
followed by the group with ≥65% reduction. It might be argued since baseline CTC
absence is associated with better survival from earlier data, that baseline CTC is a
confounder. However, when looking at the characteristics of the different groupings,
there was no obvious difference in median baseline CTCs.
The effect of baseline CTC (not just as a dichotomous variable) was further
investigated. Splitting baseline CTCs into tertiles would result in one group of all zero
CTCs and it would be impossible to adjust for these as they could only fall into two of
the four ‘change in CTC’ groups in Table 4.17. To overcome this problem, both
baseline and first post-treatment time-point CTC were divided into tertiles. Cox
proportional hazards regression was used to evaluate the effect on survival of baseline
and then separately first post-treatment time-point CTC. Then the effect of first post-
treatment time-point CTC, adjusted for the baseline CTC, was analysed. This is shown
in Table 4.18 which demonstrates that when adjusted for baseline CTC, the first post-
treatment CTC is still predictive of PFS and OS. This is shown graphically in Figure
4.11 where the model appears to be a better predictor for OS than PFS.
When looking at post-treatment time-point 2, due to missing data and the number of
cases which had already progressed or died by this time-point, it was not possible to
categorise the changes in CTCs in tertiles as was possible with post-treatment time-
point 1. However, it was possible to demonstrate a clear association between the
absolute CTC count at the second timepoint and progression at that time-point (Table
4.19, P<0.001).
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n OS HR
(95% CI)
p-value Events/n PFS HR
(95% CI)
p-value Events/n
CTC
Baseline
0 55 1.00 0.002 28/138 1.00 <0.001 40/135
1-7 39 3.27(0.98, 10.89) 3.05 (1.21, 7.68)
>7 44 5.83 (1.95, 17.45) 4.62 (1.95, 10.95)
CTC Post
treatment
0 52 1.00 <0.001 21/118 1.00 <0.001 35/117
1-5 29 6.18 (1.20, 31.88) 10.48 (2.92, 37.67)
>5 37 13.17 (2.99, 57.99) 16.60 (4.92,55.77)
CTC Post
treatment *
0 52 1.00 0.005 21/118 1.00 <0.001 35/117
1-5 29 7.54 (1.25, 45.31) 15.16 (3.72, 61.75)
>5 37 19.11 (2.95, 123.95) 42.07 (9.39, 194.25)
Table 4.18 Effect of baseline and first post-treatment time-point CTC on OS and PFS *adjusted for baseline CTC count
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Figure 4.11 Kaplan-Meier Curves demonstrating (A) PFS and (B) OS stratified by baseline CTCs divided into
tertiles; (C) PFS and (D) OS stratified by post-treatment CTCs divided into tertiles (as in table 4.18)
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Status at time-point
2*
N (%) Median CTC at time-point 2 (25th, 75th
Centiles)
Have Progressed 21(22.8) 18 (4, 31)
Have not progressed 71(77.2) 0 (0, 2)
Table 4.19 Progression at time-point 2 (10-15 weeks) after treatment and progression
*Only patients who have CTC counts at time point 2 (Wilcoxon Mann-Whitney test p<0.001)
4.3.12. Changes in CTCs in Predicting Response to Treatment
Having established that changes in CTCs with therapy predict survival, I investigated
the ability of these changes to predict response. The changes in CTCs, according to the
groupings in Table 4.18 were analysed for an association with radiological response to
treatment (Table 4.20). There was a significant association between an increase in CTCs
after treatment and radiological progression (Fisher’s exact P<0.001). Individual
changes in cases’ CTC levels, grouped by response, is depicted graphically in Figure
4.12 with a subgroup of patients who were treated for progressive disease depicted in
Figure 4.13.
Response
0-0
CTCs
≥65%
reduction
<65% reduction to
≤33% increase
≥33%
increase
Disease
progression
1 2 10 16
Disease
stabilisation*
35 18 8 10
Table 4.20 Association between changes in CTCs from baseline and radiological response to treatment
(Fisher’s exact p-value <0.001) *stable disease or partial response
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Figure 4.12 Graphs displaying CTC changes from baseline grouped by radiological response to treatment
(partial response, stable disease, progressive disease). Single dots represent cases where post-treatment
samples were not taken due to death.
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Figure 4.13 Graphs demonstrating CTC changes before and after therapy grouped by responses to
treatment in a subgroup who had progressive disease prior to treatment. Single dots represent cases
where post-treatment samples were not taken due to death.
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4.3.13. Differences in CTC Changes Across Types of Treatment
Changes in CTC levels grouped according to type of therapy is depicted in Figure 4.14.
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Figure 4.14 Graphs displaying CTC changes before and after therapy grouped by treatment type
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4.3.14. Changes in Chromogranin A with Treatment
Having looked at the dynamic nature of CTCs with treatment in predicting outcome, I
investigated changes in the existing marker CgA with 107 cases having CgA evaluated
at the first time-point following treatment. Interestingly, as shown earlier, baseline CgA
was not an independent prognostic marker. CgA at time-point 1 (3-5 weeks) after
treatment was analysed similarly to the CTC analysis. Changes in CgA were divided
into tertiles which are shown in Table 4.21, together with median baseline and post-
treatment CgA levels. Using Cox-proportional hazards regression, the effect on PFS and
OS of these groups was investigated (Table 4.22). Changes in CgA after treatment were
not predictive of outcome. Figure 4.15 shows survival curves demonstrating that
changes in CgA do not predict outcome. In fact, although not significant, the group with
greatest increase in CgA had a slightly better outcome which is contradictory.
Interestingly, baseline CgA was higher in the group with greatest CgA reduction which
may account for the paradoxical hazard ratios in univariate analyses. These changes in
CgA were not predictive of radiological response to therapy (Table 4.23, P=0.645).
Percentage change in CgA
(pmol/L)
N Median CgA Baseline
(pmol/L)
Median CgA at Time point
1 (pmol/L)
>27% reduction 36 395 172
≤27% reduction or <12%
increase
36 212 200
≥12% increase 35 107 372
Table 4.21 Changes in CgA from baseline to first time-point after treatment (3-5 weeks) divided into
tertile groups shown with median CgA levels
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Percentage change in CgA
(pmol/L)
PFS HR (95% CI) p-value Events/n OS HR
(95% CI)
p-value Events/n
>27% reduction 1.00 0.54 31/104 1.00 0.42 21/107
≤27% reduction or <12%
increase
0.95
(0.41-2.21)
0.50
(0.17-1.48)
≥12% increase 0.63
(0.25-1.58)
0.64
(0.24-1.74)
Table 4.22 Effect of changes in CgA after treatment on PFS and OS
Response >27% reduction ≤27% reduction or <12% increase ≥12% increase
Disease progression 2 13 7
Disease stabilisation* 3 34 23
Table 4.23 Association between radiological response to therapy and percentage changes of post-treatment CgA at time-point 1 (3-5 weeks)
compared to baseline CgA (Fisher’s exact p-value = 0.645) *stable disease or partial response
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Figure 4.15 Survival curves estimating differences in (A) PFS and (B) OS across
patients grouped according to changes in CgA at time-point one (3-5 weeks) after
treatment
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4.4. Discussion
The results from this study indicate that the number of CTCs detected is a useful
predictor of progression-free and overall survival in metastatic NETs. More
importantly, in patients with metastatic NETs undergoing therapy, the level of CTCs at
first follow-up at a median of 4.3 weeks are predictors of eventual response, PFS and
OS.
Using data from the initial pilot dataset comprising patients undergoing surveillance or
treatment (n=63), it appears that the absence of CTCs in metastatic NETs is associated
with stable disease as defined by RECIST, whereas the presence of CTCs is associated
with progressive disease. I recognize limitations in this analysis whereby tumours were
classified as progressive using retrospective comparisons with previous scans in
heterogeneous groups. However, the median interval between scans and the distribution
of histological grades was similar between patients who had tumour progression and
those with no tumour progression. The pilot study was hypothesis-generating and the
findings have been confirmed in the prospective study.
This relationship between CTCs and progression allowed us to investigate CTCs
prospectively as a prognostic and predictive biomarker.
Using a training set, I evaluated the prognostic value of stepwise CTC cut-offs and
confirmed a cut-off of 1 CTC or more as carrying a worse prognosis in a validation set.
This cut-off is lower than thresholds in breast (5)[204], colorectal (3)[206] and prostate
(5)[205] but is clearly the threshold at which groups are split evenly with the greatest
survival difference, identified by log-rank testing and Cox regression. Since CTC
images are analysed by an operator, human error may classify cases incorrectly as the
difference between 0 and 1 CTCs is small. However, this also applies to other
thresholds in other cancers, and is limited here by the use of two independent blinded
operators, and operator consistency has previously been demonstrated in large
studies[153].
Of note, the proportion of 138 patients who had CTCs in the prospective study were
higher than in the first CTC chapter (pancreatic NETs 48% Vs 36%, midgut NETs 60
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Vs 51%). This is probably due to a higher proportion of patients with progressive
disease (as they were all undergoing treatment) which I have shown is associated with
CTCs.
Baseline CTC count was found to be a prognostic factor in terms of PFS and OS on
univariate and multivariate analysis. The only other significant factor on multivariate
analysis was grade. However, only having a high grade NET was prognostic (not G2 vs
G1); but G3 tumours are uncommon (29/175 patients) and are already known to confer
a worse survival. Although higher CgA was associated with worse OS on univariate
analysis in the large dataset, it was not prognostic on multivariate (at either 60 or 120
pmol/L thresholds) in any dataset. A higher burden was a significant predictor on
univariate but not in the multivariate model. Thus when adjusted for other factors, CTC
count was the only clinically useful prognostic indicator.
For poorly differentiated or G3 tumours it is clear that the clinical course is aggressive
and immediate treatment is usually warranted. However, for G1 and G2 tumours, the
clinical course may be uncertain at diagnosis and during follow-up. It was therefore
important to understand if CTCs were prognostic in the G1 and G2 subgroup. For this
analysis 29 G3 tumours were excluded from the total cohort of 175. The presence of
CTCs was prognostic and had clearly separable survival curves compared to CgA and
grade (Figure 4.4). Once again, the presence of CTCs was the only significant predictor
of PFS and OS (HR 4.1 and 5.9 respectively) when adjusted for other factors. This is
important as the presence of CTCs appears to be a better prognostic marker than
grading. This could be clinically useful where those with CTCs could be treated earlier
and more aggressively than those without CTCs as they have a worse survival. These
results were similar when the subgroup of G1 NETs were analysed and did approach
significance in G2 NETs. However, these are subgroup analyses with fewer events and
must be interpreted with caution.
Some categorical variables analysed with regression, including performance status and
metastatic burden, were grouped together due to small numbers in certain categories.
Although continuous information was lost, this led to more evenly distributed groups
and robust analysis.
Importantly, the percentage change in CTCs 3 to 5 weeks after commencement of
treatment compared to baseline appears to predict PFS, OS and response to therapy. The
latter is best shown graphically (Figure 4.10) especially in those treated for progressive
disease (Figure 4.12). The best outcome occurred in those with 0 CTCs before and 0
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CTCs after therapy and the worst outcome with an ≥33% increase. Those with
detectable CTCs after treatment but with none pre-treatment had similar outcome to the
≥33% increase group and were thus incorporated into this group in further analysis.
These findings were confirmed when data were analysed by an alternative method
which may be more clinically useful. When baseline and post-treatment CTCs were
grouped into tertiles, these groups were predictive of PFS and OS. Hazard ratios for
post-treatment CTCs were higher than those of baseline CTCs indicating that the post-
treatment sample divided into tertiles could be used clinically to assess outcome. If
post-treatment CTCs were 0, this confers a good outcome compared to 1-5 CTCs, which
confers a better outcome than >5CTCs post-treatment.
My methods are alternative methods of analysing changes in CTCs which tackles the
problems with studies in other cancers where small changes across the CTC threshold
are significant which is prone to error e.g. where a change in 1 CTC could confer a
change in group[204].
Interestingly, those with a ≥65% reduction in CTCs over baseline adopted a PFS, OS
and response almost similar to that of the reference group (0 before, 0 after treatment)
implying two groups with similar outcomes. This included 15 patients who had
undetectable CTCs at this time-point, having had detectable CTCs prior to commencing
treatment. This may be a clinically useful finding to help early identification of patients
who are likely to respond to treatment.
The change in CTCs after treatment gives additional information than solely using
baseline CTC count. In other words, changing the CTC count by treating the tumour can
change the outcome. Even if high at baseline, if the CTC count can be reduced by ≥65%
with treatment, the survival can be improved. Given that this change in outcome and the
response to therapy can be predicted at 3-5 weeks into treatment, it may give the early
opportunity to stop therapies which may be toxic and expensive or to continue them if
beneficial rather than awaiting imaging several months later.
There was no significant difference in clinical factors (age, gender, burden, CgA,
baseline CTC) between the groups stratified according to percentage change in CTCs
that could account for the difference in survival. Although grade could possibly be a
confounder, there was no clear incremental association and on multivariate analysis, it
was only G3 NETs (in addition to CTCs) that were a significant factor, which is an
expected finding.
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It was impossible to adjust these groupings (according to CTC change after therapy) for
baseline CTCs (as a continuous variable) but our alternate method demonstrated that
post-treatment CTC counts were still predictive when adjusted for the baseline CTC
(when divided into tertiles). The change in CTC after treatment at 3 to 5 weeks was still
predictive of PFS in the multivariate model but only approaching significance with OS.
However, with four categories in this variable, three other variables in the model, and
few events in each group, confidence intervals were wide. Thus given the median
follow-up of 10 months, a robust multivariate analysis might require longer follow-up
when there have been more progression events and deaths.
Importantly, in addition to CgA not having the same prognostic value as CTCs at
baseline, changes in CgA were not predictive of response to therapy, nor of PFS or OS.
The group with greatest reduction in CgA had a higher baseline CgA which may
account for the paradoxical hazard ratios curiously implying worse survival with larger
reductions in CgA. Although caution must be taken in interpreting this, it is clear from
the data and the survival curves, that CgA was not a independent prognostic or
predictive biomarker.
Unfortunately when time-point 2 (10 to 15 weeks after commencing treatment) was
analysed, there were only 92 cases and it was not appropriate to split into tertiles due to
missing data and the number of cases that had already progressed or died by this time-
point. Although there was an association between the absolute CTC count at this time-
point and progressive disease, it may be that this is not an optimal time-point.
There are limitations to my study. I have analysed CTCs as a dichotomous variable i.e.
absence and presence. Such simplicity may cause some intrinsic problems, notably loss
of information and power, increased possibility of false-positive results, and
impossibility of detecting non-linear relationships between the variable and outcome
which may mean information is lost. However, this is a threshold which I have
validated with a training and validation set and is a method which has been used in
other studies[154, 155, 205]. Although I have shown variation between different
treatments in individual changes in CTCs graphically, further studies are required to
look at the effect of different treatments on CTCs in a homogenous population.
I have also analysed two overlapping populations in this chapter, one from an early
chapter and one group about to commence therapy. Although the latter was less
heterogeneous, both were recruited prospectively. Regardless of this, due to
heterogeneity in grade, treatments undertaken, time since diagnosis, further studies
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would be useful in more homogeneous populations but given the rarity of NETs, this
may be difficult.
The subgroup survival analysis of G1 and G2 NETs as well as individual NETs could
provide clinically useful information. It is often these grades where questions exist with
regards to optimum treatment and optimum timing of treatment. If CTCs predict a
prognostically worse phenotype, this may mean more aggressive treatment is required
earlier. However, given that this is subgroup analysis with smaller numbers of events,
caution must be taken.
In addition to the problems with analysing time-point 2 post-treatment (10-15 weeks)
and missing data, limitations exist in timing of sampling. The post-treatment time-point
1 (3-5 weeks) was chosen as it is a clinically useful time for review, assessing toxicity,
and is similar to other CTC studies in other cancers. However, in order to find the
optimal time-point for predictive marker, studies are required at smaller intervals and
also may be different for different therapies.
Lastly, I acknowledge that CTCs were evaluated in a heterogeneous group with
different primary NET types and heterogeneity in terms of previous and subsequent
treatments undertaken. I would recommend that these findings are validated in
prospective trials of defined treatments in defined tumour groups with longer follow up.
Current methods of monitoring for progression and response to treatment in NETs
include radiological imaging. This may be confounded by inter-observer variability and
the fibrotic reaction often seen in NETs.[259, 260] This dependency on serial imaging is
costly and exposes patients to radiation considering the varied survival with NETs
compared with other tumours. Given the varied survival with NETs compared with
other tumors, this dependency on serial imaging is costly and exposes patients to
radiation. In NETs, CTCs may be of prognostic value in discriminating progressing
from stable tumors, which may assist stratification for aggressive therapy at time of
diagnosis. Given the recent focus on the delayed response seen in NETs with
chemotherapy and radionuclides,[54, 232], CTCs may offer predictive information early
during therapy and may be useful in monitoring response to therapy without repeated
exposure to radiation.
This study met REMARK criteria for biomarker evaluation and from this study, I
conclude that CTCs are clinically prognostic and predictive biomarker in metastatic
NETs.
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Chapter 5. Circulating cell-free DNA (cfDNA) in NETs
5.1. Introduction
Nucleic acids were identified in human plasma in both healthy subjects and patients
with various diseases five years prior to Watson and Crick elucidating the double-
helical structure of DNA[261]. It was not until the 1960’s that interest was revived in
serum or plasma DNA in diseases including systemic lupus erythematosis (SLE)[262].
Hereafter, increasingly sensitive assays were developed leading to detection of DNA in
serum or plasma of healthy individuals at levels between 10 and 30ng/mL[263]. Cell-
free DNA (cfDNA) is defined as extracellular DNA occurring in blood[264].
5.1.1. Origins of cfDNA
Theories of the origin of tumour-related cfDNA in the circulation include: apoptosis or
necrosis of tumour (or of circulating tumour cells), or active release of DNA into the
circulation from a tumour.
In healthy subjects, it is assumed that cfDNA originates from lymphocytes and other
nucleated cells[265, 266] but It is not known why cancer patients have higher quantities
of plasma cfDNA. The origins of plasma cfDNA in the initial studies were thought to be
from tumour cells or from activated lymphocytes. Since DNA originating from cancer
cells has decreased strand stability when carcinogens are added, strand separation was
found to occur at lower temperatures and in vitro DNA synthesis was increased
compared with DNA from healthy subjects using electrophoresis[267]. Detection of loss
of heterozygosity (LOH) in plasma cfDNA also suggests mutant cfDNA is the
predominant subtype of cfDNA[156, 267]. This suggested that a significant fraction of
cfDNA in plasma originated from the tumour rather than from lymphocytes.
cfDNA found in plasma of cancer patients is likely to originate from necrotic or
apoptotic tumour cells. Apoptotic or necrotic cells result in small fragments of 70 to 200
base pairs and large fragments of 21 kilobases[268]. The theory of tumour necrosis is
supported by high amounts of cfDNA found in plasma with large tumours or with
advanced diseases with metastases[267, 269, 270, 271]. However, radiation therapy
reduced plasma DNA levels by up to 90% which would be inconsistent with this[156]
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as one would expect a shower of cfDNA if necrosis played an important role in the
production of cfDNA.
More recently, there has been increasing evidence to support apoptosis as the origin of
cfDNA. Plasma and serum derived cfDNA often has several bands on electrophoresis
similar to patterns shown by apoptotic cells[267, 270, 272]. An argument against this,
however, is that apoptosis is a mechanism lost by proliferating cancer cells.
The theory of circulating tumour cells as sources of cfDNA is supported by a study that
found an association between CTCs and quantity of cfDNA[273]. Certainly, a small
proportion of cfDNA comes from lysis of fragile cancer cells that become detached
from the tumour and enter the bloodstream[274]. However, if cfDNA is due to lysis of
circulating cancer cells, there needs to be many more CTCs detected than is found in
studies to date.
Another possibility is that tumour actively releases DNA into the circulation in a similar
process to lymphocytes after phytohaemaglutinin activation in vitro[275] [276]. This
has also been demonstrated in mice after a mitogenic effect of bacterial
lipopolysaccharide[277] and also from human leukaemic cell lines[278] and again
resulted in a ladder pattern.
In summary, the origins of cfDNA remains disputed.
5.1.2. Structure of cfDNA
Few studies have studied the form of soluble cfDNA in the circulation. In an early study
in a number of cancers, plasma cfDNA was found in double-stranded fragments and,
using a 32P labeled human DNA probe, was identified as human in origin[270]. Another
early study utilised transmission electron microscopy (TEM) and demonstrated the bulk
of cfDNA in normal individuals averaged 1.2-1.6 μm in length with a few at 0.1 μm and
the longest 20 μm[279].
More recent studies using nick-translation of the extracted DNA and autoradiographic
evaluation after electrophoresis, concluded that at least some of the cfDNA exists in
association with nucleosomes[280, 281, 282]. A nucleosome is a histone octamer core
wrapped twice by a 185-200base pair-long DNA strand.
Electrophoresis bands of plasma cfDNA in patients in one study were stronger and
larger than controls, with a greater aggregate density of oligonucleosomal bands in one
study in pancreatic cancer, but this may have resulted from cfDNA nicking in these
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samples[282]. Consistent with other studies, a higher concentration of cfDNA was
found in cancer patients compared to controls. Using electrophoresis, this study
demonstrated the minimum cfDNA length of ~145bp (49nm) approximating to the
length of a DNA strand wrapped around a single histone octamer[282]. Low molecular
weight bands predominated.
Higher molecular weight cfDNA found in plasma is known to originate from
apoptosis[283]. The finding that short oligonucleosomal strands comprise the majority
of plasma cfDNA suggests that degradation of genomic DNA has occurred
intracellularly during apoptosis, and not after the DNA was released into the plasma.
Under physiological conditions, nucleosomes are packed into apoptotic particles and
engulfed by macrophages[284]. Rapidly proliferating cancer cells or chemotherapy
treatment leads to saturation of macrophage engulfment process and increases the
number of nucleosomes in the circulation[285]. Increased levels of these circulating
nucleosomes have been associated with breast cancer progression[286].
Digestion of DNA during apoptosis is caused by endonucleases breaking the DNA
strands randomly between nucleosomes[287, 288, 289, 290], to date these
endonucleases have not been identified in plasma[291]. Animal studies have
demonstrated that nucleic acids are cleared from the blood by the liver and kidneys with
a half-life varying from 15 minutes to several hours[292, 293, 294]. When compared
with human fetal cfDNA, which can be detected in maternal circulation, a shorter half-
life of 4 to 30 minutes was found[295].
Although RNA is detectable in plasma RNA, the focus of this chapter was on cfDNA
and thus circulating RNA will not be discussed[296, 297].
5.1.3. Quantification of cfDNA
Using a radioimmunoassay, Leon et al. discovered high levels of circulating DNA in
various cancer patients compared to non-malignant diseases (180ng/mL versus
13ng/mL)[156]. No correlation between detected cfDNA quantity and size of tumour
was found, however higher quantities were found in those with metastases compared to
localized disease. Quantity of cfDNA detected varies depending on the cancer type. For
example, 90% of 65 patients with pancreatic carcinoma had serum DNA levels of >100
mg/mL compared to only 40% of 85 patients with colorectal carcinoma using the same
assay[269]. It must be remembered however that cfDNA is also found in other
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conditions such as SLE[298], viral hepatitis[281], following surgery and with
pulmonary embolism[299].
The range of cfDNA in plasma or serum varies between 0 and >1000ng/mL of
blood[298] in cancer patients compared to between 0 and 100ng/mL in healthy
controls[293]. The quantity or concentration of cfDNA varies according to the method
of extraction and differential sample handling as demonstrated in a multi-centre
prospective trial[300].
Plasma cfDNA appears to inversely correlate with outcome and tends to fall with
effective treatment[156, 267]. Several studies in lung cancer have also found a
correlation between response to therapy and a decrease in plasma cfDNA levels. An
increase in plasma cfDNA was associated with progression after chemotherapy[157,
301]. Following surgery, levels of cfDNA and nucleosomes can decrease to levels of
healthy individuals and when remains high, may indicate residual disease[302, 303,
304]. This suggests quantification of cfDNA may be useful as a prognostic and
predictive biomarker. However, there are also other studies suggesting no
correlation[305].
cfDNA includes coding and non-coding genomic DNA which can be used to examine
loss of heterozygosity (LOH), mutations, polymorphisms, methylation and repeated
elements.
5.1.4. Repeated Elements Throughout the Genome in cfDNA
Non-coding repetitive sequences, once thought to be ‘junk DNA’, such as ALU, a short
interspersed nucleic element (SINE), and long interspersed nucleic elements such as
LINE1 are known to be hypomethylated in cancer cells compared to normal cells[306].
Their importance have been demonstrated in DNA repair, transcription, genomic
stability and involvement in epigenetic phenomena[307, 308]. Although these assays
are in their infancy when applied to cfDNA, ALU, LINES and SINES (200-400bp) can
be found in serum or plasma with potential prognostic and diagnostic purposes in a
variety of cancers[309] [310, 311]. For example, using PCR, the integrity of ALU
sequences in blood is sensitive for early stage breast cancer including
micrometastases[312].
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5.1.5. The Use of Tumour-specific Mutations as Biomarkers in cfDNA
Cancer is characterized by multiple somatic genetic and epigenetic alterations that could
potentially be used as molecular markers for detecting tumour-specific DNA in different
bodily fluids. The development of the polymerase chain reaction (PCR) aided research
into the nature of circulating DNA with mutations in the primary tumour also being
detected in plasma DNA. For example, Anker et al. identified KRAS mutations in 7 of
14 colorectal primary tumours with Identical mutations found in the plasma of 6 of
these 7 patients[313]. These results have since been confirmed in other studies in
colorectal cancer demonstrating the same mutations in the tumours as blood
specimens[314, 315]. Clinically relevant mutations in BRAF, epidermal growth factor
receptor (EGFR) and adenomatous polyposis coli (APC) have been studied in cfDNA in
colorectal, lung cancer and melanomas[158, 316, 317, 318].
Pancreatic adenocarcinoma ls an ideal cancer to detect common mutations in plasma
since 90% of pancreatic adenocarcinomas have mutations in the KRAS gene[319].
Identical KRAS mutations have been found in tumour and plasma using restriction
fragment length polymorphism (RFLP)-PCR followed by DNA sequencing[320, 321].
It might be expected that specificity would be low since KRAS mutations have been
found in tissue from chronic pancreatitis[322]. However, KRAS mutations were not
found in these patients making raising its possibility as a diagnostic test for pancreatic
adenocarcinoma[323].
The presence of a KRAS mutation is an highly specific negative predictor of response to
EGFR tyrosine-kinase inhibition e.g. Cetuximab. Kimura et al. obtained tissue and
serum samples for EGFR mutation status in patients with lung cancer and found a
strong correlation between presence of KRAS mutation in serum and response, in
addition to a better PFS[158]. Interestingly, in a similar study, Moran et al.
demonstrated a complete response in 20% of patients with both tissue and serum KRAS
mutations and in 4% of patients with only a mutation in tissue[324]. Using digital PCR
to quantify common KRAS mutations, Yung et al. demonstrated that plasma levels of
mutant KRAS correlated with clinical response to therapy and a reduction in levels was
observed in all patients who had a partial or complete response[325]. KRAS mutations
were also found to be associated with worse overall survival in mucinous ovarian
cancer[326].
New approaches such as cfDNA sequencing have been studied recently. The BRAF
mutation, V600E, found in >70% of metastatic melanomas, can be detected using a
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quantitative real-time clamp PCR assay with higher quantities found in more advanced
disease[318]. This approach can also be used to monitor response to therapy, which
would be beneficial when assessing efficacy of anti-BRAF drugs in development[327].
Mutations in the p53 tumour suppressor gene found in ovarian[328], head and
neck[305] and colorectal cancers[329] have also been determined and analysed in
cfDNA.
Disadvantages include low assay sensitivity and specificity and in addition, the low
frequency of tumour specific somatic mutations which occur in neuroendocrine
tumours[298] [21]. Furthermore, there is no complete concordance between alterations
found in the primary tumour and cfDNA in any cancer[330, 331, 332].
5.1.6. Epigenetics
Hypermethylation of tumour suppressor promoters in tumour tissue is an important
epigenetic mechanism for tumour suppressor gene inactivation.
Aberrant DNA methylation can also be identified and utilised as a biomarker in the
serum of cancer patients. Methylation-specific PCR can determine changes in promoter
hypermethylation of the tumour suppressor gene p16, the DNA repair gene O6-
methylgunaine-DNA-methyltransferase (MGMT), and the detoxification gene
glutathione S-transferase P1 (GSTP1). When promoter methylation analysis of GSTP1
was performed on patients with non-small-cell lung cancer, aberrant methylation was
found in 15 of 22 patients, 11 of which had abnormal methylation in the matched serum
sample[159].
Bastian et al. demonstrated that hypermethylation of MDR1 was observed in serum
samples of 17% of metastatic prostate cancers[333]. When correlation with clinical
factors was studied, promoter hypermethylation of GSTP1 in serum was detected in
28% of patients with metastatic prostate cancer compared with only 12% with localized
prostate cancer[334]. Chuang et al. also found hypermethylated GSTP1 promoter in 11
of 36 plasma samples from patients with prostate cancer but did not report a correlation
with diagnostic or prognostic variables[335]. Other bodily fluids can also be used.
Promoter hypermethylation of GSTP1 in urinary derived DNA has been used to
distinguish prostate cancer from benign prostatic disease[336].
Ponomaryova et al. found methylation of the gene RARbeta2 in cfDNA was associated
with disease progression in non-small cell lung cancer[337].
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The association between circulating tumour cells and methylated DNA has been
explored. Using methylation specific PCR on serum of patients with metastatic prostate
cancer, circulating tumour cells (CTCs) were detected in 36 of 39 patients with tumour-
related methylated DNA but only in 11 of 37 without[338]. Promoter methylation was
studied in APC, GSTP1, prostaglandin-endoperoxide synthetase 2 (PTGS2), MDR1, and
Ras association domain family 1 isoform A (RASSF1a). Hypermethylation of only one
of this panel of loci conferred a shorter survival. In another study, patients with
melanoma who had CTCs and methylated RASSF1a and RARB in blood had a poorer
response to chemotherapy and a shorter PFS and OS[339]. Van der Auwera et al. also
demonstrated a correlation between promoter methylation of APC, RASSF1a and
oestrogen receptor 1 (ESR1) in cfDNA and CTCs in breast cancer[340]. This suggests
that CTCs are a potential source of cfDNA due to association of cell-free, methylated
APC, RASSF1a molecules with CTCs.
Methylation of RASSF1a and PITX2 in plasma DNA has also recently been found to be
prognostic of PFS and OS in breast cancer[341].
5.1.7. Microsatellite alterations and Loss of Heterozygosity
Microsatellites are short repetitive and highly polymorphic DNA sequences.
Microsatellite alterations defined as the presence of allelic imbalance (AI) or loss of
heterozygosity (LOH) and valuable as clonal markers for cancer[342]. These
microsatellite alterations have also been detected (and matched) in the plasma of
patients in head and neck cancers[271], lung cancer[343, 344] and renal cancer[345].
However, there are limitations using these markers in plasma and serum as LOH or
microsatellite alterations may be masked by normal DNA from lymphocytes.
5.1.8. Assays, Methodology and Technical Aspects
There are several factors which affect cfDNA yield from patient to patient such as
whether plasma or serum is used, time between blood collection and centrifugation, and
storage temperature can have influence on yield[346]. Levels of cfDNA were
unchanged in EDTA stabilized blood stored at room temperature for 8 hours or at 4°C
for 24 hours[347]. However, another study demonstrated a 3- to 5-fold increase in
serum DNA upon storage at room temperature without the addition of additives[348].
Although not comprehensively investigated, storage of frozen serum and plasma
samples may affect yield. Intact mRNA was detected in samples after 2 years of storage
at -70°C and KRAS mutations in plasma DNA after 6 years of storage at -70°C [315,
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349]. Studies on foetal DNA in serum found a decline in cfDNA by a factor of 0.66
genome equivalents/mL per month for storage at -20°C[350]. Additional freeze-thaw
cycles of plasma but not of extracted DNA affects fragmentation of cfDNA[351].
Both plasma and serum have been studied as compartments for cfDNA but there is no
definitive answer on which is better. Yield appears to be higher from serum most likely
due to clotting and release of DNA from destroyed white blood cells[352, 353].
There are a number of different methods for DNA extraction from blood. Most studies
use commercial kits, utilizing silica-gel membrane technology by selective binding and
stepwise elution, but there is no accepted standard[354]. Generally, quantities of cfDNA
are low and of poor quality irrespective of extraction technique. Use of commercial kits
over crude techniques have made extraction steps more reliable but some DNA is lost as
columns do not bind small DNA molecules (less than 150 base pairs) efficiently[355,
356].
The methods used in studies to quantify cfDNA include fluorometric methods and
spectrophotometry[357], electron microscopy[279], and more recently, real-time
quantitative PCR. A flurorescence-based (PicoGreen staining) and real-time PCR
(SybrGreen and Taqman format) were compared to quantify cfDNA in patients with
non-small cell lung cancer in one study[358]. Higher quantities of cfDNA was detected
by the fluorescence-based method and this is considered to be sensitive method to a
detection of 1 ng/mL.
Studies conflict on the fluctuation of levels of cfDNA in plasma. A variation of 2.2-fold
was demonstrated of foetal cfDNA in maternal circulation over three days[359] whereas
no fluctuation was found in three days in patients with colorectal cancer[360].
5.1.9. Theory of Genometastases
cfDNA in plasma may partake in tumorigenesis which is supported by a study where
plasma of colorectal cancer patients induced the oncogenic transformation of
susceptible cultured cells[361]. This followed on from experiments where cfDNA from
tumour-bearing rats was taken up by cells and incorporated into the genome[362]. More
specifically, tumour-specific methylated DNA fragments can penetrate into cells more
efficiently and have a higher transformation potential than unmethylated
counterparts[363]. However, this is an area which has not been extensively investigated.
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5.1.10. Circulating Nucleic Acids in NETs
Although circulating messenger RNA (mRNA) in patients’ plasma has been described
in NETs as a means for distinguishing metastatic versus local disease[140], the field of
circulating nucleic acids is not an area that has been thoroughly investigated in NETs.
RNA is more unstable than DNA as RNA is readily degraded by RNases during cellular
degeneration[296, 297] and by RNases in blood plasma[364, 365]. Hence I focused on
DNA in these experiments since the applications on cfDNA mentioned above i.e.
promoter methylation, amplification of repeated elements and mutational analyais could
then be possibly applied in patients with NETs. To date, there is no study exploring
cfDNA in NETs. Therefore the aims of these experiments were:
 to identify cfDNA in the blood of patients with NETs
 to compare cfDNA extracted between matched plasma and serum samples from
patients in NETs
 to explore the relationship between cfDNA and CTCs in patients with NETs
5.2. Materials and Methods
5.2.1. Patient Recruitment
Eighty-eight patients were recruited between December 2009 and June 2011 for blood
sampling. All eligible participants had histologically proven NET, metastatic disease
measurable by RECIST criteria. They were categorised according to the site of primary
NET: midgut, pancreas, bronchopulmonary, hindgut or of unknown primary.
Additionally 20 healthy volunteers were recruited for blood sampling. Volunteers were
excluded if they had a current or past cancer, active infection, recent surgery within 1
month, current inflammatory disease or chronic disease (apart from hypertension). This
study was approved by the Local Ethics Committee (Ref 09/H0704/44) and all patients
and volunteers provided written informed consent.
5.2.2. Blood Sample Preparation
For serum preparation, blood samples were drawn into a 10ml plain red blood collection
tube (Becton Dickinson, Oxford, UK). Samples were left to clot for approximately15
minutes and then centrifuged within two hours at 1,500 X g for 10 minutes at 4oC.
Serum was separated and aliquoted into 0.5 mL Cryobank vials (Nunc, Denmark). Vials
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containing serum were immediately transferred to a -80 °C freezer and stored until
required.
For plasma preparation, blood samples were drawn into a 4ml EDTA blood collection
tube (Becton Dickinson, Ox, UK). Samples were centrifuged within 2 hours at 1,500 X
g for 10 minutes at 4oC. 2mls plasma were separated carefully and aliquoted into
Cryobank vials. Cell pellets were discarded. Vials containing plasma were immediately
transferred to a -80 °C freezer and stored until required.
5.2.3. DNA Extraction
All samples and reagents were equilibrated to room temperature. 20μL of proteinase K
(Qiagen, Germany) was pipetted into the bottom of a 1.5mL microcentrifuge tube.
200μL of the plasma (or serum) sample, or PBS (control) was added to the tube. 200μL
of lysis buffer (Qiagen) was added to the mixture and mixed by pulse-vortexing for 15
seconds. The microcentrifuge tube was incubated at 56°C for 10 minutes. The
microcentrifuge tube was briefly centrifuged to remove drops from inside the lid.
200μL of 100% ethanol was added to the sample and mixed by pulse-vortexing for 15
seconds. The tube was once again centrifuged briefly to remove drops from the lid.
The mixture from the above steps were carefully transferred to a QIAamp Mini spin
column (Qiagen) and this was centrifuged at 6000 X g for 1 minute. After
centrifugation, the spin column was transferred to a clean 2ml collection tube. The tube
containing the filtrate was discarded.
500μL of wash buffer (Qiagen) was added to the spin column. After centrifugation at
6000 X g for 1 minute, the spin column was transferred to a clean 2ml collection tube.
The tube containing the filtrate was discarded.
500μL of wash buffer was added to the spin column. After centrifugation at 20,000 X g
for 3 minutes, the spin column was transferred to a clean 2ml collection tube and the
tube containing the filtrate discarded. This was centrifuged further at 20,000 X g for 1
minute and the spin column transferred to a clean 1.5ml microcentrifuge tube. The
filtrate was discarded.
For the elution step, 200μL distilled water was added to the spin column and incubated
at room temperature for 3 minutes. After centrifugation at 6000 X g for 1 minute, the
spin column was discarded and the extracted DNA processed for further experiments or
stored at 4°C until ready for use.
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5.2.4. DNA Separation, Sizing and Quantification
For the determination of cfDNA fragment length and quanitification, high sensitivity
DNA kits (Agilent Technologies, CA, USA) were used containing microfluidic chips.
This is useful for low concentrations of dsDNA (50pg/u μl) from 50-7000 base pairs
(bp).
Chip-based capillary electrophoresis was performed on the Agilent 2100 Bioanalyzer
(Agilent Technologies) in combination with a high sensitivity DNA kit. A validated
High Sensitivity DNA assay was available within the Agilent 2100 expert software. The
on-chip electrophoresis was performed according to the High Sensitivity DNA Kit
guide as per manufacturer’s protocol.
Briefly, to prepare the gel-dye mix, high sensitivity DNA dye concentrate and high
sensitivity DNA gel matrix were equilibrated to room temperature for 30 minutes. The
dye concentrate was vortexed, briefly centrifuged and then transferred to the vial
containing gel matrix. After vortexing, the gel-dye mixture was transferred to the top
receptacle of a spin filter. This was centrifuged at 2240 X g for 10 minutes at room
temperature.
After equilibrating to room temperature, 9μL of gel-dye mix was loaded, using a chip-
priming station, into a designated well in a 16-well high sensitivity DNA microfluidic
chip. Further 3 X 9μL of gel-dye mix were dispensed into 3 designated wells. 5μL of
high sensitivity DNA marker was dispensed into the 12 sample/ladder wells. 1μL of
high sensitivity DNA ladder was added to the designated ladder well. The chip was
vortexed carefully for 60 seconds on the IKA vortex mixer (Agilent Technologies)
before analysis on the 2100 Bioanalyzer.
5.2.5. CTC Isolation and Enumeration
The process of CTC isolation by immunomagnetic separation and subsequent
enumeration has been described previously in Chapter 3.
The total number of CTC events, i.e. including those not classified as CTCs, were also
recorded.
5.2.6. Comparison of DNA Yield from Serum and Plasma
To compare DNA extracted from plasma and serum, plasma and serum from patients
were collected. 44 pairs of samples (plasma and serum) from a subset of 44 patients
underwent DNA extraction and quantification as above. Results were compared. Serum
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from the 20 healthy volunteers were also processed for DNA extraction and
quantification and results compared to patient cases.
5.2.7. Analytical/Laboratory Reliability
5.2.7.1. Extraction Replicates
To test for reproducibility of the DNA extraction technique, 20 samples underwent
DNA extraction in duplicate. 400μL of plasma from the same aliquot was divided into
200μL fractions and both underwent DNA extraction as above. Results were compared.
5.2.7.2. DNA Quantification Replicates
To test for reproducibility of the DNA quantification assay using capillary
electrophoresis on DNA chips, 23 extracted DNA samples underwent DNA
quantification in duplicate. 2μL of extracted DNA was divided into 1μL fractions and
each were processed separately on the DNA chip as above.
5.2.7.3. Aliquot storage Replicates
To test for reproducibility after storage at different durations at -80°C, 5 plasma samples
underwent DNA extraction and quantification in duplicate. These samples were
processed, as above, within 1 month of storage and then repeated after 6 months of
storage at -80°C.
5.2.8. Intra-subject Reliability
To test for intra-subject variability, 17 patients had at least 2 blood samples for plasma
DNA extraction at different time-points. The repeat sample was taken within a range of
4 to 12 weeks. Patients were included if no new or change in therapy was planned.
Five of these patients had more than 2 samples taken at serial time-points with no
intervening treatment change.
5.2.9. Statistical Analysis
When considering the presence or absence of cfDNA i.e. a dichotomous variable,
prevalence-adjusted bias-adjusted κ (PABAK) was used to evaluate reliability of DNA
extraction replicates, DNA quantification replicates, storage replicates and intra-subject
replicates as well as validity when comparing to CTCs. This was used since some
values were 0, rendering Cohen’s κ unreliable. When cfDNA was considered as a
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continuous variable, a natural log transformation resulted in a normal distribution, thus
intraclass correlation coefficients (ICC) were calculated to evaluate reliability of DNA
extraction replicates, DNA quantification replicates, storage replicates and intra-subject
replicates. Kruskal-Wallis test was used to assess intra-subject variability of DNA
assays at serial timepoints.
Chi squared and student t tests were estimated to assess differences between healthy
controls and patients with regards to gender and age distributions respectively. Student t
test was estimated to assess difference in cfDNA concentrations between healthy
controls and patients (Chi squared when cfDNA considered as a dichotomous variable
i.e. present or absent).
Correlations between cfDNA and CTCs, between serum and plasma DNA
concentrations were assessed using Spearman’s rank test (Chi squared when presence of
cfDNA/CTC considered as a dichotomous variable).
Kaplan-Meier estimates of survival were based on the presence or absence of cfDNA.
For the purposes of survival analyses, progression-free survival (PFS) or overall
survival (OS) was defined as the time between the date when the baseline blood sample
was taken and the date of radiological progression, death due to neuroendocrine cancer
or last follow-up visit. Survival curves were compared using log-rank testing.
5.3. Results
5.3.1. Background Characteristics of Patient Population
The background characteristics of the 88 patients recruited for plasma cfDNA
evaluation are shown in Table 5.1.
178
All NETs
n=88
Pancreatic
n=12
Midgut
n=65
Broncho-
pulmonary
n=4
Unknown
Primary
n=4
Hindgut
n=3
Age, years
mean ± SD 61 ± 13 55 ± 15 61 ± 12 80 ± 0.7 61 ± 16 64 ± 18
Sex
Male
Female
47
40
7
5
36
29
1
3
2
2
1
2
Grade
Low
Intermediate
High
48
27
12
2
4
6
45
18
2
1
3
0
0
1
3
0
2
1
Burden of Liver
metastases
≤25%
25%≤50%
50%≤75%
>75%
49
22
10
6
4
3
2
3
39
18
6
2
2
2
0
0
3
0
1
0
1
0
1
1
Duration of diagnosis,
median months (range) 29
(1-150)
24
(1-146)
44
(2-150)
73
(58-87)
11
(1-30)
15
(5-22)
PS
0
1
2
3
4
58
25
3
1
0
8
4
0
0
0
45
17
3
0
0
2
2
0
0
0
2
1
0
1
0
1
2
0
0
0
Previous treatments
Resection of primary
SST
Chemotherapy
TAE
Radionuclides
Interferon
Liver resection
38
54
12
14
12
4
5
7
6
6
2
2
0
2
29
45
4
11
10
3
3
1
1
0
0
0
0
0
0
1
1
1
0
1
0
1
1
1
0
0
0
0
Table 5.1 Background characteristics of patient sample group undergoing plasma DNA evaluation
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5.3.2. Healthy Controls Vs Patient Samples
There was no significant difference observed in the proportion of males vs females in
healthy controls compared to patients (χ2=0.332 P=0.565) (Table 5.2) or age between
the control and patient groups (t=1.4 P=0.169).
In patients where plasma cfDNA was detected, this was found to have a fragment size
of 150 base pairs with additional fragment sizes at 300, 450 and 600 base pairs in
several plasma samples where total cfDNA was high (and serum samples as explained
later) (Figure 5.1). Only one of the control samples had a small quantity of DNA at 150
base pairs.
Data of healthy controls compared to patients are shown in Figure 5.2 and Table 5.3.
There was a significant higher quantity of plasma DNA in patients compared to healthy
controls (t=2.69 P=0.009).
Gender Healthy Control Patient Total
Male 9 47 56
Female 11 41 52
Total 20 88 108
Table 5.2 Distribution of gender across healthy control and patient groups
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Figure 5.1 Examples of electropherograms (EPG), demonstrating cfDNA with fragment size in base pairs
(bp) along the x-axis and cfDNA concentration along the y-axis. Corresponding traditional digital
electrophoresis gels are displayed to the right of each EPG. Each EPG displays small (lower) and large
(upper) marker DNA at 35bp and 10380bp respectively. (A) demonstration of typical calibration ‘ladder’
markers run with each batch of samples. (B) an example of sample with no cfDNA detected (apart from
upper and lower markers) which was also the finding in the majority of healthy controls. (C) an example
of a sample with detectable fragment at 150bp
A
B
C
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Figure 5.2 Plasma cfDNA in controls Vs NET patients
Control (n=20) Patients (n=88)
No. cases with detectable
cfDNA (%)
1 (5) 22 (25)
Median (pg/uL) 0 0
Range (pg/uL) 0-3.3 0-660
Mean ± SD (pg/uL) 0.17 ± 0.76 34.1 ± 117
95% CI (pg/uL) 0-0.5 9-59
Median of cfDNA>0 (pg/uL) 3.3 110
Mean of cfDNA>0 (pg/uL) 3.3 183 ± 220
Table 5.3 Plasma cell-free DNA in healthy controls and patient groups
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5.3.3. Analytical/Laboratory Reliability
5.3.3.1. DNA Extraction Reliability
Detectable cfDNA No cfDNA Total
Detectable cfDNA 19 0 19
No cfDNA 0 1 1
Total 19 1 20
Table 5.4 Reliability of assay assessed on extraction replicates
100% of samples that had cfDNA present at the 150 base pair fragment, had cfDNA
present in the extraction replicate (Table 5.4). The Prevalence-adjusted Bias-adjusted
kappa (PABAK) coefficient was estimated at 1.0 indicating a perfect agreement. When
quantity of cfDNA of was considered (Figure 5.3), the Intra-class coefficient (ICC) was
estimated at 0.762 indicating excellent reproducibility.
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Figure 5.3 Scatter plot of reproducibility between cfDNA extraction replicates
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5.3.3.2. Reliability of DNA Quantification
Detectable cfDNA No cfDNA Total
Detectable cfDNA 13 0 13
No cfDNA 0 10 10
Total 13 10 23
Table 5.5 Reliability of assay assessed on chip replicates
100% of samples processed who had detectable cfDNA at 150 base pairs had detectable
cfDNA on the chip replicate (Table 5.5). All those without detectable cfDNA had no
cfDNA on the chip replicate. The PABAK coefficient was 1.0 indicating perfect
agreement. When concentrations of cfDNA were compared, the ICC was 0.993
indicating excellent reproducibility (Figure 5.4).
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Figure 5.4 Scatterplot of reproducibility between cfDNA samples replicated on the microfluidic chip
(chip replicates)
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5.3.3.3. Reliability of Assay and Storage Duration
Detectable cfDNA No cfDNA Total
Detectable cfDNA 2 0 2
No cfDNA 0 3 3
Total 2 3 5
Table 5.6 Reliability of assay based on storage replicates
Storage replicates are shown in Table 5.6. The PABAK coefficient for storage replicates
was 1.0 indicating perfect agreement. When quantity of cfDNA was taken into
consideration, the ICC was 0.76 indicating excellent reproducibility.
5.3.4. Intra-subject Reliability
Detectable cfDNA No cfDNA Total
Detectable cfDNA 6 1 7
No cfDNA 1 9 10
Total 7 10 17
Table 5.7 Intra-subject reliability
The PABAK coefficient for intra-subject variability was 0.76 indicating substantial
agreement (Table 5.7). When concentrations of cfDNA were compared, the ICC was
estimated at 0.77 indicating excellent reproducibility (Figure 5.5).
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Figure 5.5 Scatterplot of intra-subject variability
Five patients had more than two samples taken and underwent no change in therapy.
Samples were taken at 3-5 weekly intervals for 10-16 weeks. Three patients had
detectable plasma cfDNA and continued to do so at later time-points. The other two
patients did not have detectable cfDNA and continued not to have any cfDNA on
further time-points. When cfDNA concentrations were assessed, there was no
significant difference across time-points (Kruskal-Wallis=0.31 p=0.99). Serial changes
are shown in Figure 5.6.
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Figure 5.6 Graph demonstrating changes in cfDNA concentrations over serial samples. Each line
represents a single patient except the line at y=0 which represents two cases. Sampling occurred at 3-5
weekly intervals.
5.3.5. cfDNA and Circulating Tumour Cells
75 of the patients who underwent evaluation for cfDNA also had samples taken for
CTC enumeration. There was a significant association between presence of CTCs and
presence of cfDNA (Χ2=11.6 P=0.001) (Table 5.8). When cfDNA was detected, (19/22)
86% of patients had CTCs.
cfDNA levels were higher in those with CTCs present compared to patients without
CTCs (Mann-Whitney P=0.001). This is shown in Figure 5.7 and Figure 5.9. The
quantity of cfDNA positively correlated with number of CTCs (r-0.45 P<0.001) but not
with the total number of CTC events (r=0.21 P=0.08). Interestingly, in a handful of
cases with very high CTCs counts, fragments of 300 base pairs were detected in
addition to the 150 base pair fragments (Figure 5.9). If the presence of cfDNA was used
as a marker for presence of CTCs, the PABAK coefficient was 0.31, indicating only fair
concordance.
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cfDNA detected No cfDNA Total
CTC ≥1 19 23 42
CTC =0 3 30 33
Total 22 53 75
Table 5.8 Presence of CTCs and detection of cfDNA
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Figure 5.7 Quantity of cfDNA in patients without and with CTCs
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5.3.6. Comparison of DNA Yield from Serum and Plasma
Compared to plasma of the 20 healthy controls where negligible cfDNA was detected,
cfDNA was detected at multiple fragment lengths in serum of controls but no fragment
of 150 base pairs was demonstrated (Figure 5.8).
44 patients with NETs had serum and plasma samples from which cfDNA was extracted
and analysed. Compared to plasma where cfDNA was mainly present at 150 base pair
fragments, serum contained a greater number of larger size fragments (Figure 5.9).
However, when there was cfDNA detected in plasma at 150 base pairs, invariably
(94%) there was cfDNA detected in serum at 150 base pairs (Table 5.9). When there
was no cfDNA at 150 base pairs in plasma, despite a number larger size fragments in
serum, 78% did not have any cfDNA at 150 base pairs. Thus there was an association
between presence serum and plasma cfDNA (Fisher’s exact = 21.5 P<0.001).
cfDNA was detected at higher quantities in serum of patient cases compared to controls
(Mann-Whitney P<0.001) (Figure 5.10).
Figure 5.11 demonstrates levels of cfDNA at 150 base pairs in plasma compared to the
same patient’s serum. The concentration of cfDNA at 150 base pair in serum was higher
than the concentration of the same fragment size in plasma (Wilcoxon P<0.001).
DNA at 150bp Serum Yes Serum No
Plasma Yes 16 1 17
Plasma No 6 21 27
22 22 44
Table 5.9 Presence of 150 base pair fragment of cfDNA when extracted from plasma and serum
189
A
B
C
D
E
F
G
H
Figure 5.8 Electropherograms from control cases demonstrating difference in DNA fragments obtained in
plasma (A, B, C, D) and corresponding serum (E, F, G, H respectively). There was no demonstrable
fragment (at 150 base pairs, or otherwise, apart from the upper and lower assay markers) in the plasma of
control cases. Multiple fragments of cfDNA in a ladder pattern were found in corresponding serum but no
150 base pair fragment was found.
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Figure 5.9 Electropherograms from cases of NETs demonstrating difference between cfDNA detected in
plasma (A, B, C, D) and corresponding serum (E, F, G, H respectively). CTC count is displayed for each
case. Large numbers of CTCs were associated with a fragment of 300 base pairs in addition to 150 base
pair fragments (C, D). A ladder pattern with multiple fragment lengths were found in serum compared to
corresponding plasma.
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Figure 5.10 Levels of serum cfDNA at 150 base pairs in healthy controls and NET patients (horizontal
line representing median)
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Figure 5.11 Quantities of cfDNA in plasma and serum (lines represent increase/decrease when serum
analysed)
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5.3.7. cfDNA and Survival
Outcomes were available in 87 of patients who had plasma cfDNA evaluated, median
follow up 21 months. PFS was significantly worse in those with detectable cfDNA (log-
rank P<0.001). Median PFS was 12 months in those with detectable cfDNA and not
reached in those without cfDNA. OS appeared to be worse in those with detectable
cfDNA but did not reach statistical significance (P=0.162). Kaplan-Meier survival
curves are shown in Figure 5.12 and Figure 5.13.
Patients were grouped into those with no cfDNA and no CTCs (group A); either
detectable cfDNA or CTCs (group B); or both detectable cfDNA and CTCs (group C).
Both PFS and OS appeared to be worse for group C than group B than group A but only
reached statistical significance for group C Versus group A. Kaplan-Meier survival
curves are shown in Figure 5.14 and Figure 5.15.
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Figure 5.12 Progression-free survival of those with and without detectable cfDNA
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Figure 5.13 Overall survival of those with and without detectable cfDNA
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Figure 5.14 Progression-free survival of those with no cfDNA and no CTCs (group A); either detectable
cfDNA or CTCs (group B); or both detectable cfDNA and CTCs (group C). Logrank A Vs B P=0.145; B
Vs C P=0.177; A Vs C P=0.004
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Figure 5.15 Overall survival of those with no cfDNA and no CTCs (group A); either detectable cfDNA or
CTCs (group B); or both detectable cfDNA and CTCs (group C). Logrank A Vs B P=0.022; B Vs C
P=0.614; A Vs C P=0.001
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5.4. Discussion
To date, circulating free-DNA (cfDNA) has not been identified or investigated in
patients with NETs yet with these experiments, I have demonstrated that cfDNA is
detectable in patients with NETs in both plasma and serum and correlates with numbers
of CTCs.
I have shown that when cfDNA is present in plasma of patients with NETs, it is
predominantly at a fragment length of 150 base pairs (bp) which is a small fragment
length previously found released from necrotic or apoptotic cells[268]. This is
approximately the length of single strand of DNA wrapped around a single histone
octamer, a length measured by electron microscopy when investigating plasma
oligonucleosomes in a study in pancreatic cancer[282].
In certain cases, there were fragments of cfDNA found at multiples of 150bp e.g. 150,
300, 450, 600. These were present in plasma of cases with extreme high counts of CTCs
(over approximately 100 per 7.5ml blood). This ‘ladder’ pattern was also demonstrated
in serum. An explanation for higher counts of CTCs in blood being associated with a
‘ladder’ pattern of cfDNA theory may be that circulating nucleases that break down
cfDNA are saturated in this situation resulting in release of excess larger fragments in
multiples of 150bp. Why serum has multiple fragment lengths cannot be explained but
may be due to the clotting process, which occurs when collecting serum, causing
shearing of DNA, perhaps from leucocytes.
However, in a recent study, using qPCR with primers targeting fragments <100bp in
colorectal cancer, a significant proportion of cfDNA was found in shorter lengths[366].
This study was the first to suggest that the size distribution profile of cfDNA fragments
can be used to distinguish healthy from cancer patients using grouping by <100bp, 150-
400bp and >400bp fragments, the latter two groups which I have demonstrated in our
sample. However, our methodology may not be as sensitive to detect smaller fragments
<100bp. This group showed that fragmentation increased with tumour size and cfDNA
concentration. They also demonstrated that non-tumoral cfDNA is less fragmented than
cfDNA from tumours.
In our study, although one out of twenty healthy volunteers had a small quantity of
cfDNA, patients had much higher concentrations of cfDNA with a greater proportion
(25%) having cfDNA present. This is consistent with previous studies demonstrating
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greater quantities of cfDNA in patients with other solid cancers when compared to
healthy controls.
Quantities of cfDNA in healthy controls ranged from 10 to 30 ng/mL in some of the
early studies in the 1970s with radioimmunoassays[156, 263] which are considerably
higher than found in our healthy subjects (range 0-3.3 pg/uL equivalent to ng/mL).
However these previous studies utilised serum and did not focus on one particular
fragment length as I have done. More recent studies utilizing qPCR, spectrometry or
fluorometric methods on plasma have found similar concentrations to early studies with
a range from 7 to 63 ng/mL[267, 352, 367, 368, 369].
Quantities of cfDNA in patients with other cancers in previous studies range from 41 to
709 ng/mL[157, 267, 305, 368, 369, 370, 371, 372, 373] which is similar to the cfDNA
range of 0-660 ng/mL found in our study. When considering specific gastrointestinal
cancers in previous experiments, concentrations in metastatic colorectal cancer ranged
from 101 to 709 ng/mL[372, 374] and 568 ng/mL in pancreatic adenocarcinoma[375].
Thus I have demonstrated concentrations of cfDNA in NET patients similar to those in
other cancers.
However, only 25% of our patient samples had detectable plasma cfDNA despite all
having metastatic disease, which is less frequent than the majority of previous studies.
A possible explanation is our NET population mainly consisting of performance status 0
or 1 (94%) and few having high-grade tumours (14%). Furthermore, previous studies
vary significantly in reported frequencies of detectable cfDNA. In a study of head and
neck cancers, 35% had measurable plasma cfDNA[305] using QIamp blood kit
(QIagen) for DNA extraction and fluorometry for quantification. Another study in lung
cancer found cfDNA in 53% of patients[301] using the same extraction method as our
experiments but quantifying with qPCR. Yet, again with the same techniques, all 20
patients in one study with oesophageal cancer had detectable cfDNA[371]. Although
direct comparisons are difficult due to heterogeneous populations, the frequency of
detectable cfDNA I demonstrated was lower in NETs using this methodology. A
possible explanation is the quantification method I employed i.e. microfluidic chips,
which have not been reported extensively in the literature for plasma, albeit using the
‘high-sensitivity’ chip (Agilent). The extraction method is unlikely to be a plausible
explanation since the Qiamp Blood Kit or Blood Mini Kit (which I use) have been
employed by the majority of studies. Other explanations are the delay in centrifugation
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after sample collection or the differential storage durations at -80°C resulting in a lower
yield over a longer time period as has been shown with foetal cfDNA[350].
Interestingly, the presence of fragments of 150bp in serum was associated with
fragments of the same length in plasma. Despite healthy serum producing fragments of
multiple lengths, there was no healthy case with a 150bp fragment. The results
demonstrating higher levels of this fragment in serum than in plasma and the fact that in
some cases, this fragment length was present in serum and not in plasma, could indicate
that quantification of cfDNA is more sensitive in serum than plasma. This is consistent
with previous studies demonstrating higher yields in serum but this could be at the
expense of purity since DNA is released from destroyed leucocytes[352, 353]. Our
study and previous studies have focused on total concentration of cfDNA or of
fragments of 150 base pairs or longer.
I have demonstrated an association between the presence of cfDNA and presence of
CTCs in patients with NETs as has been demonstrated in previous studies in breast and
prostate cancer (including methylated cfDNA)[273, 340]. However, not all patients with
cfDNA had CTCs and not all patients with CTCs had presence of cfDNA. Certainly, I
have shown that concentrations of cfDNA are higher in those with CTCs than those
without. If CTCs are validated as being a prognostic marker elsewhere in this thesis, the
presence of cfDNA is still not sensitive enough as a surrogate marker for CTCs since
only fair concordance was seen between cfDNA and CTCs. This may support the theory
of cfDNA originating from CTCs but as mentioned, a few patients without CTCs did
have cfDNA. I also looked at the total number of ‘CTC events’ produced by the
CellSearch™ system which includes events that appear (on the semi-automated
microscope images) to consist of nuclear material not defined as clear CTCs. These did
not correlate with cfDNA and thus I do not have sufficient evidence that this nuclear
material relates to cfDNA.
Our preliminary survival data suggests that presence of cfDNA conferred a worse PFS
and although not statistically significant, a suggestion of poorer OS. However, this is
limited by the few events of progression and death. When combining presence of
cfDNA with presence of CTCs, the presence of both conferred a worse PFS and OS
than if both were absent. This needs to validated with a longer follow-up period in order
to analyse more events but this preliminary data suggests that cfDNA could be
combined with CTCs in a prognostic model.
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Reliability of an assay is defined as the degree to which the results obtained by a
measurement can be replicated and is interchangeable with the terms repeatability and
reproducibility. When considering cfDNA as a dichotomous variable i.e. presence of
absence, I demonstrate perfect reliability when duplicating DNA extractions from
samples, duplicating cfDNA quantification on the microfluidic chips and when
repeating measurement on samples stored at -80°C for 6 months.
When considering cfDNA as a continuous variable i.e. cfDNA concentration, although
not perfect, reliability was excellent when duplicating measurements on microfluidic
chips. There was more variability when replicating DNA extractions from samples and
when repeating measurements after storage at -80°C for 6 months but even then,
reproducibility was classed as excellent. One limitation of this validation is the few
samples without cfDNA in the extraction replicate subgroup.
When looking at intra-subject reliability at two sample points, there was excellent
reliability for both presence of cfDNA and as a continuous variable. However, two (of
17) samples had cfDNA at one time-point and none at the other time-point. This may be
due to true appearance or disappearance of cfDNA but may also be explained by a
sample not being representative of the whole circulation or slight differences in
analytical methods on that day. The five patients who had more than two sample time-
points confirmed excellent reliability over a longer period but I do not have enough
evidence to discuss changes in cfDNA over the natural course of disease without any
interventions. I demonstrate good intra-subject reliability but ideally further studies are
required to validate quantification of cfDNA with more homogenous, larger samples
and stricter time intervals although this would be a difficult study to conduct in this
patient group.
Even if presence or quantification of cfDNA is not perfect as a biomarker, the
consequence of its detection in NET patients could be significant. Specific mutations in
midgut and pancreatic NETs have not been extensively established as in other cancers.
However, as recently discovered in sporadic pancreatic NETs, MEN1 and DAXX/ATRX
mutations[21] could be studied in cfDNA and since associated with a better prognosis,
these mutations in cfDNA could be developed as a biomarker. A disadvantage is the
heterogeneity of mutations in these genes. Similarly, deletion of p16/MTS1 in pancreatic
NETs could be explored[22]. Important epigenetic alterations implicated in some NETs
are suggested by DAXX/ATRX mutations, hypermethylation of RASSF1 in bronchial
NETs[376] and p16 methylation (associated with poor outcome in foregut/midgut
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NETs)[377]. Thus, methylation specific PCR could be utilised to detect these epigenetic
alterations in cfDNA in the development of future biomarkers.
Overall, presence of cfDNA as a dichotomous variable is highly reproducible with
slightly less reliability when measuring concentration of cfDNA. Concentrations of
cfDNA are higher in patients with NETs than in healthy controls and higher in serum
than in plasma with the predominant fragment length 150bp. However, in serum, and in
plasma in patients with high CTC counts, a ‘ladder’ pattern is demonstrated. Yields are
lower than in other studies which may be due to methodology differences but these
results produce a platform for biomarker development studies utilising cfDNA.
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Chapter 6. Circulating Endothelial Cells
6.1. Introduction
Circulating endothelial cells (CECs) were first described almost 40 years ago with
techniques including vital light microscopy, Giemsa staining and separation density
centrifugation[378, 379], and were identified in various conditions such as smoking,
acute myocardial infarction[379]. These older studies identified CECs by morphological
criteria only, but current methods isolate CECs using immunomagnetic isolation or
fluorescence-activated cells sorting (FACS) based on a defined immunophenotype.
CECs are thought to represent mature endothelial cells that have been shed into the
circulation from the vascular cell lining due to vascular damage. In healthy individuals,
the endothelial layer is continuously renewed at a low replication rate of 0-1% per
day[380]. It is therefore no surprise that in healthy adults, detection of CECs is a rare
event with a frequency of about 0-12/ml blood, or a representation of 0.01 to 0.0001%
of mononuclear cells. The rarity of these cells creates a challenge for developing
detection assays that are sensitive and specific[381, 382, 383]. The size of CECs spans a
wide spectrum ranging from multi-nucleated cell conglomerates to single cells and
endothelial microparticles but a consensus paper suggests they are greater than
10μm[384].
Immunomagnetic separation isolates endothelial cells from whole blood with
paramagnetic particles which have been coated with anti-endothelial antibodies, most
commonly CD146[385, 386]. CD146 (also known as melanoma cell adhesion molecule)
is involved in cytoskeleton formation and signalling, and is present on endothelial cells,
activated T-lymphocytes, mesenchymal stem cells and some malignant cells[387, 388].
Using immunomagnetic separation, whole blood is incubated with antibody-coated
magnetic particles. Then, target cells with bound anti-endothelial antibody and magnetic
particles are recovered with a magnetic field. CECs can then be enumerated with
fluorescent antibodies to other EC markers. To distinguish activated T-lymphocytes
from CECs, co-staining with CD45 or CD3 may be of use. CD133 or CD34 may
identify endothelial progenitor cells (EPCs) and CD105 can identify activated CECs in
cancer patients although agreement of phenotypic differentiation is lacking[389, 390].
The semi-automated immunomagnetic Cellsearch™ platform, designed to detect CTCs,
can also be used for CEC detection utilising expression of CD105 (endoglin) to identify
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malignant CECs (Figure 6.1). The system characterises CD146+CD105+CD45-DAPI+
cells as CECs, and this approach has been validated by morphology and global gene
expression using this platform[391, 392].
CECs have been found to be raised in a variety of conditions including those with
widespread vascular damage, infection, vasculitis, and myocardial infarction[161, 381].
Since angiogenesis is crucial for tumour growth and metastasis, there has been interest
in CECs associated with cancer and they have been reported to be increased in a number
of human malignancies[391, 393, 394]. A number of anti-cancer agents target tumour
vasculature including monoclonal antibodies to VEGF and small molecule tyrosine
kinase inhibitors . Circulating biomarkers including VEGF, s-VEGFR-2, placenta
growth factor, soluble Tie2, E-selectin, and vascular endothelial cadherin have been
examined as surrogates of response but none have been clinically validated[395, 396].
Given the importance of targeting tumour vasculature, CECs may be a potential tool to
assess drug effect on tumour vasculature.
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Figure 6.1 Schematic representation of immunomagnetic separation and immunoflurorescent staining
employed by the CellSearch platform to enrich CECs from peripheral blood; CEC Circulating Endothelial
Cell; CD146 (MelCAM, Melanooma Cell Adhesion Molecule); CD105-PE CD105(Endoglin)-
Phycoerythrin; CD-45APC CD-45 Allophyocyan DAPI 4’, 6-diamidino-2-phenylindole
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Neuroendocrine tumours often produce hypervascular metastases with elevated levels of
pro-angiogenic factors, such as VEGF[397] and angiopoeitin-2[134]. Consequently
there had been interest in anti-angiogenic therapies for NETs and both Bevacizumab
and sorafenib have been investigated in small studies[398] [399] [400]. However
recently a large, multicentre, randomised, placebo-controlled trial reported sunitinib
improved PFS, OS and response in well differentiated pancreatic NETs[61]. Sunitinib is
a multi-targeted tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2,
VEGFR-3, KIT (stem cell factor [SCF] receptor), platelet derived growth factor
receptor (PDGFR-a), and PDGRF-b[401]. With reports that anti-angiogenic therapy
may elicit tumour adaptation with heightened invasiveness and increased metastatic
potential in animal models of pancreatic NETs and glioblastoma, real-time biomarkers
which can reflect the dynamic nature of angiogenesis would be valuable[402].
In earlier chapters, I have demonstrated the utility of CTCs as a biomarker to predict
progression and response to therapy in patients with NETs. Similarly, there is a need for
clinically effective biomarkers to determine optimal dosing, monitoring response and
selecting or stratifying patients most likely to benefit from anti-angiogenic therapy.
Given the lack of any data on CECs in NETs, I went onto conduct a pilot study
exploring numbers of CECs compared to healthy controls and the relationship with
clinicopathological factors.
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6.2. Materials and Methods
6.2.1. Patient Recruitment
Patients (n=55) were recruited between July and December 2009 from the Royal Free
Hospital. All eligible participants had histologically proven NET and metastatic disease
measurable by RECIST criteria. They were categorised according to the site of primary
NET: midgut, pancreas, bronchopulmonary, hindgut or of unknown primary. This study
was approved by the Local Ethics Committee (Ref 09/H0704/44) and all patients
provided written informed consent.
Patients that had undergone chemotherapy, interferon, receptor-targeted radiolabeled
therapy, or embolisation within the previous 2 months were excluded.
Data were collected on primary site, duration of diagnoses, any previous treatment
received, WHO performance status and whether the primary tumour had been resected.
Grade of tumour according to Ki-67 proliferation index was recorded according to
ENETs guidelines[23, 24]. Radiological burden was assessed by quantification of
hepatic tumour load from 4 to 6 slices of a CT/MRI scan with the most amount of
disease by a semi-quantitative approach. Hepatic tumour burden was categorised as
25% or less, more than 25% but 50% or less, more than 50% but 75% or less, or more
than 75%.
6.2.2. Healthy Volunteer Recruitment
Healthy volunteers (n=23) were recruited for blood sampling. Volunteers were excluded
if they had a current or past cancer, active infection, recent surgery within 1 month,
current inflammatory disease or chronic disease (apart from hypertension). All healthy
volunteers provided written informed consent.
6.2.3. Circulating Endothelial Cells (CEC) Isolation
Blood samples (4ml) from patients and volunteers were drawn into CellSave tubes
(Veridex LLC) containing EDTA and a cellular preservative. Samples were maintained
at room temperature and processed within 96 hours using the Cellsearch™ (Veridex
LLC) platform for the isolation and enumeration of CECs. The platform consists of a
semi-automated system that enriches the sample for cells expressing CD146 by
immunomagnetic separation. The system incubates samples with ferrofluids coated with
CD146 and labels the cells with the fluorescent nucleic acid DAPI. Fluorescently-
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labelled monoclonal antibodies specific for leukocytes (CD45–allophycocyan) and
activated endothelial cells in cancer (PE-CD105/endoglin) were used to distinguish
CECs from leukocytes.
Briefly, 4mL of blood were mixed with 10mL of buffer, centrifuged at 800 X g for 10
minutes and then placed on the AutoPrep component of the platform. The instrument
then added ferrofluids after aspirating the plasma and buffer layer. After incubation and
subsequent magnetic separation, unbound cells and remaining plasma were aspirated.
The staining reagents were added together with a permeabilisation agent to
fluorescently label the immunomagentically labelled cells. After incubation, excess
staining reagents were aspirated and magnetic separation repeated. In the final step,
cells were resuspended in the MagNest Cell Presentation device (Veridex LLC) which
consists of a chamber and two magnets that orient the cells for analysis.
6.2.4. CEC Analysis
The identification and enumeration of CECs on the display unit were performed with the
use of the CellSearch™ Analyzer II, a semi-automated fluorescence-based microscopy
system that permits computer-generated reconstruction of cellular images in the
MagNest Cell Presentation device. All evaluations were performed without knowledge
of the clinical status of the patients by 2 independent operators (M.K and T.T.). Out of
the total events detected by the platform, CECs were defined as nucleated cells (DAPI+)
lacking CD45 and expressing CD105 (Figure 6.2). Any discordant results were
reviewed together to reach agreement. The total number of CEC events was also
recorded i.e. including all CD146 positive events that the machine recorded despite not
meeting the criteria for CEC identification. The total number of CEC events thus
included nuclear material (DAPI+) with or without associated CD45, leucocytes and
nuclear material with associated CD105.
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Figure 6.2 Image reconstruction from the CellSearch™ Analyzer with identification of CECs. Each
horizontal ‘event’ is a possible cell or cells focused on by the automated microscope; there are 4 events
depicted here. The columns refer to channels where the same event is imaged through different filters to
view staining patterns: from right to left, CD45 (APC filter), DAPI (for nuclear staining), CD105 (PE
filter) and a composite of all 3 stains. Event number 1 demonstrates a CEC - a nucleus within a CD105
skeleton with absence of CD45 expression. Event 4 represents a leucocyte rather than a CEC as the cell
stains for CD45. Events 2 and 3 demonstrate further CECs.
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6.2.5. Interobserver Reliability
Since the identification of CECs has not been extensively validated compared to CTCs,
the interobserver reliability of enumerating CECs was assessed by comparing the two
observers CEC counts.
6.2.6. CTC Isolation and Enumeration
Blood collected in Cellsave tubes (Veridex, LLC) was used for Circulating Tumour Cell
(CTC) isolation and enumeration according to methods detailed in a previous chapter.
6.2.7. Statistical Analysis
Differences in gender and age distributions between healthy control and patient samples
were assessed by Chi-squared and student t tests. Differences in number of CECs across
groups were assessed using Mann-Whitney and Kruskal-Wallis tests. Spearman’s rank
assessed correlation of CTCs with CECs.
Interobserver reliability was assessed by intraclass correlation coefficient (ICC) and
Bland-Altman plots. Kaplan-Meier estimates of survival were based on groups below
and above a CEC threshold identified from baseline data. For the purposes of survival
analyses, progression-free survival (PFS) or overall survival (OS) was defined as the
time between the date when the baseline blood sample was taken and the date of
radiological progression, death due to neuroendocrine cancer or last follow-up visit.
Survival curves were compared using log-rank testing.
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6.3. Results
6.3.1. Healthy Controls
The gender distribution across healthy controls and NET patients is shown in Table 6.1.
There was no significant difference in proportion of males or females between controls
and patients (χ2=0.98 p=0.323).
There was also no significant difference in age between healthy controls (mean 53.6,
standard deviation 17) and NET patients (mean 58.2 standard deviation 13) (t test,
P=0.234).
Gender Healthy Control Patient Total
Male 11 (48%) 22 (40%) 33
Female 12 (52%) 33 (60%) 45
Total 23 (100%) 55 (100%) 78
Table 6.1 Gender distribution across healthy controls and NET patients
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6.3.2. Background Characteristics of NET Patients
The background characteristics of the NET patient group for CEC evaluation are shown
in Table 6.2.
Pancreatic
n=15
Midgut
n=27
Broncho-
pulmonary
n=9
Unknown
Primary
n=4
All NETs
n=55
Age, years
mean ±
SD
61.5 ± 11.6 62.6 ±
11.4
46.6 ±
10.3
48.3 ±
16.8
58.2 ±
13
Sex
Male
Female
9
6
8
19
5
4
0
4
22
33
Grade
Low
Intermediate
High
9
3
3
15
10
2
3
4
2
1
3
0
28
20
7
Burden of Liver
metastases
None
≤25%
25%≤50%
50%≤75%
>75%
3
6
5
1
0
0
8
14
4
1
3
4
1
1
0
0
2
2
0
0
6
20
22
6
1
Duration of diagnosis,
median months
(range)
53.2
(1-164)
59.6
(1-274)
49.6
(9-283)
35.2
(12-86)
30.3
(1-283)
Performance Status
0
1
2
3
4
12
3
0
0
0
15
9
3
0
0
4
5
0
0
0
3
1
0
0
0
34
18
3
0
0
Previous treatments
Resection of primary
SST
Chemotherapy
TAE
Radionuclides
Interferon
Liver resection
2
1
3
1
2
0
1
11
11
2
4
6
0
2
3
1
2
0
1
0
0
0
1
3
1
0
0
0
16
14
10
5
9
0
3
Table 6.2 Background characteristics of patients undergoing CEC evaluation
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6.3.3. Circulating Endothelial Cells (CECs) in Patients and Controls
Although there appeared to be a higher number of CECs in NET patients than in healthy
controls, there was not strong enough statistical evidence to support this (Mann-
Whitney, P=0.056) (Table 6.3). However, the distribution of CECs varied much less in
the healthy controls compared to NET patients (standard deviation 12 Vs 148 CECs/4ml
respectively). This can be seen in Figure 6.3 with the F-test supporting this (F=25.1
P<0.001). Looking at the distribution, it appears that healthy controls did not have
greater than 45 CECs/4ml blood but NET patients did. 31% of NET patients had greater
than 45 CECs/4ml and 27% had greater than 50 CECs/4ml. The majority of CECs were
irregular or spindle-shaped. However, a minority were small and round (Figure 6.4).
Controls Patients
n 23 55
CECs
Mean ± SD
95% CI
27 ± 12
12-82
66 ±148
26-106
Median, range 30, 5-44 23, 0-985
Interquartile range 15 38
No. ≥ 45 0/23 (0%) 17/55 (31%)
No. ≥ 50 0/23 (0%) 15/55 (27%)
Total CEC Events
Median 349 432
Mean ± SD
95% CI
504 ± 388
336-672
534 ± 752
331-738
Table 6.3 Statistics of CECs and total CEC events in healthy controls and NET Patients
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Figure 6.3 Number of CECs in healthy controls and NET patients (horizontal line representing median)
Figure 6.4 Image reconstruction from the CellSearch™ Analyzer with
identification of one CEC which appears small and round compared to the
‘normal’ phenotype seen in
Figure 6.2
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6.3.4. Total CEC Events
The total number of CEC events, including those that did not meet the definition criteria
as stated in the methods, was recorded. There was no significant difference in these total
events between healthy controls and NET patients (Mann-Whitney P=0.926) (Table
6.3) (Figure 6.5). Thus the total number of CD146 events detected by the platform did
not appear to have any clinical relevance.
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Figure 6.5 Total CEC events in healthy controls and NET patients
6.3.5. CECs Across Different Primary Tumours
The number of CECs across different primary NET types is shown in Figure 6.6. Using
Kruskal-Wallis test for variance, the number of CECs was not different between tumour
types (P=0.051). Although statistical significance was almost reached, the number of
CECs was not dependent on tumour primary.
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Figure 6.6 Number of CECs according to primary NET
6.3.6. Relationship with CTCs
A scatterplot demonstrating relationship between CECs and CTCs is shown in Figure
6.7. There was no significant correlation between CECs and CTCs (Spearman’s
ρ=0.029 P=0.855). When dichotomised, there was no association with presence of
CTCs and number of CECs (P=0.398). There was also no correlation between total
CEC events and CTCs (Spearman’s ρ=0.6 P=0.208).
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Figure 6.7 Relationship between CECs and CTCs
6.3.7. Relationship of CECs with Clinical Parameters
Liver metastases burden groups 25-50%, 50-75% and >75% were combined due to
small numbers so that the group with <25% was compared with that ≥25%. Grades 2
and 3 were also combined for the same reason and so too were performance statuses 2,
3 and 4. There was no association between tumour burden and CECs (Mann-Whitney
P=0.278) (Figure 6.8). nor between grade of tumour and CECs (Mann-Whitney
P=0.079) (Figure 6.9). There was also no association between performance status – PS
0-1 vs PS 2-4 – and CECs (Mann-Whitney P=0.444).
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Figure 6.8 Relationship between burden of liver metastases and number of CECs
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Figure 6.9 Relationship between grade of NET and number of CEcs
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6.3.8. Interobserver Reliability
There was excellent correlation between the CECs counts assessed by observer A and
observer B (r=0.99 P<0.001) (Figure 6.10).
A better method of assessing interobserver agreement is the Bland-Altman plot shown
in Figure 6.11. The interobserver difference was generally low. It appeared to be larger
on higher counts. The 95% limits of agreement were estimated from -11 to 8 CECs. The
intraclass correlation coefficient was 0.999 (P<0.001) indicating excellent agreement.
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Figure 6.10 Association between observer A and observer B CEC counts
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Figure 6.11 Bland-Altman plot of the average CEC count between observers plotted against the
interobserver difference (dashed lines represent 95% limits of agreement)
6.3.9. CECs and Survival
Patients were grouped in to those above and below the threshold of 45 CECs/4ml blood
defined above. Kaplan-Meier survival curves demonstrating PFS and OS according to
these groups are shown in Figure 6.12. Median follow-up was 20 months (range 5-25).
Although it appears that patients with CEC counts over 45 had a worse PFS and OS,
this did not reach statistical significance (P=0.300, P=0.148 respectively).
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Figure 6.12 Survival curves of patients grouped by below and above the threshold 45 CECs/4ml blood
defined from earlier data
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6.4. Discussion
My data failed to show that CECs were increased compared to healthy controls which is
in contradiction to other studies. CECs have been found to be increased in a number of
human malignancies including head and neck, prostate, colorectal, breast, renal cell,
gastric and oesophageal cancers[391, 393, 394, 403]. For example, in breast cancer and
lymphoma, CECs, measured by flow cytometry, are increased 5-fold and correlate with
plasma vascular endothelial growth factor (VEGF)[404].
CECs have also been found to be raised in conditions with vascular damage such as
rickettsial infection, sickle cell anaemia or vasculitis[381]. Elevated CEC numbers have
been detected in vascular conditions including acute coronary syndrome[161], cardiac
failure[405], ischaemic stroke[406], pulmonary hypertension[407]. Additionally,
pathogens such as cytomegalovirus (CMV) have been identified in CECs[408]. In
patients with renal transplantation, highest CEC numbers were seen in those with acute
vascular rejection[409]. In order to limit this effect of non-cancer pathology in our
pathology, healthy controls were recruited with exclusion of chronic or vascular
conditions such as these. However I acknowledge that co-existing vascular pathology in
the patient group may have had an effect on CEC numbers.
Our numbers of CECs in healthy controls are comparable to other studies using the
CellSearch platform™. We demonstrate that CECs ranged from 0 to 45 CECs per 4ml
blood. When expressed differently, this is 0-11 cells/ml, similar to the 1-20 cells/ml
found in one study using the same platform[391]. Immunomagnetic capture and density
centrifugation techniques tend to show values of 1-20 cells/ml but numbers yielded by
flow cytometry are greater (up to 1000-fold increase)[404, 410, 411]. The reasons for
this variation are unknown but are probably methodological (choices of cell surface
markers or technical gating) and a consensus of CEC definition is required which is
being addressed by a European collaborative group.
My data did not show elevated CEC numbers in cases which may be particular to NETs
compared to other cancers. However, a false negative result may have arisen given the
relatively small numbers in the control sample or the heterogeneous nature of the NET
sample with inevitable varying levels of tumour vascularity. Another reason for
conflicting with previous studies is the non-standard methods of CEC isolation and
identification throughout the literature. However, this was limited by using a semi-
automated platform with generally accepted antibodies. I also addressed this limitation
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by using two independent observers to identify CECs from events obtained by the
automated microscope based on staining pattern and intact cells, regardless of
morphology. The interobserver reliability was excellent with, expected, higher
variability at lower CEC counts.
However, when looking at the spread of the data, numbers of CECs were widely spread
with a standard deviation of 148 compared to 12 of healthy controls with standard
deviation. This is statistically significant when using the F-test and an interesting
finding. The range of CECs in healthy controls was narrow with a cut-off identified of
45 CECs/4ml which suggests a reference range may be possible but requires further
validation in larger studies. Although levels of CECs were not higher in NETs, this
variation suggests that CECs may reflect underlying tumour biology, perhaps a
reflection of angiogenesis. Varying CEC levels add support to the vast heterogeneity of
NETs, even within metastatic NETs, as suggested by published and unpublished genetic
studies [21]
Considering the variation in CECs in NETs, there was no difference in levels across
different primary tumours. However, I acknowledge the small numbers and limitations
of this subgroup analysis. There was also no relationship with grade, performance status
or tumour burden. This may be due to an insufficient sample size to detect these. The
latter contradicts one study which looked at CECs isolated by the CellSearch
platform[412]. This group found the number of CECs was found to correlate with
tumour size and also revealed a dose-dependent decrease with anti-angiogenic agents,
bevacizumab and cedirinab[412]. This group also characterised apoptosis in CECs with
the addition of the terminal deoxynucleotodyl transferase dUTP nick end labelling
(TUNEL) assay on the CellSearch™ platform and found that round CECs were
apoptotic or deactivated CECs. There was a 3-fold induction in CEC apoptosis and
inhibition of VEGFR2 in CTCs with the anti-angiogenic agents at 24-hours with no
change in number of CTCs.
Similarly, in my study, there was no relationship between CECs and CTCs which
suggest that CECs may not reflect the metastatic potential and radiological progression
that CTCs represent. Interestingly, in a recent study, NET tissue expression of endoglin
(CD105) was shown to be increased compared to normal tissue and associated with
tumour burden and presence of neuroendocrine metastases[413]. CD105 is a co-receptor
for TGF-β1 which is a multifunctional cytokine involved in numerous physiological and
pathological processes. Due to its principal expression on endothelial cells of newly
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formed blood vessels, studies suggest that CD105 is a specific marker of
neovascularistaion in cancer[414, 415]. The expression of CD146 in NETs is unknown
but given the similarity between melanoma (which strongly express CD146) and NETs,
it may be that some of the CECs identified, especially the unusually shaped small and
round CECs, were actually neuroendocrine CTCs, bearing a similar morphology too.
Further studies investigating these markers in NETs are required.
I also looked at the total number of events (which were CD146+) obtained by the
automated microscope on the platform. This added no further information as there was
no relationship with CTCs or elevation in NETs. This is not surprising as contaminating
leukocytes would be included into this group.
When using the cut-off of 45 CECs/4ml identified about, those NET patients with CECs
above this cut-off appeared to have worse overall survival but this did not reach
statistical significance. Baseline CEC may be prognostic with low CEC levels
associated with better outcome in several studies in colorectal and breast cancer[416,
417, 418, 419]. However, other studies using the Cellsearch™ platform suggested
baseline CECs were not prognostic in breast and prostate cancer[393, 420, 421]. With a
longer follow up period and larger homogenous sample, this potential as a prognostic
marker could be explored in a future study in NETs.
The clinical significance of CECs in cancer is poorly understood and it is unsure
whether they are markers of altered vascular integrity or contributors to the neoplastic
process. However, there is limited data on their use as biomarkers. There are a limited
number of studies studying the change of CEC numbers in response to treatment and
survival. In patients with prostate cancer treated with docetaxel-based regimens, an
early increase of CECs was associated with worse overall survival especially when
combined with CTC numbers. Another supportive study at the same time suggested an
increase in CECs at seven days predicts survival and response in cancer patients treated
with various chemotherapeutics[422]. A number of studies have studied outcome after
anti-angiogenic therapy with increase of CEC numbers associated with clinical benefit,
specifically in renal cancer[423], gastrointestinal stromal tumour (GIST)[424], and
breast cancer[420]. Other studies have noted an increase in mature CECs in response to
anti-angiogenic agents[425]. However, in contrast, other studies showed an increase in
CECs was associated with worse clinical outcome in colorectal cancer and
glioblastoma[426, 427]. Several studies have shown correlation between changes in
CECs and objective response to treatment such as RECIST[419, 428, 429]. These
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discrepancies may be accounted for by differences in timing of CEC detection,
inclusion of apoptotic CECs, different assays and different treatments. Other uses of
CECs include as biomarkers for optimal biological drug dosage[430] and identification
of new novel tumour-associated endothelial markers for potential therapeutic
targets[431].
My study is hypothesis-generating but this is the first systematic evaluation of CECs in
NETs. We have focussed on patients with advanced, metastatic disease to make the
group more homogenous. Although 3 patients in a small study had ‘carcinoid’, the
sample was very small and grouped with large numbers of other cancers without any
details of primary site[403]. Although not elevated in significant numbers compared to
controls, there is considerable variability in CEC numbers in patients with NETs which
need to be explored. Initially, validation studies similar to that conducted with CTCs
need to be performed, looking at intra-sample and temporal variation of CECs in order
to calculate a coefficient of variation. The significance of CECs in NETs needs to be
explored by studying relationships with circulating level of angiogenic factors including
VEGF, VEGFR, angiopoeitin; with vascularity on imaging; and with microvessl density
on histopathological samples. Apoptotic markers on CECs may be useful, once
validated, to identify response to anti-angiogenic agents. Finally, the use of CECs as a
prognostic and predictive biomarker needs to be explored in large prospective studies in
homogenous groups, especially in patients undergoing treatment with sunitinib.
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Chapter 7. Summary and Future Directions
NETs are heterogeneous malignancies with diverse biology ranging from indolent to
highly aggressive cancers. With the varied survival and increasing number of treatment
options available, there is a requirement for biomarkers to predict prognosis and to
predict outcome with therapy.
The aim of this thesis was to look at the current state of biomarkers in NETs and to
explore new biomarkers in the circulation of patients with NETs: CTCs, CECs, and
cfDNA. In chapter 1, I concluded that despite plasma CgA and urinary 5-HIAA being
accepted as established blood biomarkers, there are a lack of prospective studies
systematically investigating their prognostic and predictive value.
In chapter 2, I investigated the established histopathological biomarker, Ki-67
proliferation index, which forms part of a number of international NET clinical
guidelines. ENETS propose a three-tiered grading system separate from their TNM
staging classification. This stipulates that either Ki-67 or mitotic count on NET tissue
can be used to assign grade but there is no evidence to suggest that these indices are
equivalent in their prognostic value. In a series of 131 metastatic pancreatic and 136
metastatic midgut NETs, I demonstrated a discordance of 44% and 38% respectively
when assigning grade using Ki-67 or mitotic count. This may have important
implications if one index is used over the other, since treatment decisions are often
based on grade. On univariate and multivariate analyses, grade according to Ki-67, but
not mitotic index, was able to determine three prognostically different groups in both
pancreatic and midgut NETs. The prognostic value of Ki67 was not improved if tertiles
were used as cut-offs, but was improved when the low-grade threshold was raised to a
Ki-67 of 5% (from 3%). Since Ki-67 index and mitotic count are both measures of
proliferation, and I have demonstrated that Ki67 index is a superior prognostic marker,
the additional value of mitotic index is questioned. I conclude that the international
guidelines in NETs need to be changed so grade is assigned using Ki-67 alone and not
mitotic count.
In chapter 3, EpCAM expression was investigated in a series of 74 NET tissue samples.
All midgut and pancreatic NETs demonstrated strong EpCAM expression, which
implies that NETs could be epithelial in origin, adding evidence against NETs
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originating from the neural crest. With EpCAM directed therapy being investigated in
other cancers, this also opens up this targeting area to NETs.
NET EpCAM expression allowed me to investigate whether it would be possible to
isolate CTCs from blood of patients with NETs, using the semi-automated Cellsearch™
platform, which uses an EpCAM-based immunomagnetic separation technique. In 175
patients prospectively recruited with metastatic NETs, CTCs were clearly identifiable in
blood. Although there is no ‘gold standard’ technique for CTC isolation, the
Cellsearch™ platform has been extensively validated, approved by the FDA, and hence
I did not recruit healthy controls. One or more CTCs were present (in 7.5ml blood) in
51% of midgut and 36% of pancreatic NETs with 42% of cases having 2 or more CTCs.
The frequency and levels of CTCs in metastatic NETs was similar to that in metastatic
breast and prostate cancers and may pave the way for more studies investigating CTCs
in NETs.
Having proven the existence of CTCs in NETs, in chapter 4, I demonstrated that the
presence of one or more CTCs was associated with progressive disease (defined by
RECIST 1.1) in a pilot dataset of 63 patients with metastatic NETs. Consequently, I
went on to investigate CTCs as prognostic and predictive biomarkers by prospectively
recruiting 138 patients with metastatic NETs who were about to commence a new
treatment. This is one of the largest prospective biomarker studies in this tumour type.
Using a validation and training set, I identified a cut-off of one CTC as the optimal
threshold. A baseline of one or more CTCs was a poor prognostic factor in terms of PFS
and OS.
In the prospective study in chapter 4, grade according to Ki-67 was also a prognostic
factor confirming retrospective findings from chapter 2. However, on multivariate
analysis, only the G3 stratum was a significant factor, which constitutes a very small
proportion of NETs. Importantly, when studying a large subgroup of G1 and G2
tumours where decisions on when and how to treat are difficult, CTCs were of more
prognostic value than grade.
Importantly, a change in CTCs at 3 to 5 weeks after commencing therapy was predictive
of response to treatment, PFS and OS. Using CTCs as an early marker of response may
provide an opportunity to stop or change treatment sooner in those that are not
benefiting. However, the validity of making treatment decisions based on CTCs needs
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to be investigated in prospective studies, in more homogenous groups in terms of
tumour type and treatment. Such trials are currently being conducted in breast cancer.
Given the varied survival of patients with NETs, grade may be based on a small sample
of tumour mass taken many years ago and may not reflect current tumour biology.
Therefore, grade as a ‘biomarker’ has limitations and biomarkers that can be repeated in
a relatively non-invasive manner, such as from blood, may better reflect current tumour
biology and can be used dynamically. With this in mind, although grade at the time of
diagnosis provides some prognostic information, CTCs have a dynamic advantage over
histological grade as they can be repeated at various time-points throughout what can be
a variable time course. Baseline CTCs, especially in G1 and G2 NETs, could be used be
used to stratify those patients who should have more aggressive or earlier therapy.
However, prospective studies utilising baseline CTCs in making treatment decisions are
required.
Notably, in chapter 4, CTCs were also of more prognostic value than baseline CgA, a
generally accepted biomarker. Using CgA to monitor response to therapy was also not
of value. This suggests the established biomarker, CgA, when subjected to a prospective
study, does not provide as much as much information as consensus suggests.
Having characterised CTCs as neuroendocrine in origin using additional markers,
synaptophysin and CD56, further protein, genetic, and epigenetic investigation of CTCs
may also facilitate the understanding of the process of metastases and tumour biology of
NETs, reflecting the term ‘liquid biopsy’ given to CTCs. However, due to their
infrequency, sensitive single cell technology is required and other isolation techniques
which increase the CTC yield may be better suited for this purpose than the
Cellsearch™ platform. Given the long survival of some patients with NETs, changes in
CTCs could also be used as a surrogate outcome in order to facilitate more rapid drug
development.
Another potential circulating biomarker, cfDNA, was evaluated in chapter 5. For the
first time, I demonstrated cfDNA in plasma and serum in a series 88 patients with
NETs. Interestingly, the predominant fragment length was 150 base pairs approximately
the length of DNA associated with oligonucleosomes, which are found in apoptotic
cells. In certain cases, especially those with large quantities of cfDNA, a ‘ladder’ of
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cfDNA was observed, indicating fragmentation, the significance of which is uncertain
but could include circulating nucleases or shearing during processing.
Consistent with other studies, I demonstrated a higher concentration of cfDNA in
patients with cancer (0-660 ng/mL) than in healthy controls (0-3.3ng/mL). However,
only 25% of the patient samples had detectable cfDNA which may be explained by
indolence of the tumour type or sample processing. I demonstrated that there is an
association between cfDNA and CTCs and that the presence of cfDNA conferred a
worse survival but not statistically significant. Given that 75% of cases did not have
detectable cfDNA and the requirement statistically to dichotomise cfDNA as a variable,
cfDNA may not be as useful as CTCs as a prognostic or predictive biomarker.
However, large prospective studies are required. If the yield of cfDNA is increased with
more sensitive and reliable technology, by analysing the primary tumour from the
patient it may be possible to identify genetic mutations or epigenetic signatures of NETs
in cfDNA. This may provide a ‘tailored’ biomarker, repeatable throughout the course of
the patient’s disease course, offering personalised therapy.
In chapter 5, I demonstrated the presence of CECs in a series of 55 patients with NETs
using the same platform for CTC isolation and enumeration. Although not significantly
elevated in NETs compared to healthy controls, there was significantly increased
variation in numbers and a wider range of CECs in NETs. No definite conclusions can
be derived from this but it suggests that CECs can vary in NETs and may reflect some
underlying angiogenic process. Although no correlation with CTCs were found, given
that CD105 is expressed in NETs, it may be that some of these CECs are actually CTCs.
I did not demonstrate any correlation between CECs and tumour burden or survival.
However, further studies are required, investigating intra-sample and temporal
variation, relationship with circulating and histological markers of angiogenesis, and
changes with anti-angiogenic therapy. CECs may offer a different facet in the
circulating biomarker field to CTCs given recent anti-angiogenic therapies studied in
NETs.
The population studied all had metastatic disease since this makes up the majority of
clinical practice and gives a less heterogeneous group. However, these biomarkers
should be studied in patients with localised disease undergoing therapy, resection or
surveillance in order to compare their concentrations/frequencies to levels demonstrated
in this thesis.
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In conclusion, the incidence and prevalence of NETs is increasing. Given the increasing
number of treatment options available and prolonged survival, it is unclear what
treatments to offer, in which patients, and in which order. Grade according to Ki-67, but
not mitotic count, certainly offers some prognostic information at the time of diagnosis.
However, my research suggests that circulating biomarkers, specifically CTCs, offer
additional and better prognostic and predictive information and provide the opportunity
for sequential monitoring.
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